



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07H 21/04, C07K 1/00, 16/00, A61K 38/00, G01N 33/00, 33/566, A01N 37/18	A1	(11) International Publication Number: WO 98/07736 (43) International Publication Date: 26 February 1998 (26.02.98)
(21) International Application Number: PCT/US97/14585 (22) International Filing Date: 18 August 1997 (18.08.97) (30) Priority Data: 08/699,591 19 August 1996 (19.08.96) US 08/753,007 19 November 1996 (19.11.96) US (71) Applicant: MILLENNIUM BIOTHERAPEUTICS, INC. [US/US]; 640 Memorial Drive, Cambridge, MA 02139 (US). (72) Inventors: GEARING, David, P.; 23 Standish Road, Wellesley, MA 02181 (US). BUSFIELD, Samantha, J.; Apartment 1, 15 Trowbridge Street, Cambridge, MA 02138 (US). (74) Agent: MEIKLEJOHN, Anita, L.; Fish & Richardson P.C., 225 Franklin Street, Boston, MA 02110 (US).		(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: DON-1 GENE AND POLYPEPTIDES AND USES THEREFOR (57) Abstract The present invention relates to the identification and characterization of a novel gene called <i>don-1</i> related to epidermal growth factors (EGF) such as the neuregulins, and methods of preparing and using alternate splice forms of this gene to express new Don-1 polypeptides.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

- 1 -

DON-1 GENE AND POLYPEPTIDES AND USES THEREFORBackground of the Invention

This invention relates to a new gene, called don-
5 1, related to growth factors such as the neuregulins, and
methods of preparing and using alternate splice forms of
this gene to express new Don-1 polypeptides. The
invention also relates to the use of these new genes and
corresponding polypeptides.

10 The growth, differentiation, and survival of many
cell types depends on the binding of protein ligands to
specific cell surface receptors. Misregulation of this
interaction has been implicated in a wide variety of
tumors and developmental irregularities. For example,
15 the epidermal growth factor receptor (EGFR) family of
receptor-type tyrosine kinases are frequently
overexpressed, mutated, or deleted in carcinomas of the
breast, lung, ovary, brain, and gastrointestinal tract
(Prignent et al., *Prog. Growth Factor Res.*, 4:1-24,
20 1992). This family of receptors, which includes
receptors referred to as EGFR, erbB2 (also called "neu"
or HER2, the human homolog of erbB2), erbB3 (HER3), and
erbB4 (HER4), respectively, may play an important role in
the modulation of tumor growth and progression. In
25 particular, it has been shown in several studies that
overexpression of erbB2 in a variety of human
adenocarcinomas, e.g., in breast and ovarian cancer,
correlates with a poor prognosis (see, e.g., Slamon et
al., *Science*, 235:177-182, 1987).

30 One group of ligands that bind to this family of
receptors is referred to as the neuregulin family of
ligands, which all share a common structural domain known
as an EGF motif that contains six cysteines. This motif
not only allows these ligands to bind to the receptors,
35 but to mediate biological effects as well (Barbacci et
al, *J. Biol. Chem.*, 270:9585-9589, 1995)). Although

- 2 -

there appear to be multiple ligands capable of binding to and activating members of the EGFR family, the growth factors that bind to and activate the other members of this receptor family, erbB2, erbB3, and erbB4, are less well characterized.

Neuregulins are also referred to as neuro differentiation factors (NDF), glial growth factors (GGF), heregulins, and acetylcholine-receptor-inducing activity (ARIA) ligands, all of which are expressed as variant splice forms of a single gene. These different names reflect the diverse biological activities of the neuregulins *in vitro*, as glial cell mitogens, receptor binding proteins, mammary differentiation factors, and muscle trophic factors.

Each of the neuregulin glycoproteins has been shown to activate one or more of the receptors erbB2, erbB3, and erbB4 (for a review, see Ben-Baruch et al., *Proc. Soc. Exp. Biol. Med.*, 206:221-227, 1994). These factors were first purified on the basis of their ability to activate, i.e., cause phosphorylation of, the erbB2 receptor, although it has been shown subsequently that these factors do not bind erbB2 directly (Tzahar et al., *J. Biol. Chem.*, 269:25226-25233, 1994). In addition, it has been shown that NDF causes the differentiation of human mammary tumor cells (Peles et al., *Cell*, 69:559-572, 1992).

Summary of the Invention

The present invention relates to the identification and characterization of a new gene, referred to as *don-1*, and alternate splice variants of *don-1*, which are related to the neuregulin gene family. The invention also relates to the polypeptides encoded by *don-1*. *Don-1* mRNA transcripts were expressed in various tissues including murine brain, spleen, and lung, and

- 3 -

human fetal brain and fetal lung. No Don-1 transcripts were detected in normal adult human tissues; however, Don-1 transcripts were detected in several human carcinoma cells. In each case, message sizes were about
5 3.0 kb and 4.4 kb (human) and 4.0 kb (murine).

Both murine and human cDNAs corresponding to various splice variants of *don-1* have been cloned. A murine cDNA corresponding to a first splice variant of this gene is represented by SEQ ID NO:1, and the amino
10 acid sequence of the polypeptide it encodes is represented by SEQ ID NO:2, which is a membrane-bound polypeptide approximately 605 amino acids in length (Fig. 1). A second murine cDNA corresponding to a second splice variant of the *don-1* gene is represented by SEQ ID
15 NO:3, and the amino acid sequence of the polypeptide it encodes is represented by SEQ ID NO:4, which is a secreted polypeptide about 181 amino acids in length (Fig. 2).

A human cDNA corresponding to a first splice
20 variant of the human *don-1* gene is represented by SEQ ID NO:5, and the amino acid sequence of the polypeptide it encodes is represented by SEQ ID NO:6, which is a membrane-bound polypeptide approximately 407 amino acids in length (Fig. 3). A second human cDNA corresponding to
25 a second splice variant of the human *don-1* gene is represented by SEQ ID NO:7, and the amino acid sequence of the polypeptide it encodes is represented by SEQ ID NO:8, which is a membrane-bound polypeptide of about 469 amino acids in length (Fig. 4).

30 A third human cDNA corresponding to a third splice variant of the human *don-1* gene was isolated by further screening of a human fetal lung library. This sequence had an extended sequence compared to the first two clones, and included a termination codon. This sequence
35 is represented by SEQ ID NO:31, and the amino acid

- 4 -

sequence of the polypeptide it encodes is represented by SEQ ID NO:32, which is a membrane-bound polypeptide of about 647 amino acids in length (Fig. 7). This sequence appears to be an extended version of the second splice
5 variant (SEQ ID NO:8), although three amino acids differ at the 3' end of SEQ ID NO:32. This third splice variant extends a further 178 amino acids compared to the second human splice variant, and is 94% homologous to murine Don-1 (SEQ ID NO:2) over this region.

10 In addition, the invention relates to methods of obtaining additional novel ligands that activate some or all members of the EGF receptor family of receptor-type tyrosine kinases, and methods of treating and diagnosing cell proliferative diseases.

15 In general, the invention features an isolated nucleic acid which encodes a mammalian Don-1 polypeptide, e.g., a polypeptide encoded by any splice variant of a *don-1* gene. For example, the nucleic acid can include all or a portion of the nucleotide sequence of, e.g.,
20 Fig. 1, SEQ ID NO:1 (murine), Fig. 2, SEQ ID NO:3 (murine), Fig. 3, SEQ ID NO:5 (human), Fig. 4, SEQ ID NO:7 (human), Fig. 7, SEQ ID NO:31 (human), the sequence encoding the epidermal growth factor (EGF) domain of Don-1 having SEQ ID NO:11, or the extracellular domain of
25 Don-1.

The term "nucleic acid" encompasses both RNA and DNA, including cDNA, genomic DNA, and synthetic (e.g., chemically synthesized) DNA. The nucleic acid may be double-stranded or single-stranded. Where single-
30 stranded, the nucleic acid may be a sense strand or an antisense strand.

By "isolated nucleic acid" is meant a DNA or RNA that is not immediately contiguous with both of the coding sequences with which it is immediately contiguous
35 (one on the 5' end and one on the 3' end) in the

- 5 -

naturally occurring genome of the organism from which it is derived. Thus, in one embodiment, an isolated nucleic acid includes some or all of the 5' non-coding (e.g., promoter) sequences which are immediately contiguous to the coding sequence. The term therefore includes, for example, a recombinant DNA which is incorporated into a vector, into an autonomously replicating plasmid or virus, or into the genomic DNA of a prokaryote or eukaryote, or which exists as a separate molecule (e.g., a cDNA or a genomic DNA fragment produced by PCR or restriction endonuclease treatment) independent of other sequences. It also includes a recombinant DNA which is part of a hybrid gene encoding additional polypeptide sequence. The term "isolated" as used herein also refers to a nucleic acid or peptide that is substantially free of cellular material, viral material, or culture medium when produced by recombinant DNA techniques, or chemical precursors or other chemicals when chemically synthesized. Moreover, an "isolated nucleic acid" is meant to include nucleic acid fragments which are not naturally occurring as fragments and would not be found in the natural state.

A nucleic acid sequence that is "substantially identical" to a *don-1* nucleotide sequence is at least 80% or 85%, preferably 90%, and more preferably 95% or more (e.g. 99%) identical to the nucleotide sequence of the human *don-1* cDNA of SEQ ID NO:5, NO:7, or NO:31, or the murine *don-1* cDNA of SEQ ID NO:1 or NO:3. For purposes of comparison of nucleic acids, the length of the reference nucleic acid sequence will generally be at least 40 nucleotides, preferably at least 60 nucleotides, more preferably at least 75 to 110, or more nucleotides.

Sequence identity can be measured using sequence analysis software (e.g., Sequence Analysis Software Package of the Genetics Computer Group, University of

- 6 -

Wisconsin Biotechnology Center, 1710 University Avenue,
Madison, WI 53705).

The invention also encompasses nucleic acid
sequences that encode forms of Don-1 in which naturally
5 occurring amino acid sequences are altered or deleted.

The invention also features isolated nucleic acid
sequences that encode one or more portions or domains of
Don-1, including but not limited to the Ig domain, the TM
domain, the extracellular domain, the cytoplasmic domain,
10 and various functional domains of Don-1, such as the EGF
domain. The nucleic acids also include those of the *don-1*
gene contained in A.T.C.C. deposit numbers 98096,
98097, or 98098.

Preferred nucleic acids encode polypeptides that
15 are soluble under normal physiological conditions. Also
within the invention are nucleic acids encoding fusion
proteins in which a portion of Don-1 (e.g., one or more
domains) is fused to an unrelated protein or polypeptide
(e.g., a marker polypeptide or a fusion partner) to
20 create a fusion protein. For example, the polypeptide
can be fused to a hexa-histidine tag to facilitate
purification of bacterially expressed protein, or to a
hemagglutinin tag to facilitate purification of protein
expressed in eukaryotic cells.

25 The fusion partner can be, for example, a
polypeptide which facilitates secretion, e.g., a
secretory sequence. Such a fused protein is typically
referred to as a preprotein. The secretory sequence can
be cleaved by the host cell to form the mature protein.
30 Also within the invention are nucleic acids that encode
mature Don-1 fused to a polypeptide sequence to produce
an inactive proprotein. Proproteins can be converted
into the active form of the protein by removal of the
inactivating sequence.

- 7 -

The nucleic acids further include nucleic acids that hybridize, e.g., under stringent hybridization conditions (as defined herein), to all or a portion (e.g., the TM or EGF domains) of the nucleotide sequence of SEQ ID NO:1, 3, 5, 7, 31, or its complement, or to the nucleotide sequence of the *don-1* gene contained in A.T.C.C. deposit 98096, 98097, or 98098, e.g., nucleic acids that encode polypeptides that activates receptor-type tyrosine kinases that have a molecular weight of about 185 kDa.

The hybridizing portion of the hybridizing nucleic acids are preferably 20, 30, 50, or 70 bases long. Preferably, the hybridizing portion of the hybridizing nucleic acid is 80%, more preferably 95%, or even 98% identical to the sequence of a portion or all of a nucleic acid encoding a Don-1 polypeptide. Hybridizing nucleic acids of the type described above can be used as a cloning probe, a primer (e.g., a PCR primer), or a diagnostic probe. Preferred hybridizing nucleic acids encode a polypeptide having some or all of the biological activities possessed by a naturally-occurring Don-1 polypeptide, e.g., as determined in the p185 assay described below.

Hybridizing nucleic acids can be additional splice variants of the *don-1* gene. Thus, they may encode a protein which is shorter or longer than the different forms of Don-1 described herein. Hybridizing nucleic acids may also encode proteins that are related to Don-1 (e.g., proteins encoded by genes which include a portion having a relatively high degree of identity to the *don-1* gene described herein).

In another embodiment, the invention features cells, e.g., transformed host cells, harboring a nucleic acid encompassed by the invention. By "transformed cell" is meant a cell into which (or into an ancestor of which)

- 8 -

has been introduced, by means of recombinant DNA techniques, a DNA molecule encoding a Don-1 polypeptide.

The invention also features vectors and plasmids that include a nucleic acid of the invention which is operably linked to a transcription and/or translation sequence to enable expression, e.g., expression vectors. By "operably linked" is meant that a selected nucleic acid, e.g., a DNA molecule encoding a Don-1 polypeptide, is positioned adjacent to one or more sequence elements, e.g., a promoter, which direct transcription and/or translation of the sequence such that the sequence elements can control transcription and/or translation of the selected nucleic acid.

The invention also features purified or isolated Don-1 polypeptides. As used herein, both "protein" and "polypeptide" mean any chain of amino acids, regardless of length or post-translational modification (e.g., glycosylation or phosphorylation). Thus, the term "Don-1 polypeptide" (or Don-1) includes full-length, naturally occurring Don-1 protein, as well as recombinantly or synthetically produced polypeptides that correspond to a full-length, naturally occurring Don-1 protein or to particular domains or portions of a naturally occurring protein.

By a "purified" or "isolated" compound is meant a composition which is at least 60% by weight (dry weight) the compound of interest, e.g., a Don-1 polypeptide or antibody. Preferably the preparation is at least 75%, more preferably at least 90%, and most preferably at least 99%, by weight the compound of interest. Purity can be measured by any appropriate standard method, e.g., column chromatography, polyacrylamide gel electrophoresis, or HPLC analysis.

Preferred Don-1 polypeptides include a sequence substantially identical to all or a portion of a

- 9 -

naturally occurring Don-1 polypeptide, e.g., including all or a portion of the human sequence shown in Fig. 3 (SEQ ID NO:6), Fig. 4 (SEQ ID NO:8), or Fig. 7 (SEQ ID NO:32), or the murine sequence shown in Fig. 1 (SEQ ID NO:2) or Fig. 3 (SEQ ID NO:6). Polypeptides "substantially identical" to the Don-1 polypeptide sequences described herein have an amino acid sequence that is at least 80% or 85%, preferably 90%, and more preferably 95% or more (e.g. 99%) identical to the amino acid sequence of the Don-1 polypeptides of SEQ ID NOs:2, 4, 6, or 8. For purposes of comparison, the length of the reference Don-1 polypeptide sequence will generally be at least 16 amino acids, preferably at least 20 amino acids, more preferably at least 25 amino acids, and most preferably 35 amino acids.

In the case of polypeptide sequences which are less than 100% identical to a reference sequence, the non-identical positions are preferably, but not necessarily, conservative substitutions for the reference sequence. Conservative substitutions typically include substitutions within the following groups: glycine and alanine; valine, isoleucine, and leucine; aspartic acid and glutamic acid; asparagine and glutamine; serine and threonine; lysine and arginine; and phenylalanine and tyrosine.

Where a particular polypeptide is said to have a specific percent identity to a reference polypeptide of a defined length, the percent identity is relative to the reference peptide. Thus, a peptide that is 50% identical to a reference polypeptide that is 100 amino acids long can be a 50 amino acid polypeptide that is completely identical to a 50 amino acid long portion of the reference polypeptide. It also might be a 100 amino acid long polypeptide which is 50% identical to the reference

- 10 -

polypeptide over its entire length. Of course, many other polypeptides will meet the same criteria.

The polypeptides of the invention include, but are not limited to: recombinant polypeptides, natural
5 polypeptides, and synthetic polypeptides as well as polypeptides, which are preproteins or proproteins.

Polypeptides identical or substantially identical to one or more domains of human, murine, or other mammalian Don-1, e.g., the EGF domain (e.g., SEQ ID
10 NO:11)(about amino acid 142 to about amino acid 178 of human Don-1 cDNA SEQ ID NOs:8 and 32, or amino acids 104 to 140 of human Don-1 cDNA SEQ ID NO:6 described herein), or the transmembrane (TM) domain (e.g., SEQ ID
NO:20)(about amino acid 203 to about amino acid 225 of
15 human Don-1 cDNA SEQ ID NOs:8 and 32, or amino acids 173 to 195 of human Don-1 cDNA SEQ ID NO:6 described herein), are also within the scope of the invention.

Polypeptides encoded by the *don-1* gene contained in A.T.C.C. deposit 98096, 98097, or 98098 are also
20 included within the invention.

Preferred polypeptides are those which are soluble under normal physiological conditions. Also within the invention are soluble fusion proteins in which a full-length form of Don-1 or a portion (e.g., one or more
25 domains) thereof is fused to an unrelated protein or polypeptide (i.e., a fusion partner) to create a fusion protein.

The invention also features isolated polypeptides (and the nucleic acids that encode these polypeptides)
30 that include a first portion and a second portion; the first portion includes a Don-1 polypeptide, e.g., the epidermal growth factor (EGF) domain of Don-1, and the second portion includes an immunoglobulin constant (Fc) region or a detectable marker.

- 11 -

In addition, the invention features a pharmaceutical composition which includes a Don-1 polypeptide and a physiologically acceptable or inert carrier, such as saline.

5 The invention also features purified or isolated antibodies that specifically bind to a Don-1 polypeptide, or a specific region or domain of a naturally occurring Don-1 protein. By "specifically binds" is meant an antibody that recognizes and binds to a particular
10 antigen, e.g., a Don-1 polypeptide, but which does not substantially recognize and bind to other molecules in a sample, e.g., a biological sample, which naturally includes Don-1. In a preferred embodiment the antibody is a monoclonal antibody.

15 The invention also features antagonists and agonists of Don-1. Antagonists can inhibit one or more of the functions of Don-1. Suitable antagonists include large or small molecules, antibodies to Don-1, and Don-1 polypeptides which compete with a native form of Don-1.
20 Agonists of Don-1 enhance or facilitate one or more of the functions of Don-1. Suitable agonists include, for example, large or small molecules and anti-idiotypic antibodies that mimic the biological effects of Don-1.

 Also within the invention are nucleic acid
25 molecules that can be used to interfere with Don-1 expression, e.g., antisense molecules and ribozymes.

 In another aspect, the invention features a method for detecting a Don-1 polypeptide. This method includes: obtaining a biological sample; contacting the sample with
30 an antibody, that specifically binds a Don-1 polypeptide, under conditions that allow the formation of Don-1-antibody complexes; and detecting the complexes, if any, as an indication of the presence of Don-1 in the biological sample.

- 12 -

In another aspect, the invention features a method for stimulating proliferation of a cell, by administering to the cell an amount of a Don-1 polypeptide effective to stimulate proliferation of the cell. The invention also
5 features a method for decreasing proliferation of a cell, by administering to the cell an amount of a Don-1 polypeptide inhibitor effective to decrease proliferation of the cell. This method can be used to treat tumors, e.g., adenocarcinomas, caused by the over-proliferation
10 of cells in a patient. Preferably the inhibitor is an antibody which selectively binds to Don-1.

In another embodiment, the invention features a method of obtaining a splice variant cDNA of the *don-1* gene. The method includes the steps of obtaining a
15 labeled probe comprising an isolated nucleic acid that encodes all or a portion of the epidermal growth factor (EGF) domain of Don-1, e.g., having the amino acid sequence of SEQ ID NO:11; screening a nucleic acid fragment library with the labeled probe under conditions
20 that allow hybridization of the probe to nucleic acid fragments in the library to form nucleic acid duplexes, isolating labeled duplexes, if any; and preparing a full-length cDNA from the fragments in any labeled duplex to obtain a splice variant cDNA of the *don-1* gene.

25 The invention further features a method of obtaining a gene related to the *don-1* gene, by obtaining a labeled probe comprising an isolated nucleic acid that encodes all or a portion of the transmembrane (TM) domain of Don-1, e.g., having the amino acid sequence of SEQ ID
30 NO:20; screening a nucleic acid fragment library with the labeled probe under conditions that allow hybridization of the probe to nucleic acid fragments in the library to form nucleic acid duplexes; isolating labeled duplexes, if any; and preparing a full-length gene sequence from

- 13 -

the nucleic acid fragments in any labeled duplex to obtain a gene related to the *don-1* gene.

The invention also features a purified protein that functionally interacts with Don-1, and a nucleic acid that encodes a protein that functionally interacts with Don-1.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are described herein. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In the case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and are not intended to be limiting

Other features and advantages of the invention will be apparent from the following detailed descriptions, and from the claims.

Brief Description of the Drawings

Fig. 1 is a representation of the nucleic acid (SEQ ID NO:1) of a murine cDNA corresponding to a membrane-bound splice variant of the *don-1* gene, and the amino acid sequence (SEQ ID NO:2) it encodes.

Fig. 2 is a representation of the nucleic acid (SEQ ID NO:3) of a second murine cDNA corresponding to a secreted splice variant of the *don-1* gene, and the amino acid sequence (SEQ ID NO:4) it encodes.

Fig. 3 is a representation of the nucleic acid (SEQ ID NO:5) of a human cDNA corresponding to a

- 14 -

membrane-bound splice variant of the human *don-1* gene, and the amino acid sequence (SEQ ID NO:6) it encodes.

Fig. 4 is a representation of the nucleic acid (SEQ ID NO:7) of a human cDNA corresponding to a second
5 splice variant of the human *don-1* gene, and the amino acid sequence (SEQ ID NO:8) it encodes.

Fig. 5 is a multi-sequence alignment of the amino acid SEQ ID NOs:2, 4, 6, and 8 of Figs. 1 to 4, as well as the amino acid sequence of rat neu differentiation
10 factor (NDF) (Genbank Accession No. A38220; SEQ ID NO:9) and human heregulin- β (Genbank Accession No. B43273; SEQ ID NO:10). In this figure, an asterisk above the aligned sequences indicates the location of conserved cysteines in the EGF domain. The transmembrane domains are boxed.

15 Fig. 6 is a representation of a sequence alignment of the EGF domain of Don-1 (SEQ ID NO:11) with the growth factor domains of members of the neuregulin/heregulin family and human heparin binding-EGF (hb-EGF). The domain is bounded by cysteines, and contains a total of
20 six conserved cysteines. Fig. 6 shows additional amino acids upstream and downstream of the EGF domain. Amino acid sequences correspond to a Don-1 EGF polypeptide (SEQ ID NO:11), human heregulin- α (Genbank Accession No. A43273, SEQ ID NO:12), rat NDF (Genbank Accession No.
25 A38220; SEQ ID NO:13), human heregulin- β 1 (Genbank Accession No. A43273; SEQ ID NO:14), chicken ARIA (Genbank Accession No. A45769; SEQ ID NO:15); human heparin binding-EGF (Genbank Accession No. A38432; SEQ ID NO:16); human EGF (Genbank Accession No. P01133; SEQ ID
30 NO:17); human amphiregulin (Genbank Accession No. 179040; SEQ ID NO:18); and human TGF- α (Genbank Accession No. 339546; SEQ ID NO:19).

Fig. 7 is a representation of the nucleic acid (SEQ ID NO:31) of a human cDNA corresponding to a third

- 15 -

splice variant of the human *don-1* gene, and the amino acid sequence (SEQ ID NO:32) it encodes.

Detailed Description

Don-1 polypeptides, described here for the first time, are a family of novel glycoprotein ligands related to epidermal growth factors such as the neuregulins. The different Don-1 polypeptides are encoded by different splice variants of the *don-1* gene. Don-1 plays a role in proliferation of carcinomas including adenocarcinoma, myeloma, glioma, melanomas, as well as in cell differentiation, proliferation, and survival.

Don-1 polypeptides have a mosaic grouping of functional domains similar to those found in neuregulins (Wen et al., *Cell*, **69**, 559-572, 1992). For example, similar to NDF, both secreted and membrane-bound forms of Don-1 polypeptides include an EGF domain, which enables these ligands to bind to EGF receptors, and to mediate biological effects. As described herein, the EGF domain can also be used to obtain additional splice variants of the *don-1* gene.

Also like NDF, membrane-bound forms of Don-1 (SEQ ID NOS:2, 6, 8, and 32) contain a recognized Ig domain, a transmembrane (TM) domain (VLTITGICVALLVVGIVCVVAYC, SEQ ID NO:20), and a cytoplasmic domain. The Ig domain should be important in protein-protein interactions. As described herein, the TM domain can be used to obtain additional new genes related to the *don-1* gene. A secreted form of murine Don-1 (SEQ ID NO:4) is a variant splice form that lacks the transmembrane sequence. These domains are described in detail below.

As shown in Fig. 5, comparison of a sequence of a human cDNA of Don-1 (SEQ ID NO:8) isolated from human fetal brain, revealed that the EGF domain (about amino acid 142 to about amino acid 178) is 100% identical to

- 16 -

the EGF domain in the mouse Don-1 amino acid sequence of SEQ ID NO:2 (about amino acids 104 to 140). In addition, the TM domains (boxed in Fig. 5) appear to be highly conserved between mouse and human Don-1 (identical; SEQ ID NO:20), and between Don-1, NDF, and heregulin (2 differences of 23 amino acids). The generic TM domain sequence is VLTITGICX₁ALLVVGIX₂CVVAYC (SEQ ID NO:21), where X₁ is I or V, and X₂ is M or V.

The two neighboring basic amino acids adjacent the transmembrane region (amino acids Lys-171 and Arg-172 in the human SEQ ID NO:6; amino acids Lys-201 and Arg-202 in the human SEQ ID NOS:8 and 32; amino acids Lys-163 and Arg-164 in the murine form SEQ ID NO:2) provide for the possibility of processing these proteins with proteolytic enzymes to detach them from the cell membrane.

Fig. 5 shows the primary structure of both murine and human forms of Don-1 (SEQ ID NOS:2, 4, 6, and 8), as well as the primary structures of rat NDF (SEQ ID NO:9), human heregulin- β (SEQ ID NO:10). As can be seen from this figure, these sequences have highly conserved Ig, EGF (extracellular) and TM domains. Further, there is high homology in the cytoplasmic domains.

Expression of Don-1 in human tissues appeared to be restricted to fetal brain and lung tissues. No Don-1 transcripts were detected in normal adult human tissues using a murine Don-1 cDNA as a probe. However, Don-1 transcripts were detected in a human colon adenocarcinoma cell line SW480 and in a human melanoma cell line G361. In these tissues there were two major Don-1 transcripts of about 4.4 kb and about 3 kb each.

Overall, the human Don-1 cDNA of SEQ ID NO:8 described herein is 95% identical and 98% similar (based on conservative substitutions) at the amino acid level to the murine Don-1 cDNA of SEQ ID NO:2 described herein. The highest homology between the two forms is found in

- 17 -

the EGF and transmembrane domains, suggesting that both domains have important functional roles. High homology between the two forms is also found in the Ig and cytoplasmic domains.

5 Don-1 Proteins and Polypeptides

Don-1 proteins and polypeptides and Don-1 fusion proteins can be prepared for a wide range of uses including, but not limited to, generation of antibodies, preparation of reagents for diagnostic assays,
10 identification of other molecules involved in neoplastic and proliferation (particularly adenocarcinoma), preparation of reagents for use in screening assays for neoplasm modulators, and preparation of therapeutic agents for treatment of tumor-related disorders.

15 The *don-1* gene was originally isolated from a screen of a murine choroid plexus cDNA library. Further screening of other murine and human tissue sources yielded three additional clones of this gene, all representing different splice variants. Based on these
20 cDNA sequences, the *don-1* gene can also be obtained by chemical synthesis using one of the methods described in Engels et al. (*Agnew. Chem. Int. Ed. Engl.*, 28:716-734, 1989). These methods include triester, phosphite, phosphoramidite and H-Phosphonate methods, PCR and other
25 autoprimer methods, and oligonucleotide syntheses on solid supports. These methods may be used if the entire nucleic acid sequence of the gene is known, or the sequence of the nucleic acid complementary to the coding strand is available, or alternatively, if the target
30 amino acid sequence is known, one may infer potential nucleic acid sequences using known and preferred coding residues for each amino acid residue.

In particular, Fig. 1 shows the cDNA of one murine splice variant of *don-1* (SEQ ID NO:1), which encodes a

- 18 -

predicted protein of about 605 amino acids (SEQ ID NO:2). This clone was isolated from a murine lung cDNA library. The Ig domain begins at a cysteine at about location 16 and extends to a cysteine at about location 70, and
5 should be important in protein-protein interactions. The EGF domain (SEQ ID NO:11), which is predicted to contain the active part of the protein, begins at a cysteine at about amino acid location 104 and extends to a cysteine at about amino acid location 140 in this cDNA.

10 The spacing of the 6 cysteine residues and an important glycine residue (amino acid 137) in the EGF domain, are conserved between Don-1 and EGF, although homology over this region reveals that Don-1 is more similar to NDF (47% identity) than EGF (35% identity).
15 In general, the EGF domain of Don-1 related polypeptides requires the following formula: the first C, followed by 7 amino acids; the second C, followed by 4 or 5 amino acids; the third C, followed by 10-13 amino acids; the fourth C, followed by 1 amino acid; the fifth C, followed
20 by 8 amino acids; and then the sixth C.

The EGF domain of Don-1 (CNETAKSYCVNGGVCYYIEGINQL-SCKCPNGFFGQRC, SEQ ID NO:11) is identical in all five splice variants, both murine and human. Thus, probes designed based on the nucleotide region encoding this EGF
25 domain can be used, as described herein, to obtain, in humans, mice, and other animals, additional splice variant cDNAs of the *don-1* gene.

The murine Don-1 polypeptide of Fig. 1 also includes a TM domain of approximately 23 amino acids
30 extending from about amino acid location 165 to about amino acid location 187. Immediately prior to the TM domain are two basic residues (amino acids 163 and 164) that should function as a proteolytic cleavage site. This would result in the release of soluble ligand from
35 the cell membrane. The cytoplasmic domain of Don-1

- 19 -

extends from about amino acid 183 to about amino acid 605.

The Don-1 TM domain (VLTITGICVALLVVGIVCVVAYC, SEQ ID NO:20), like the EGF domain, is also highly conserved in the murine and human membrane-bound splice variants of Don-1 that include this domain (murine SEQ ID NO:4 does not). In fact, the TM domain is identical in both human splice variants and the membrane-bound form of the murine splice variants. As shown in Fig. 5, this Don-1 TM domain is also highly conserved in other, related proteins, such as rat NDF, and human heregulin- β . Thus, probes designed based on the nucleotide region encoding this TM domain can be used as described herein to obtain, in humans, mice, and other animals, additional genes related to the *don-1* gene.

Fig. 2 shows a second murine cDNA that corresponds to another splice variant of murine *don-1* (SEQ ID NO:3), which encodes a Don-1 polypeptide of 181 amino acids (SEQ ID NO:4). To obtain the nucleotide and amino acids sequences in Fig. 2, a 1.4kb cDNA that contained an open reading frame of 139 amino acids was isolated from a mouse choroid plexus library. This partial clone contained no 5' ATG initiation codon and terminated after the EGF domain. This original clone was then used as a probe to isolate other mouse and human splice variants. The other murine splice variant, SEQ ID NO:1 (Fig. 1), represents a longer, transmembrane-bound version of the original clone. Based on the high homology between the two mouse clones over the Ig and EGF domains, the chimeric clone of Fig. 2 was constructed and designated as the murine Don-1 cDNA of SEQ ID NO:3. This cDNA encompasses the nucleotide sequence encoding the first 42 amino acids of murine Don-1 SEQ ID NO:2, and the remaining 139 amino acids of the original murine Don-1

- 20 -

clone. This resulting chimera is 181 amino acids in length.

This splice variant does not contain a TM domain, and is thus a secreted protein. The structure of this
5 second splice variant is identical to the polypeptide of SEQ ID NO:2 from amino acid 1 to amino acid 155. Thus, the EGF domain (SEQ ID NO:11), which is predicted to contain the biologically active part of the protein, begins at about amino acid location 104 and extends to
10 amino acid location 140 in this cDNA.

Fig. 3 shows a cDNA of a human splice variant of the *don-1* gene (SEQ ID NO:5), which encodes a polypeptide of about 407 amino acids in length (SEQ ID NO:6). This clone was isolated from a human fetal lung cDNA library.
15 This polypeptide includes an apparent Ig domain extending from a cysteine at about location 16 to a cysteine at about location 70; an EGF domain extending from a cysteine at about location 104 to a cysteine at about amino acid location 140; a transmembrane domain from
20 about amino acid 173 to about amino acid 195; and a cytoplasmic domain of approximately 211 amino acids extending from about amino acid 196 to about amino acid 407. In addition, this splice variant includes an extra 8 amino acids in the juxtamembrane region (at locations
25 157 to 164) compared to the other three splice variants.

Fig. 4 shows a second human cDNA corresponding to another splice variant of human *don-1* (SEQ ID NO:7), which encodes a polypeptide of about 469 amino acids in length (SEQ ID NO:8). This second human clone was also
30 isolated from a human fetal lung cDNA library. This polypeptide includes an apparent Ig domain extending from a cysteine at about location 54 to a cysteine at about location 108; an EGF domain extending from about amino acid location 142 to about amino acid location 178; a
35 transmembrane domain from about amino acid location 203

- 21 -

to about amino acid location 225; and a cytoplasmic domain of approximately 243 amino acids extending from about amino acid 226 to amino acid 469.

Fig. 7 shows a third human cDNA corresponding to a
5 third splice variant of the human *don-1* gene (SEQ ID NO:31), which encodes a polypeptide of about 647 amino acids in length (SEQ ID NO:32). This third human clone was also isolated from a human fetal lung cDNA library. This polypeptide includes an apparent Ig domain extending
10 from a cysteine at about location 54 to a cysteine at about location 108; an EGF domain extending from about amino acid location 142 to about amino acid location 178; a transmembrane domain from about amino acid location 203 to about amino acid location 225; and a cytoplasmic
15 domain of approximately 421 amino acids extending from about amino acid 226 to amino acid 647 (which is the end of the polypeptide in view of the termination codon).

The invention encompasses, but is not limited to, Don-1 proteins and polypeptides that are functionally
20 related to Don-1 encoded by the nucleotide sequences of Fig. 1 (murine SEQ ID NO:1), Fig. 2 (murine SEQ ID NO:3), Fig. 3 (human SEQ ID NO:5), Fig. 4 (human SEQ ID NO:7), and Fig. 7 (human SEQ ID NO:31). Functionally related proteins and polypeptides include any protein or
25 polypeptide sharing a functional characteristic with Don-1, e.g., the ability to affect cell differentiation, proliferation, or survival, and those that are active in the p185 assay described herein.

Such functionally related Don-1 polypeptides
30 include, but are not limited to, polypeptides with additions or substitutions of amino acid residues within the amino acid sequence encoded by the *don-1* cDNA sequences described herein which result in a silent change, thus producing a functionally equivalent gene
35 product. Amino acid substitutions may be made on the

- 22 -

basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues involved. The function of the new polypeptide can then be tested in the p185 assay

5 described herein.

For example, nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine; polar neutral amino acids include glycine, serine, threonine, cysteine, 10 tyrosine, asparagine, and glutamine; positively charged (basic) amino acids include arginine, lysine, and histidine; and negatively charged (acidic) amino acids include aspartic acid and glutamic acid.

While random mutations can be made to *don-1* DNA 15 (using random mutagenesis techniques well known in the art) and the resulting mutant Don-1 proteins can be tested for activity, site-directed mutations of the *don-1* coding sequence can be engineered (using site-directed mutagenesis techniques well known to those skilled in the 20 art) to generate mutant Don-1 polypeptides with increased function, e.g., greater modulation of cell proliferation, differentiation or survival, or decreased function, e.g., down-modulation of cell proliferation, differentiation, or survival.

25 To design functionally related and/or variant Don-1 polypeptides, it is useful to distinguish between conserved positions and variable positions. Fig. 5 shows an alignment between the amino acid sequences of the human and murine Don-1 polypeptides. This alignment can 30 be used to determine the conserved and variable amino acid positions. To preserve Don-1 function, it is preferable that conserved residues are not altered. Moreover, alteration of non-conserved residues are preferably conservative alterations, e.g., a basic amino 35 acid is replaced by a different basic amino acid. To

- 23 -

produce altered function variants, it is preferable to make non-conservative changes at variable and/or conserved positions. Deletions at conserved and variable positions can also be used to create altered function variants.

Other mutations to the *don-1* coding sequence can be made to generate Don-1 polypeptides that are better suited for expression, scale up, etc. in a selected host cell. For example, N-linked glycosylation sites can be altered or eliminated to achieve, for example, expression of a homogeneous product that is more easily recovered and purified from yeast hosts which are known to hyperglycosylate N-linked sites. To this end, a variety of amino acid substitutions at one or both of the first or third amino acid positions of any one or more of the glycosylation recognition sequences which occur (in N-X-S or N-X-T), and/or an amino acid deletion at the second position of any one or more of such recognition sequences, will prevent glycosylation at the modified tripeptide sequence. (See , e.g., Miyajima et al., *EMBO J.*, 5:1193, 1986).

Preferred Don-1 polypeptides are those polypeptides, or variants thereof, that activate receptor-type tyrosine kinases which have a molecular weight of 185 kDa, which includes p185 (erbB2). Activating Don-1 polypeptides can be determined by a standard p185 assay as described herein. Briefly, the activity of the EGF domain of Don-1 was ascertained by testing the ability of an EGF domain-containing fusion polypeptide to phosphorylate a 185 kDa protein in the breast adenocarcinoma cell line MDA-MB453. Serum-starved cells were treated with EGF, NDF, conditioned media from mock-transfected or Don-1 EGF-transfected 293Ebna cells as described below. Analysis of phosphorylated proteins by Western blotting revealed that Don-1 EGF induced

- 24 -

phosphorylation of p185 at a level comparable to saturating amounts of NDF, which represented an approximate ten-fold increase in phosphorylation over uninduced cells. This result demonstrates that the EGF domain of Don-1 binds and activates a known member of the EGFR family, p185.

Preferred Don-1 polypeptides and variants have 20%, 50%, 75%, 90%, or even 100% or more of the activity of the human form of Don-1 (SEQ ID NOS:6, 8, and 32) described herein. Such comparisons are generally based on equal concentrations of the molecules being compared. The comparison can also be based on the amount of protein or polypeptide required to reach 50% of the maximal activation obtainable.

In addition to the *don-1* cDNA sequences described above, additional splice variants of the *don-1* gene, and related family members of the *don-1* gene present in the mouse, humans, or other species can be identified and readily isolated without undue experimentation by well known molecular biological techniques given the specific sequences described herein. Further, genes may exist at other genetic loci within the genome that encode proteins which have extensive homology to Don-1 polypeptides or one or more domains of Don-1 polypeptides. These genes can be identified via similar techniques.

For example, to obtain additional splice variants of the *don-1* gene, an oligonucleotide probe based on the cDNA sequences described herein, or fragments thereof, e.g., the nucleotide region encoding the EGF domain can be labeled and used to screen a cDNA library constructed from mRNA obtained from an organism of interest. To obtain additional neuregulin-related genes related to the *don-1* gene, an oligonucleotide probe based on the nucleotide region encoding the TM domain of Don-1, can be used to screen a suitable cDNA library.

- 25 -

The preferred method of labeling is to use ^{32}P -labeled ATP with polynucleotide kinase, as is well known in the art, to radiolabel the oligonucleotide probe. However other methods may be used to label the
5 oligonucleotide, including, but not limited to, biotinylation or enzyme labeling.

Hybridization is performed under stringent conditions. Alternatively, a labeled fragment can be used to screen a genomic library derived from the
10 organism of interest, again, using appropriately stringent conditions. Such stringent conditions are well known, and will vary predictably depending on the specific organisms from which the library and the labeled sequences are derived.

15 Nucleic acid duplex or hybrid stability is expressed as the melting temperature or T_m , which is the temperature at which a probe dissociates from a target DNA. This melting temperature is used to define the required stringency conditions. If sequences are to be
20 identified that are related and substantially identical to the probe, rather than identical, then it is useful to first establish the lowest temperature at which only homologous hybridization occurs with a particular SSC or SSPE concentration. Then assume that 1% mismatching
25 results in 1°C decrease in the T_m and reduce the temperature of the final wash accordingly (for example, if sequences with $\geq 95\%$ identity with the probe are sought, decrease the final wash temperature by 5°C). Note that this assumption is very approximate, and the
30 actual change in T_m can be between 0.5° and 1.5°C per 1% mismatch.

As used herein, high stringency conditions include hybridizing at 68°C in 5x SSC/5x Denhardt solution/1.0% SDS, or in 0.5 M NaHPO_4 (pH 7.2)/1 mM EDTA/7% SDS, or in
35 50% formamide/0.25 M NaHPO_4 (pH 7.2)/0.25 M NaCl/1 mM

- 26 -

EDTA/7% SDS; and washing in 0.2x SSC/0.1% SDS at room temperature or at 42°C, or in 0.1x SSC/0.1% SDS at 68°C, or in 40 mM NaHPO₄ (pH 7.2)/1 mM EDTA/5% SDS at 50°C, or in 40 mM NaHPO₄ (pH 7.2) 1 mM EDTA/1% SDS at 50°C.

5 Moderately stringent conditions include washing in 3x SSC at 42°C. The parameters of salt concentration and temperature can be varied to achieve the desired level of identity between the probe and the target nucleic acid.

For guidance regarding such conditions see, for
10 example, Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual, Cold Springs Harbor Press, N.Y.; and Ausubel et al. (eds.), 1995, Current Protocols in Molecular Biology, (John Wiley & Sons, N.Y.) at Unit 2.10.

15 In one approach, appropriate human cDNA libraries can be screened. Such cDNA libraries can, for example, include human breast, human prostate, or fetal human brain or lung cDNA libraries. For example, panels of human breast cells can be screened for *don-1* expression
20 by, for example, Northern blot analysis. Upon detection of *don-1* transcript, cDNA libraries can be constructed from RNA isolated from the appropriate cell line, utilizing standard techniques well known to those of skill in the art. The human cDNA library can then be
25 screened with a *don-1* probe to isolate a human *don-1* cDNA. As described below, this method was used to determine the human *don-1* cDNAs in Figs. 2, 4, and 7.

Alternatively, a human total genomic DNA library can be screened using *don-1* probes. *Don-1*-positive
30 clones can then be sequenced and, further, the intron/exon structure of the human *don-1* gene can be elucidated. Once genomic sequence is obtained, oligonucleotide primers can be designed based on the sequence for use in the isolation, via, for example
35 Reverse Transcriptase-coupled PCR, of human *don-1* cDNA.

- 27 -

Further, a previously unknown gene sequence can be isolated by performing PCR using two degenerate oligonucleotide primer pools designed on the basis of nucleotide sequences within the *don-1* cDNAs defined
5 herein. The template for the reaction can be cDNA obtained by reverse transcription of mRNA prepared from human or non-human cell lines or tissue known or suspected to express a *don-1* gene allele. The PCR product can be subcloned and sequenced to insure that the
10 amplified sequences represent the sequences of a *don-1* or *don-1*-like gene nucleic acid sequence.

The PCR fragment can then be used to isolate a full length cDNA clone by a variety of methods. For example, the amplified fragment can be labeled and used
15 to screen a bacteriophage cDNA library. Alternatively, the labeled fragment can be used to screen a genomic library.

PCR technology also can be used to isolate full length cDNA sequences. For example, RNA can be isolated,
20 following standard procedures, from an appropriate cellular or tissue source. A reverse transcription reaction can be performed on the RNA using an oligonucleotide primer specific for the most 5' end of the amplified fragment for the priming of first strand
25 synthesis. The resulting RNA/DNA hybrid can then be "tailed" with guanines using a standard terminal transferase reaction, the hybrid can be digested with RNAase H, and second strand synthesis can then be primed with a poly-C primer. Thus, cDNA sequences upstream of
30 the amplified fragment can easily be isolated. For a review of useful cloning strategies, see e.g., Sambrook et al., supra; and Ausubel et al., supra.

In cases where the gene identified is the normal (wild type) gene, this gene can be used to isolate mutant
35 alleles of the gene. Such an isolation is preferable in

- 28 -

processes and disorders which are known or suspected to have a genetic basis. Mutant alleles can be isolated from individuals either known or suspected to have a genotype which contributes to tumor, e.g.,

5 adenocarcinoma, proliferation or progression. Mutant alleles and mutant allele gene products can then be utilized in the therapeutic and diagnostic assay systems described below.

A cDNA of a mutant gene can be isolated, for
10 example, by using PCR, a technique which is well-known to one skilled in the art. In this case, the first cDNA strand can be synthesized by hybridizing a oligo-dT oligonucleotide to mRNA isolated from tissue known or suspected of being expressed in an individual putatively
15 carrying the mutant allele, and by extending the new strand with reverse transcriptase. The second strand of the cDNA can then be synthesized using an oligonucleotide that hybridizes specifically to the 5'- end of the normal gene. Using these two primers, the product is then
20 amplified via PCR, cloned into a suitable vector, and subjected to DNA sequence analysis by methods well known in the art. By comparing the DNA sequence of the mutant gene to that of the normal gene, the mutation(s) responsible for the loss or alteration of function of the
25 mutant gene product can be ascertained.

Alternatively, a genomic or cDNA library can be constructed and screened using DNA or RNA, respectively, from a tissue known to or suspected of expressing the gene of interest in an individual suspected of or known
30 to carry the mutant allele. The normal gene or any suitable fragment thereof can then be labeled and used as a probe to identify the corresponding mutant allele in the library. The clone containing this gene can then be purified through methods routinely practiced in the art,

- 29 -

and subjected to sequence analysis using standard techniques as described herein.

Additionally, an expression library can be constructed using DNA isolated from or cDNA synthesized
5 from a tissue known to or suspected of expressing the gene of interest in an individual suspected of or known to carry the mutant allele. In this manner, gene products made by the putatively mutant tissue can be expressed and screened using standard antibody screening
10 techniques in conjunction with antibodies raised against the normal gene product, as described herein. For screening techniques, see, for example, Harlow, E. and Lane, eds., 1988, "Antibodies: A Laboratory Manual," Cold Spring Harbor Press, Cold Spring Harbor.

15 In cases where the mutation results in an expressed gene product with altered function (e.g., as a result of a missense mutation), a polyclonal set of antibodies is likely to cross-react with the mutant gene product. Library clones detected via their reaction with
20 such labeled antibodies can be purified and subjected to sequence analysis as described herein.

Polypeptides corresponding to one or more domains of full-length Don-1 protein, e.g., the Ig, TM, and EGF domains, are also within the scope of the invention.
25 Preferred polypeptides are those which are soluble under normal physiological conditions. Also within the invention are fusion proteins in which a portion (e.g., one or more domains) of Don-1 is fused to an unrelated protein or polypeptide (i.e., a fusion partner) to create
30 a fusion protein. The fusion partner can be a moiety selected to facilitate purification, detection, or solubilization, or to provide some other function. Fusion proteins are generally produced by expressing a hybrid gene in which a nucleotide sequence encoding all
35 or a portion of Don-1 is joined in-frame to a nucleotide

- 30 -

sequence encoding the fusion partner. Fusion partners include, but are not limited to, the constant region of an immunoglobulin (IgFc). A fusion protein in which a Don-1 polypeptide is fused to IgFc can be more stable and
5 have a longer half-life in the body than the Don-1 polypeptide on its own.

Also within the scope of the invention are various soluble forms of Don-1. For example, the entire extracellular domain of Don-1 or a portion or domain
10 thereof can be expressed on its own or fused to a solubilization partner, e.g., an immunoglobulin.

The invention also features Don-1 polypeptides which can inhibit proliferation of adenocarcinoma cells. The ability of the Don-1 polypeptides to inhibit
15 proliferation of carcinoma cells can be determined using a standard proliferation assay, as follows. Cell, e.g., adenocarcinoma cell, proliferation and viability can be measured by the cleavage of MTT as described by the manufacturer (Boehringer Mannheim, Catalog No. 1465007).
20 Briefly, cells (2×10^3) are seeded in separate 100 μ L volumes into 96 well tissue culture plates with media containing various concentrations of a Don-1 polypeptide. The plates are then incubated for various times (1 to 3 days) in a humidified atmosphere of 5% CO₂ at 37°C. 0.5
25 mg/ml MTT labeling reagent is added to each well, and the plates are incubated for an additional four hours at 37°C. 100 μ L of solubilization buffer is then added to each well and the plates are allowed to stand for 12 hours at 37°C. The spectrophotometrical absorbance at
30 550 and 690 nm is then measured as a gauge of cell proliferation and viability.

In general, Don-1 proteins according to the invention can be produced by transformation
(transfection, transduction, or infection) of a host cell
35 with all or part of a Don-1-encoding DNA fragment (e.g.,

- 31 -

one of the cDNAs described herein) in a suitable expression vehicle. Suitable expression vehicles include: plasmids, viral particles, and phage. For insect cells, baculovirus expression vectors are
5 suitable. The entire expression vehicle, or a part thereof, can be integrated into the host cell genome. In some circumstances, it is desirable to employ an inducible expression vector, e.g., the LACSWITCH™ Inducible Expression System (Stratagene; LaJolla, CA).

10 Those skilled in the field of molecular biology will understand that any of a wide variety of expression systems can be used to provide the recombinant protein. The precise host cell used is not critical to the invention. The Don-1 protein can be produced in a
15 prokaryotic host (e.g., *E. coli* or *B. subtilis*) or in a eukaryotic host (e.g., *Saccharomyces* or *Pichia*; mammalian cells, e.g., COS, NIH 3T3 CHO, BHK, 293, or HeLa cells; or insect cells).

Proteins and polypeptides can also be produced in
20 plant cells. For plant cells viral expression vectors (e.g., cauliflower mosaic virus and tobacco mosaic virus) and plasmid expression vectors (e.g., Ti plasmid) are suitable. Such cells are available from a wide range of sources (e.g., the American Type Culture Collection,
25 Rockland, MD; also, see, e.g., Ausubel et al., *Current Protocols in Molecular Biology*, John Wiley & Sons, New York, 1994). The methods of transformation or transfection and the choice of expression vehicle will depend on the host system selected. Transformation and
30 transfection methods are described, e.g., in Ausubel et al., supra; expression vehicles may be chosen from those provided, e.g., in *Cloning Vectors: A Laboratory Manual* (P.H. Pouwels et al., 1985, Supp. 1987).

The host cells harboring the expression vehicle
35 can be cultured in conventional nutrient media adapted as

- 32 -

need for activation of a chosen gene, repression of a chosen gene, selection of transformants, or amplification of a chosen gene.

One preferred expression system is the mouse 3T3
5 fibroblast host cell transfected with a pMAMneo
expression vector (Clontech, Palo Alto, CA). pMAMneo
provides an RSV-LTR enhancer linked to a dexamethasone-
inducible MMTV-LTR promotor, an SV40 origin of
10 replication which allows replication in mammalian
systems, a selectable neomycin gene, and SV40 splicing
and polyadenylation sites. DNA encoding a Don-1 protein
would be inserted into the pMAMneo vector in an
orientation designed to allow expression. The
recombinant Don-1 protein would be isolated as described
15 below. Other preferable host cells that can be used in
conjunction with the pMAMneo expression vehicle include
COS cells and CHO cells (ATCC Accession Nos. CRL 1650 and
CCL 61, respectively).

Don-1 polypeptides can be produced as fusion
20 proteins. For example, the expression vector pUR278
(Ruther et al., *EMBO J.* 2:1791, 1983), can be used to
create lacZ fusion proteins. The pGEX vectors can be
used to express foreign polypeptides as fusion proteins
with glutathione S-transferase (GST). In general, such
25 fusion proteins are soluble and can be easily purified
from lysed cells by adsorption to glutathione-agarose
beads followed by elution in the presence of free
glutathione. The pGEX vectors are designed to include
thrombin or factor Xa protease cleavage sites so that the
30 cloned target gene product can be released from the GST
moiety.

In an insect cell expression system, Autographa
californica nuclear polyhidrosis virus (AcNPV), which
grows in Spodoptera frugiperda cells, is used as a vector
35 to express foreign genes. A Don-1 coding sequence can be

- 33 -

cloned individually into non-essential regions (for example the polyhedrin gene) of the virus and placed under control of an AcNPV promoter, e.g., the polyhedrin promoter. Successful insertion of a gene encoding a Don-
5 1 polypeptide or protein will result in inactivation of the polyhedrin gene and production of non-occluded recombinant virus (i.e., virus lacking the proteinaceous coat encoded by the polyhedrin gene). These recombinant viruses are then used to infect *spodoptera frugiperda*
10 cells in which the inserted gene is expressed (see, e.g., Smith et al., *J. Virol.* 46:584, 1983; Smith, U.S. Patent No. 4,215,051).

In mammalian host cells, a number of viral-based expression systems can be utilized. When an adenovirus
15 is used as an expression vector, the Don-1 nucleic acid sequence can be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene can then be inserted into the adenovirus genome by *in vitro* or *in*
20 *vivo* recombination. Insertion into a non-essential region of the viral genome (e.g., region E1 or E3) will result in a recombinant virus that is viable and capable of expressing a Don-1 gene product in infected hosts (see, e.g., Logan, *Proc. Natl. Acad. Sci. USA* 81:3655,
25 1984).

Specific initiation signals may be required for efficient translation of inserted nucleic acid sequences. These signals include the ATG initiation codon and adjacent sequences. In cases where an entire native Don-
30 1 gene or cDNA, including its own initiation codon and adjacent sequences, is inserted into the appropriate expression vector, no additional translational control signals may be needed. In other cases, exogenous translational control signals, including, perhaps, the
35 ATG initiation codon, must be provided. Furthermore, the

- 34 -

initiation codon must be in phase with the reading frame of the desired coding sequence to ensure translation of the entire insert. These exogenous translational control signals and initiation codons can be of a variety of
5 origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators (Bittner et al., Methods in Enzymol. 153:516, 1987).

10 In general, the signal sequence can be a component of the expression vector, or it may be a part of *don-1* DNA that is inserted into the vector. The native *don-1* DNA is thought to encode a signal sequence at the amino terminus of the polypeptide that is cleaved during post-
15 translational processing to form the mature Don-1 polypeptide that binds to the p185 receptor. However, a conventional signal structure is not apparent. Native Don-1 is secreted from cells, but may remain lodged in the membrane because it contains a transmembrane domain
20 and a cytoplasmic region in the carboxyl terminal region of the polypeptide. Thus, in a secreted, soluble version of Don-1, the carboxyl terminal domain of the molecule, including the transmembrane domain, is ordinarily deleted. This truncated form of the Don-1 polypeptide
25 may be secreted from the cell, provided that the DNA encoding the truncated variant encodes a signal sequence recognized by the host.

Don-1 polypeptides can be expressed directly or as a fusion with a heterologous polypeptide, such as a
30 signal sequence or other polypeptide having a specific cleavage site at the N-and/or C-terminus of the mature protein or polypeptide. Included within the scope of this invention are Don-1 polypeptides with the native signal sequence deleted and replaced with a heterologous
35 signal sequence. The heterologous signal sequence

- 35 -

selected should be one that is recognized and processed, i.e., cleaved by a signal peptidase, by the host cell. For prokaryotic host cells that do not recognize and process the native Don-1 signal sequence, the signal
5 sequence is substituted by a prokaryotic signal sequence selected, for example, from the group of the alkaline phosphatase, penicillinase, lpp, or heat-stable enterotoxin II leaders. For yeast secretion the native Don-1 signal sequence may be substituted by the yeast
10 invertase, alpha factor, or acid phosphatase leaders. In mammalian cell expression the native signal sequence is satisfactory, although other mammalian signal sequences may be suitable.

A host cell may be chosen which modulates the
15 expression of the inserted sequences, or modifies and processes the gene product in a specific, desired fashion. Such modifications (e.g., glycosylation) and processing (e.g., cleavage) of protein products may be important for the function of the protein. Different
20 host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein
25 expressed. To this end, eukaryotic host cells that possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product can be used. Such mammalian host cells include, but are not limited to,
30 CHO, VERO, BHK, HeLa, COS, MDCK, 293, 3T3, WI38, and in particular, choroid plexus cell lines.

Alternatively, a Don-1 protein can be produced by a stably-transfected mammalian cell line. A number of vectors suitable for stable transfection of mammalian
35 cells are available to the public, see, e.g., Pouwels et

- 36 -

al. (supra); methods for constructing such cell lines are also publicly available, e.g., in Ausubel et al. (supra). In one example, cDNA encoding the Don-1 protein is cloned into an expression vector that includes the dihydrofolate reductase (DHFR) gene. Integration of the plasmid and, therefore, the Don-1 protein-encoding gene into the host cell chromosome is selected for by including 0.01-300 μ M methotrexate in the cell culture medium (as described in Ausubel et al., supra). This dominant selection can be accomplished in most cell types.

Recombinant protein expression can be increased by DHFR-mediated amplification of the transfected gene. Methods for selecting cell lines bearing gene amplifications are described in Ausubel et al. (supra); such methods generally involve extended culture in medium containing gradually increasing levels of methotrexate. DHFR-containing expression vectors commonly used for this purpose include pCVSEII-DHFR and pAdD26SV(A) (described in Ausubel et al., supra). Any of the host cells described above or, preferably, a DHFR-deficient CHO cell line (e.g., CHO DHFR⁻cells, ATCC Accession No. CRL 9096) are among the host cells preferred for DHFR selection of a stably-transfected cell line or DHFR-mediated gene amplification.

A number of other selection systems can be used, including but not limited to the herpes simplex virus thymidine kinase, hypoxanthine-guanine phosphoribosyltransferase, and adenine phosphoribosyltransferase genes can be employed in *tk*, *hgp**rt*, or *aprt* cells, respectively. In addition, *gpt*, which confers resistance to mycophenolic acid (Mulligan et al., *Proc. Natl. Acad. Sci. USA*, **78**:2072, 1981); *neo*, which confers resistance to the aminoglycoside G-418 (Colberre-Garapin et al., *J. Mol. Biol.*, **150**:1, 1981); and *hygro*, which confers

- 37 -

resistance to hygromycin (Santerre et al., *Gene*, **30**:147, 1981), can be used.

Alternatively, any fusion protein can be readily purified by utilizing an antibody specific for the fusion protein being expressed. For example, a system described in Janknecht et al., *Proc. Natl. Acad. Sci. USA*, **88**:8972 (1981), allows for the ready purification of non-denatured fusion proteins expressed in human cell lines. In this system, the gene of interest is subcloned into a vaccinia recombination plasmid such that the gene's open reading frame is translationally fused to an amino-terminal tag consisting of six histidine residues. Extracts from cells infected with recombinant vaccinia virus are loaded onto Ni²⁺ nitriloacetic acid-agarose columns, and histidine-tagged proteins are selectively eluted with imidazole-containing buffers.

Alternatively, Don-1 or a portion thereof, can be fused to an immunoglobulin Fc domain. Such a fusion protein can be readily purified using a protein A column. Moreover, such fusion proteins permit the production of a dimeric form of a Don-1 polypeptide having increased stability *in vivo*.

Don-1 proteins and polypeptides can also be expressed in transgenic animals. Animals of any species, including, but not limited to, mice, rats, rabbits, guinea pigs, pigs, micro-pigs, goats, and non-human primates, e.g., baboons, monkeys, and chimpanzees, can be used to generate Don-1-expressing transgenic animals. Various known techniques can be used to introduce a *don-1* transgene into animals to produce the founder lines of transgenic animals. Such techniques include, but are not limited to, pronuclear microinjection (U.S. Pat. No. 4,873,191); retrovirus mediated gene transfer into germ lines (Van der Putten et al., *Proc. Natl. Acad. Sci., USA*, **82**:6148, 1985); gene targeting into embryonic stem

- 38 -

cells (Thompson et al., *Cell*, 56:313, 1989); and electroporation of embryos (Lo, *Mol. Cell. Biol.*, 3:1803, 1983).

The present invention provides for transgenic
5 animals that carry the *don-1* transgene in all their cells, as well as animals that carry the transgene in some, but not all of their cells, i.e., mosaic animals. The transgene can be integrated as a single transgene or in concatamers, e.g., head-to-head tandems or head-to-
10 tail tandems. The transgene can also be selectively introduced into and activated in a particular cell type (Lasko et al., *Proc. Natl. Acad. Sci. USA*, 89:6232, 1992). The regulatory sequences required for such a cell-type specific activation will depend upon the
15 particular cell type of interest, and will be apparent to those of skill in the art.

When it is desired that the *don-1* transgene be integrated into the chromosomal site of the endogenous *don-1* gene, gene targeting is preferred. Briefly, when
20 such a technique is to be used, vectors containing some nucleotide sequences homologous to an endogenous *don-1* gene are designed for the purpose of integrating, via homologous recombination with chromosomal sequences, into and disrupting the function of the nucleotide sequence of
25 the endogenous gene. The transgene also can be selectively introduced into a particular cell type, thus inactivating the endogenous *don-1* gene in only that cell type (Gu et al., *Science*, 265:103, 1984). The regulatory sequences required for such a cell-type specific
30 inactivation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art.

Once transgenic animals have been generated, the expression of the recombinant *don-1* gene can be assayed
35 utilizing standard techniques. Initial screening may be

- 39 -

accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to assay whether integration of the transgene has taken place. The level of mRNA expression of the transgene in the tissues of the
5 transgenic animals may also be assessed using techniques which include, but are not limited to, Northern blot analysis of tissue samples obtained from the animal, *in situ* hybridization analysis, and RT-PCR. Samples of don-1 gene-expressing tissue, also can be evaluated
10 immunocytochemically using antibodies specific for the Don-1 transgene product.

Once the recombinant Don-1 protein is expressed, it is isolated. Secreted forms can be isolated from the culture media, while non-secreted forms must be isolated
15 from the host cells. Proteins can be isolated by affinity chromatography. In one example, an anti-Don-1 protein antibody (e.g., produced as described herein) is attached to a column and used to isolate the Don-1 protein. Lysis and fractionation of Don-1 protein-
20 harboring cells prior to affinity chromatography can be performed by standard methods (see, e.g., Ausubel et al., supra). Alternatively, a Don-1 fusion protein, for example, a Don-1-maltose binding protein, a Don-1- β -galactosidase, or a Don-1-trpE fusion protein, can be
25 constructed and used for Don-1 protein isolation (see, e.g., Ausubel et al., supra; New England Biolabs, Beverly, MA).

Once isolated, the recombinant protein can, if desired, be further purified, e.g., by high performance
30 liquid chromatography using standard techniques (see, e.g., Fisher, *Laboratory Techniques In Biochemistry And Molecular Biology*, eds., Work and Burdon, Elsevier, 1980).

Given the amino acid sequences described herein,
35 polypeptides of the invention, particularly short Don-1

- 40 -

polypeptides, can be produced by standard chemical synthesis (e.g., by the methods described in *Solid Phase Peptide Synthesis*, 2nd ed., The Pierce Chemical Co., Rockford, IL, 1984).

5 These general techniques of polypeptide expression and purification can also be used to produce and isolate useful Don-1 polypeptide analogs (described herein).

 The invention also features proteins which interact with Don-1 and are involved in the function of
10 Don-1. Also included in the invention are the genes encoding these interacting proteins. Interacting proteins can be identified using methods known to those skilled in the art. One suitable method is the "two-hybrid system," which detects protein interactions in
15 *vivo* (Chien et al., *Proc. Natl. Acad. Sci. USA*, **88**:9578, 1991). A kit for practicing this method is available from Clontech (Palo Alto, CA).

Anti-Don-1 Antibodies

 Human Don-1 proteins and polypeptides (or
20 immunogenic fragments or analogs) can be used to raise antibodies useful in the invention, and such polypeptides can be produced by recombinant or peptide synthetic techniques (see, e.g., *Solid Phase Peptide Synthesis*, supra; Ausubel et al., supra). In general, the peptides
25 can be coupled to a carrier protein, such as KLH, as described in Ausubel et al., supra, mixed with an adjuvant, and injected into a host mammal. Antibodies can be purified by peptide antigen affinity chromatography.

30 In particular, various host animals can be immunized by injection with a Don-1 protein or polypeptide. Host animals include rabbits, mice, guinea pigs, and rats. Various adjuvants can be used to increase the immunological response, depending on the

- 41 -

host species, including but not limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil
5 emulsions, keyhole limpet hemocyanin, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and *Corynebacterium parvum*. Polyclonal antibodies are heterogeneous populations of antibody molecules derived from the sera of the immunized animals.

10 Antibodies within the invention include monoclonal antibodies, polyclonal antibodies, humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab')₂ fragments, and molecules produced using a Fab expression library.

15 Monoclonal antibodies, which are homogeneous populations of antibodies to a particular antigen, can be prepared using the Don-1 proteins described above and standard hybridoma technology (see, e.g., Kohler et al., *Nature*, 256:495, 1975; Kohler et al., *Eur. J. Immunol.*,
20 6:511, 1976; Kohler et al., *Eur. J. Immunol.*, 6:292, 1976; Hammerling et al., In Monoclonal Antibodies and T Cell Hybridomas, Elsevier, NY, 1981; Ausubel et al., supra).

 In particular, monoclonal antibodies can be
25 obtained by any technique that provides for the production of antibody molecules by continuous cell lines in culture such as described in Kohler et al., *Nature*, 256:495, 1975, and U.S. Patent No. 4,376,110; the human B-cell hybridoma technique (Kosbor et al., *Immunology Today*, 4:72, 1983; Cole et al., *Proc. Natl. Acad. Sci. USA*, 80:2026, 1983), and the EBV-hybridoma technique (Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96, 1983). Such antibodies
30 can be of any immunoglobulin class including IgG, IgM, IgE, IgA, IgD, and any subclass thereof. The hybridoma

- 42 -

producing the mAb of this invention can be cultivated *in vitro* or *in vivo*. The ability to produce high titers of mAbs *in vivo* makes this the presently preferred method of production.

5 Once produced, polyclonal or monoclonal antibodies are tested for specific Don-1 recognition by Western blot or immunoprecipitation analysis by standard methods, e.g., as described in Ausubel et al., supra. Antibodies that specifically recognize and bind to Don-1 are useful
10 in the invention. For example, such antibodies can be used in an immunoassay to monitor the level of Don-1 produced by a mammal (for example, to determine the amount or subcellular location of Don-1).

Preferably, antibodies of the invention are
15 produced using fragments of the Don-1 protein which lie outside highly conserved regions and appear likely to be antigenic, by criteria such as high frequency of charged residues. In one specific example, such fragments are generated by standard techniques of PCR, and are then
20 cloned into the pGEX expression vector (Ausubel et al., supra). Fusion proteins are expressed in *E. coli* and purified using a glutathione agarose affinity matrix as described in Ausubel, et al., supra.

Antibodies can also be prepared to bind
25 specifically to one or more particular domains of Don-1, such as the EGF domain (SEQ ID NO:11), by immunizing an animal with a polypeptide corresponding to only the desired domain or domains.

In some cases it may be desirable to minimize the
30 potential problems of low affinity or specificity of antisera. In such circumstances, two or three fusions can be generated for each protein, and each fusion can be injected into at least two rabbits. Antisera can be raised by injections in a series, preferably including at
35 least three booster injections.

- 43 -

Antisera is also checked for its ability to immunoprecipitate recombinant Don-1 proteins or control proteins, such as glucocorticoid receptor, CAT, or luciferase.

5 The antibodies can be used, for example, in the detection of the Don-1 in a biological sample as part of a diagnostic assay. Antibodies also can be used in a screening assay to measure the effect of a candidate compound on expression or localization of Don-1.
10 Additionally, such antibodies can be used in conjunction with the gene therapy techniques described to, for example, evaluate the normal and/or engineered Don-1-expressing cells prior to their introduction into the patient. Such antibodies additionally can be used in a
15 method for inhibiting abnormal Don-1 activity.

Techniques developed for the production of "chimeric antibodies" (Morrison et al., *Proc. Natl. Acad. Sci.*, **81**:6851, 1984; Neuberger et al., *Nature*, **312**:604, 1984; Takeda et al., *Nature*, **314**:452, 1984) can be used
20 to splice the genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity. A chimeric antibody is a molecule in which different portions are derived from different animal
25 species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region.

Alternatively, techniques described for the production of single chain antibodies (U.S. Patent
30 4,946,778; and U.S. Patents 4,946,778 and 4,704,692) can be adapted to produce single chain antibodies against a Don-1 protein or polypeptide. Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a
35 single chain polypeptide.

- 44 -

Antibody fragments that recognize and bind to specific epitopes can be generated by known techniques. For example, such fragments can include but are not limited to $F(ab')_2$ fragments, which can be produced by
5 pepsin digestion of the antibody molecule, and Fab fragments, which can be generated by reducing the disulfide bridges of $F(ab')_2$ fragments. Alternatively, Fab expression libraries can be constructed (Huse et al., *Science*, **246**:1275, 1989) to allow rapid and easy
10 identification of monoclonal Fab fragments with the desired specificity.

Antibodies to Don-1 can, in turn, be used to generate anti-idiotypic antibodies that resemble a portion of Don-1, using techniques well known to those skilled in
15 the art (see, e.g., Greenspan et al., *FASEB J.*, **7**:437, 1993; Nissinoff, *J. Immunol.*, **147**:2429, 1991). For example, antibodies that bind to Don-1 and competitively inhibit the binding of a ligand of Don-1 can be used to generate anti-idiotypes that resemble a ligand binding
20 domain of Don-1 and, therefore, bind and neutralize a ligand of Don-1. Such neutralizing anti-idiotypic antibodies or Fab fragments of such anti-idiotypic antibodies can be used in therapeutic regimens.

In addition, antibodies can be expressed within an
25 intracellular compartment of a cell, such as the endoplasmic reticulum, to specifically bind to a target protein or polypeptide within the cell. Such specific binding can be used to alter, e.g., inhibit, the function of the target protein. Intracellular expression of
30 antibodies is achieved by introducing into the cells nucleic acids that encode the antibodies, e.g., by using a recombinant viral vector or other vector system suitable for delivering a gene to a cell *in vivo*.

Preferably the antibody is a single chain Fv
35 fragment, although whole antibodies, or antigen binding

- 45 -

fragments thereof, e.g., Fab fragments, can be used. Targeting of an antibody to an intracellular compartment can be accomplished by incorporating an appropriate signal sequence into the antibody. For example, a
5 nucleic acid can be designed to include a first nucleotide sequence encoding a signal sequence (e.g., to an endoplasmic reticulum), operatively linked in a 5' to 3' direction by a phosphodiester bond to a second nucleotide sequence encoding a single chain Fv fragment
10 that binds to a Don-1 polypeptide. These techniques are described in detail in Curiel et al., PCT Publication No. WO 96/07321.

Modulating Don-1 Expression

Don-1 polypeptides can be administered to
15 stimulate the proliferation of cells, such as epithelial cells, e.g., to promote wound healing. Other therapies, e.g., anti-tumor therapies, can be designed to reduce the level of endogenous Don-1 gene expression, e.g., using antisense or ribozyme approaches to inhibit or prevent
20 translation of Don-1 mRNA transcripts; triple helix approaches to inhibit transcription of the Don-1 gene; or targeted homologous recombination to inactivate or "knock out" the Don-1 gene or its endogenous promoter.

Because the Don-1 gene is expressed in the brain,
25 delivery techniques should be preferably designed to cross the blood-brain barrier (see, e.g., PCT Publication No. WO89/10134). Alternatively, the antisense, ribozyme, or DNA constructs described herein could be administered directly to the site containing the target cells; e.g.,
30 brain, kidney, lung, uterus, endothelial and epithelial cells, fibroblasts, and breast and prostate cells.

Antisense Nucleic Acids

Antisense approaches involve the design of oligonucleotides (either DNA or RNA) that are

- 46 -

complementary to Don-1 mRNA. The antisense oligonucleotides bind to the complementary Don-1 mRNA transcripts and prevent translation. Absolute complementarity, although preferred, is not required. A
5 sequence "complementary" to a portion of an RNA, as referred to herein, means a sequence having sufficient complementarity to be able to hybridize with the RNA and form a stable duplex; in the case of double-stranded antisense nucleic acids, a single strand of the duplex
10 DNA can be tested, or triplex formation can be assayed. The ability to hybridize will depend on both the degree of complementarity and the length of the antisense nucleic acid. Generally, the longer the hybridizing nucleic acid, the more base mismatches with an RNA it may
15 contain and still form a stable duplex (or triplex, as the case may be). One skilled in the art can ascertain a tolerable degree of mismatch by use of standard procedures to determine the melting point of the hybridized complex.

20 Oligonucleotides that are complementary to the 5' end of the message, e.g., the 5' untranslated sequence up to and including the AUG initiation codon, should work most efficiently at inhibiting translation. However, sequences complementary to the 3' untranslated sequences
25 of mRNAs have been shown to be effective at inhibiting translation of mRNAs as well (Wagner, *Nature*, 372:333, 1984). Thus, oligonucleotides complementary to either the 5'- or 3'- non-translated, non-coding regions of the *don-1* gene, e.g., the human gene, as represented by the
30 cDNA (SEQ ID NO:5) shown in Fig. 3, can be used in an antisense approach to inhibit translation of endogenous Don-1 mRNA. Oligonucleotides complementary to the 5' untranslated region of the mRNA should include the complement of the AUG start codon.

- 47 -

Antisense oligonucleotides complementary to mRNA coding regions are less efficient inhibitors of translation but could be used in accordance with the invention. Whether designed to hybridize to the 5'-, 3'-
5 , or coding region of Don-1 mRNA, antisense nucleic acids should be at least six nucleotides in length, and are preferably oligonucleotides ranging from 6 to about 50 nucleotides in length. In specific aspects the oligonucleotide is at least 10 nucleotides, at least 17
10 nucleotides, at least 25 nucleotides or at least 50 nucleotides.

Regardless of the choice of target sequence, it is preferred that *in vitro* studies are first performed to quantitate the ability of the antisense oligonucleotide
15 to inhibit gene expression.

It is preferred that these studies utilize controls that distinguish between antisense gene inhibition and nonspecific biological effects of oligonucleotides. It is also preferred that these
20 studies compare levels of the target RNA or protein with that of an internal control RNA or protein. Additionally, it is envisioned that results obtained using the antisense oligonucleotide are compared with those obtained using a control oligonucleotide. It is
25 preferred that the control oligonucleotide is of approximately the same length as the test oligonucleotide and that the nucleotide sequence of the oligonucleotide differs from the antisense sequence no more than is necessary to prevent specific hybridization to the target
30 sequence.

The oligonucleotides can be DNA or RNA, or chimeric mixtures, or derivatives or modified versions thereof, and can be single-stranded or double-stranded. The oligonucleotides can be modified at the base moiety,
35 sugar moiety, or phosphate backbone, for example, to

- 48 -

improve stability of the molecule, hybridization, etc. The oligonucleotide may include other appended groups such as peptides (e.g., for targeting host cell receptors *in vivo*), or agents facilitating transport across the
5 cell membrane (as described, e.g., in Letsinger et al., *Proc. Natl. Acad. Sci. USA*, **86**:6553, 1989; Lemaitre et al., *Proc. Natl. Acad. Sci. USA*, **84**:648, 1987; PCT Publication No. WO 88/09810) or the blood-brain barrier (see, e.g., PCT Publication No. WO 89/10134), or
10 hybridization-triggered cleavage agents (see, e.g., Krol et al., *BioTechniques*, **6**:958, 1988), or intercalating agents (see, e.g., Zon, *Pharm. Res.*, **5**:539, 1988). To this end, the oligonucleotide can be conjugated to
15 another molecule, e.g., a peptide, hybridization triggered cross-linking agent, transport agent, or hybridization-triggered cleavage agent.

The antisense oligonucleotide can include at least one modified base moiety selected from the group including, but not limited to, 5-fluorouracil, 5-
20 bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xantine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethyl-aminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-
25 methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-
30 methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-theouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid
35 methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-

- 49 -

thiouracil, 2-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine.

The antisense oligonucleotide can also include at least one modified sugar moiety selected from the group including, but not limited to, arabinose, 2-fluoroarabinose, xylulose, and hexose.

In yet another embodiment, the antisense oligonucleotide includes at least one modified phosphate backbone, e.g., a phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl phosphotriester, and a formacetal, or an analog of any of these backbones.

In addition, the antisense oligonucleotide can be an α -anomeric oligonucleotide that forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual β -units, the strands run parallel to each other (Gautier et al., *Nucl. Acids. Res.*, **15**:6625, 1987). The oligonucleotide can be a 2'-O-methylribonucleotide (Inoue et al., *Nucl. Acids Res.*, **15**:6131, 1987), or a chimeric RNA-DNA analog (Inoue et al., *FEBS Lett.*, **215**:327, 1987).

Antisense oligonucleotides of the invention can be synthesized by standard methods known in the art, e.g., by use of an automated DNA synthesizer (such as are commercially available from Biosearch, Applied Biosystems, etc.). As examples, phosphorothioate oligonucleotides can be synthesized by the method of Stein et al., *Nucl. Acids Res.*, **16**:3209, 1988, and methylphosphonate oligonucleotides can be prepared by use of controlled pore glass polymer supports (Sarin et al., *Proc. Natl. Acad. Sci. USA*, **85**:7448, 1988).

While antisense nucleotides complementary to the Don-1 coding region sequence could be used, those

- 50 -

complementary to the transcribed untranslated region are most preferred.

One example of a 15 nucleotide antisense sequence to the human *don-1* gene is directed against the EGF domain: 5'-GACTTGGCTCTCTCG-3' (SEQ ID NO:22). Another example of a 15 nucleotide antisense sequence to the human *don-1* gene is: 5'-GGACTCCGACCATTCT-3' (SEQ ID NO:23), where the underlined sequence represents the complement of the initiator methionine codon.

The antisense molecules should be delivered to cells that express Don-1 *in vivo*, e.g., brain, kidney, lung, uterus, endothelial and epithelial cells, fibroblasts, and breast and prostate cells. A number of methods have been developed for delivering antisense DNA or RNA to cells; e.g., antisense molecules can be injected directly into the tissue site, or modified antisense molecules, designed to target the desired cells (e.g., antisense linked to peptides or antibodies that specifically bind receptors or antigens expressed on the target cell surface) can be administered systemically.

However, it is often difficult to achieve intracellular concentrations of the antisense molecules sufficient to suppress translation of endogenous mRNAs. Therefore, a preferred approach uses a recombinant DNA construct in which the antisense oligonucleotide is placed under the control of a strong *pol* III or *pol* II promoter. The use of such a construct to transfect target cells in the patient will result in the transcription of sufficient amounts of single stranded RNAs that will form complementary base pairs with the endogenous Don-1 transcripts and thereby prevent translation of the Don-1 mRNA. For example, a vector can be introduced *in vivo* such that it is taken up by a cell and directs the transcription of an antisense RNA. Such a vector can remain episomal or become chromosomally

- 51 -

integrated, as long as it can be transcribed to produce the desired antisense RNA.

Such vectors can be constructed by recombinant DNA technology methods standard in the art. Vectors can be
5 plasmid, viral, or others known in the art, used for replication and expression in mammalian cells. Expression of the sequence encoding the antisense RNA can be by any promoter known in the art to act in mammalian, preferably human, cells. Such promoters can be inducible
10 or constitutive. Such promoters include, but are not limited to: the SV40 early promoter region (Bernoist et al., *Nature*, 290:304, 1981); the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto et al., *Cell*, 22:787-797, 1988); the herpes
15 thymidine kinase promoter (Wagner et al., *Proc. Natl. Acad. Sci. USA*, 78:1441, 1981); or the regulatory sequences of the metallothionein gene (Brinster et al., *Nature*, 296:39, 1988).

Any type of plasmid, cosmid, YAC, or viral vector
20 can be used to prepare the recombinant DNA construct which can be introduced directly into the tissue site; e.g., the brain, kidney, lung, uterus, endothelial and epithelial cells, fibroblasts, and breast and prostate cells. Alternatively, viral vectors can be used that
25 selectively infect the desired tissue (e.g., for brain, herpesvirus vectors may be used), in which case administration can be accomplished by another route (e.g., systemically).

Ribozymes

30 Ribozyme molecules designed to catalytically cleave Don-1 mRNA transcripts also can be used to prevent translation of Don-1 mRNA and expression of Don-1 (see, e.g., PCT Publication WO 90/11364; Saraver et al., *Science*, 247:1222, 1990). While various ribozymes that
35 cleave mRNA at site-specific recognition sequences can be

- 52 -

used to destroy Don-1 mRNAs, the use of hammerhead ribozymes is preferred. Hammerhead ribozymes cleave mRNAs at locations dictated by flanking regions that form complementary base pairs with the target mRNA. The sole
5 requirement is that the target mRNA have the following sequence of two bases: 5'-UG-3'. The construction and production of hammerhead ribozymes is known in the art (Haseloff et al., *Nature*, 334:585, 1988). There are numerous examples of potential hammerhead ribozyme
10 cleavage sites within the nucleotide sequence of human Don-1 cDNAs (Figs. 2 and 4). Preferably, the ribozyme is engineered so that the cleavage recognition site is located near the 5' end of the Don-1 mRNA, i.e., to increase efficiency and minimize the intracellular
15 accumulation of non-functional mRNA transcripts.

Examples of potential ribozyme sites in human Don-1 include 5'-UG-3' sites which correspond to the initiator methionine codon (nucleotides 664-666 in human SEQ ID NO:5 and 69-71 in human SEQ ID NOS:7 and 31) and
20 the codons for each of the cysteine residues of the EGF domain (e.g., nucleotides 493-494, 517-519, 535-537, 568-570, 574-576, and 601-603 in human SEQ ID NOS:7 and 31, and nucleotides 973-975, 997-999, 1015-1017, 1048-1050, 1054-1056, and 1081-1083 in human SEQ ID NO:5).

25 The ribozymes of the present invention also include RNA endoribonucleases (hereinafter "Cech-type ribozymes"), such as the one that occurs naturally in *Tetrahymena Thermophila* (known as the IVS or L-19 IVS RNA), and which has been extensively described by Cech
30 and his collaborators (Zaug et al., *Science*, 224:574, 1984; Zaug et al., *Science*, 231:470, 1986; Zug et al., *Nature*, 324:429, 1986; PCT Application No. WO 88/04300; and Been et al., *Cell*, 47:207, 1986). The Cech-type ribozymes have an eight base-pair sequence that
35 hybridizes to a target RNA sequence, whereafter cleavage

- 53 -

of the target RNA takes place. The invention encompasses those Cech-type ribozymes that target eight base-pair active site sequences present in Don-1 polypeptides.

As in the antisense approach, the ribozymes can be composed of modified oligonucleotides (e.g., for improved stability, targeting, etc.), and should be delivered to cells which express the Don-1 *in vivo*, e.g., brain, kidney, lung, uterus, endothelial and epithelial cells, fibroblasts, and breast and prostate cells. A preferred method of delivery involves using a DNA construct "encoding" the ribozyme under the control of a strong constitutive *pol* III or *pol* II promoter, so that transfected cells will produce sufficient quantities of the ribozyme to destroy endogenous Don-1 messages and inhibit translation. Because ribozymes, unlike antisense molecules, are catalytic, a lower intracellular concentration is required for efficiency.

Other Methods for Reducing Don-1 Expression

Endogenous *don-1* gene expression can also be reduced by inactivating or "knocking out" the *don-1* gene or its promoter using targeted homologous recombination (see, e.g., U.S. Patent No. 5,464,764). For example, a mutant, non-functional *don-1* (or a completely unrelated DNA sequence) flanked by DNA homologous to the endogenous *don-1* gene (either the coding regions or regulatory regions of the *don-1* gene) can be used, with or without a selectable marker and/or a negative selectable marker, to transfect cells that express Don-1 *in vivo*. Insertion of the DNA construct, via targeted homologous recombination, results in inactivation of the *don-1* gene. Such approaches are particularly suited for use in the agricultural field where modifications to ES (embryonic stem) cells can be used to generate animal offspring with an inactive *don-1* gene. This approach can be adapted for use in humans, provided the recombinant DNA constructs

- 54 -

are directly administered or targeted to the required site *in vivo* using appropriate viral vectors, e.g., herpes virus vectors for delivery to brain tissue.

Alternatively, endogenous *don-1* gene expression
5 can be reduced by targeting deoxyribonucleotide sequences complementary to the regulatory region of the *don-1* gene (i.e., *don-1* promoters and/or enhancers located upstream to the start codon in the untranslated region) to form triple helical structures that prevent transcription of
10 the *don-1* gene in target cells in the body (Helene, *Anticancer Drug Des.*, 6:569, 1981; Helene et al., *Ann. N.Y. Acad. Sci.*, 660:27, 1992; and Maher, *Bioassays*, 14:807, 1992).

Identification of Proteins That Interact With Don-1

15 The invention also features proteins that interact with Don-1 polypeptides. Any method suitable for detecting protein-protein interactions can be employed to identify transmembrane, intracellular, or extracellular proteins that interact with Don-1 polypeptides. Among
20 the traditional methods which can be employed are co-immunoprecipitation, crosslinking and co-purification through gradients or chromatographic columns of cell lysates or proteins obtained from cell lysates, and the use of Don-1 polypeptides to identify proteins in the
25 lysate that interact with the Don-1 polypeptide.

For these assays, the Don-1 polypeptide can be a full length Don-1, a soluble extracellular domain of Don-1, or some other suitable Don-1 polypeptide, e.g., a polypeptide including the EGF domain of Don-1. Once
30 isolated, such an interacting protein can be identified and cloned and then used, in conjunction with standard techniques, to identify proteins with which it interacts. For example, at least a portion of the amino acid sequence of a protein which interacts with a Don-1

- 55 -

polypeptide can be ascertained using techniques well known to those of skill in the art, such as via the Edman degradation technique. The amino acid sequence obtained can be used as a guide to generate oligonucleotide mixtures that can be used to screen for gene sequences encoding the interacting protein. Screening can be accomplished, for example, by standard hybridization or PCR techniques. Techniques for generating oligonucleotide mixtures and the screening are known.

10 See, e.g., Ausubel, *supra*; and PCR Protocols: A Guide to Methods and Applications, 1990, Innis et al., eds. Academic Press, Inc., New York.

Additionally, methods may be employed which result in the direct identification of genes that encode proteins that interact with Don-1 polypeptides. These methods include, for example, screening expression libraries, in a manner similar to the well known technique of antibody probing of λ gt11 libraries, using a labeled Don-1 polypeptide or a Don-1 fusion protein, e.g., a Don-1 domain fused to a marker such as an enzyme, fluorescent dye, a luminescent protein, or to an IgFc domain.

There are also methods for detecting protein interactions, e.g., the *in vivo* two-hybrid system (Chien et al., *Proc. Natl. Acad. Sci. USA*, **88**:9578, 1991). A kit for practicing this method is available from Clontech (Palo Alto, CA). Briefly, to use this system, plasmids are constructed that encode two hybrid proteins. One plasmid includes a nucleotide sequence encoding the DNA-binding domain of a transcription activator protein fused to a nucleotide sequence encoding a full-length Don-1 protein, a Don-1 polypeptide, or a Don-1 fusion protein. The other plasmid includes a nucleotide sequence encoding the transcription activator protein's activation domain fused to a cDNA encoding an unknown protein from which a

- 56 -

cDNA library has been recombined into this plasmid. The DNA-binding domain fusion plasmid and the cDNA library are transformed into a strain of the yeast *Saccharomyces cerevisiae* that contains a reporter gene (e.g., HBS or
5 lacZ) whose regulatory region contains the transcription activator's binding site.

Either hybrid protein alone cannot activate transcription of the reporter gene. The DNA-binding domain hybrid cannot because it does not provide
10 activation function, and the activation domain hybrid cannot because it cannot localize to the activator's binding sites. Interaction of the appropriate two hybrid proteins reconstitutes the functional activator protein and results in expression of the reporter gene, which is
15 detected by an assay for the reporter gene product.

The two-hybrid system and related methods can be used to screen activation domain libraries for proteins that interact with a "bait" gene product. By way of example, a Don-1 polypeptide can be used as the bait gene
20 product. Total genomic or cDNA sequences are fused to DNA encoding an activation domain. This library and a plasmid encoding a hybrid of bait Don-1 gene product fused to the DNA-binding domain are cotransformed into a yeast reporter strain, and the resulting transformants
25 are screened for those that express the reporter gene. For example, a bait *don-1* gene sequence encoding a Don-1 polypeptide, or a domain of Don-1, can be cloned into a vector such that it is translationally fused to DNA encoding the DNA-binding domain of the GAL4 protein.
30 These colonies are purified and the library plasmids responsible for reporter gene expression are isolated. DNA sequencing is then used to identify the proteins encoded by the library plasmids.

A cDNA library of the cell line from which
35 proteins that interact with bait *don-1* gene product are

- 57 -

to be detected can be made using methods routinely practiced in the art. According to the particular system described herein, for example, cDNA fragments can be inserted into a vector such that they are translationally fused to the transcriptional activation domain of GAL4. This library can be co-transformed along with the bait *don-1* gene-GAL4 fusion plasmid into a yeast strain which contains a lacZ gene driven by a promoter that contains a GAL4 activation sequence. A cDNA encoded protein, fused to GAL4 transcriptional activation domain, that interacts with bait *don-1* gene product will reconstitute an active GAL4 protein and thereby drive expression of the HIS3 gene. Colonies that express HIS3 then can be purified from these strains, and used to produce and isolate the bait *don-1* gene-interacting protein using techniques routinely practiced in the art.

Therapeutic Applications

The Don-1 proteins and polypeptides described herein stimulate proliferation of epithelial cells and are thus particularly implicated in melanomas and adenocarcinomas in which epithelial cells proliferate out of control. Accordingly, undesirable tumors, such as melanomas and adenocarcinomas of the skin, esophagus, lung, breast, liver, pancreas, gastrointestinal tract, colon, prostate, and uterus can be reduced by the administration of a compound that interferes with Don-1 expression or function (e.g., an antibody). Compounds that interfere with Don-1 function can also be used to treat other undesirable disease processes, e.g., cyst and polyp formation.

In addition, since Don-1 polypeptides promote or stimulate epithelial cell proliferation, the topical administration of Don-1 polypeptides to wounds promotes wound healing.

- 58 -

Because Don-1 is highly expressed in the brain, Don-1 also may play a significant role regulating tumor formation and progression in the brain. Of course, in some circumstances, including certain phases of many of the above-described conditions, it may be desirable to enhance Don-1 function, e.g., to stimulate cell proliferation or differentiation, or enhance or suppress apoptosis.

Recombinant Don-1 should facilitate the production of pharmacologic modifiers and inhibitors of Don-1 function. Compounds that interfere with Don-1 function include molecules that bind to Don-1, such as antibodies, and prevent it from binding with its receptors, e.g., p185, or small molecules or anti-idiotypic antibodies, that mimic certain domains of Don-1, such as the EGF domain, and bind, preferably irreversibly, to Don-1 receptors without activating these receptors, e.g., without causing phosphorylation or dimerization of these receptors. For example, using standard techniques, a Don-1 EGF polypeptide can be mutated and tested in the p185 assay described herein. Any of these mutant polypeptides that bind to the receptor with high affinity, but do not cause phosphorylation and/or dimerization, are candidates for anti-tumor therapy.

Therapeutic Don-1 polypeptides, antibodies, or small molecules of the invention can be administered by any appropriate route, e.g., injection or infusion by intravenous, intraperitoneal, intracerebral, intramuscular, intraocular, intraarterial, or intralesional routes, or by sustained release systems as note below. Don-1 is administered continuously by infusion or by bolus injection. Don-1 antibodies are administered in the same fashion, or by administration into the blood stream or lymph. Treatment is repeated as necessary for alleviation of disease symptoms.

- 59 -

Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the protein, which matrices are in the form of shaped articles, e.g., films or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (e.g., poly(2-hydroxyethyl-methacrylate) as described by Langer et al., *J. Biomed. Mater. Res.*, **15**:167-277 (1981), and Langer, *Chem. Tech.*, **12**:98-105 (1982), or polyvinylalcohol), or polylactides (as described in U.S. Pat. No. 3,773,919, and EPA 58,481).

Sustained-release Don-1 polypeptide or antibody compositions also include liposomally entrapped Don-1 or Don-1 antibodies. Liposomes containing Don-1 or antibody are prepared by methods known per se. See, e.g., Epstein et al., P.N.A.S., USA, **82**:3688-3692 (1985); Hwang et al., P.N.A.S., USA, **77**:4030-4034 (1980); and U.S. Pat. Nos. 4,485,045 and 4,544,545. The liposomes are preferably about 200-800 Angstroms in diameter and are unilamellar. The lipid content is generally greater than about 30 mol. percent cholesterol, the selected proportion being adjusted for the optimal Don-1 therapy. Liposomes with enhanced circulation time are disclosed in U.S. Pat. No. 5,013,556.

An effective amount of Don-1 or Don-1 antibody to be employed therapeutically will depend, for example, upon the therapeutic objectives, the route of administration, and the condition of the patient. Accordingly, it will be necessary for the therapist to titer the dosage and modify the route of administration as required to obtain the optimal therapeutic effect. A typical daily dosage might range from about 1.0 μ g/kg to about 100 mg/kg or more, depending on the factors mentioned above. Typically, the clinician will administer Don-1 or Don-1 antibody until a dosage is

- 60 -

reached that achieves the desired effect. The progress of this therapy is easily monitored by conventional assays.

Diagnostic Applications

5 The polypeptides of the invention and the antibodies specific for these polypeptides are also useful for identifying those compartments of mammalian cells that contain proteins important to the function of Don-1. Antibodies specific for Don-1 can be produced as
10 described above. The normal subcellular location of the protein is then determined either *in situ* or using fractionated cells by any standard immunological or immunohistochemical procedure (see, e.g., Ausubel et al., supra; Bancroft and Stevens, Theory and Practice of
15 Histological Techniques, Churchill Livingstone, 1982).

 Antibodies specific for Don-1 also can be used to detect or monitor Don-1-related diseases. For example, levels of a Don-1 protein in a sample can be assayed by any standard technique using these antibodies. For
20 example, Don-1 protein expression can be monitored by standard immunological or immunohistochemical procedures (e.g., those described above) using the antibodies described herein. Alternatively, Don-1 expression can be assayed by standard Northern blot analysis or can be
25 aided by PCR (see, e.g., Ausubel et al., supra; PCR Technology: Principles and Applications for DNA Amplification, ed., H.A. Ehrlich, Stockton Press, NY). If desired or necessary, analysis can be carried out to detect point mutations in the Don-1 sequence (for
30 example, using well known nucleic acid mismatch detection techniques). All of the above techniques are enabled by the Don-1 sequences described herein.

- 61 -

Examples

Example 1 describes the identification and sequencing of several cDNAs corresponding to different splice variants of murine and human *don-1* genes. Example 2 describes the characterization of Don-1 using a p185 assay, and differential expression pattern experiments. Example 3 describes chromosomal mapping of the *don-1* gene.

Example 1: Cloning of the *don-1* Gene

10 The gene for murine Don-1 was identified in a mouse choroid plexus cDNA library. The first murine splice variant of the *don-1* gene was used to identify an additional murine splice variant in a mouse lung cDNA library and two splice variants of the human *don-1* gene
15 in a human fetal lung cDNA library. The identification and sequencing of both murine and human genes is described in this first example.

cDNA Library Screening

To obtain a full length cDNA sequence, a mouse
20 lung library (Stratagene, La Jolla, Ca) was screened using the 1.4 kb Not I/Sal I fragment originally isolated from a choroid plexus library as described below. Screening protocols were as described by Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd ed., (Cold
25 Spring Harbor Press, 1989). A homologous human sequence was obtained from a human fetal brain library (Clontech, Palo Alto, Ca) by hybridization with a 1.4 kb NotI/SalI fragment of the murine cDNA of SEQ ID NO:1 as described above.

30 Choroid-Plexus mRNA Isolation

The murine mRNA used to create the murine choroid plexus library was prepared as follows. Total RNA was isolated from mouse choroid plexus tissue using the guanidinium isothiocyanate/CsCl method of Chirgwin et al.

- 62 -

(*Biochemistry* 18:5294, 1979) as described in Current Protocols for Molecular Biology (*supra*). The RNA was quantitated, diluted to 1 mg/ml in water, and then incubated for 30 minutes at 37°C with an equal volume of
5 DNase solution (20 mM MgCl₂, 2 mM DTT, 0.1 units DNase, 0.6 units RNase inhibitor in TE) to remove contaminating DNA. The RNA was then extracted with phenol/chloroform/isoamyl, and ethanol precipitated. After quantitation at 260 nm, an aliquot was
10 electrophoresed to check the integrity of the RNA. Next, Poly A⁺ RNA was isolated using an Oligotex-dT kit from Qiagen (Chatsworth, CA) as described by the manufacturer. After quantitation, the mRNA was precipitated in ethanol and resuspended at a concentration of 1 mg/ml in water.
15 Choroid plexus mRNA was used as a template for preparation of cDNA according to the method of Gubler et al. (*Gene* 25:263, 1983) using a Superscript Plasmid cDNA synthesis kit (Life Technologies; Gaithersburg, MD). The cDNA obtained was ligated into the NotI/Sal I sites of
20 the mammalian expression vector pMET7, a modified version of pME18S, which utilizes the SRa promoter as described previously (Takebe, *Mol. Cell. Bio.* 8:466, 1988). Ligated cDNA was transformed into electrocompetent DH10B *E. coli* either prepared by standard procedures or
25 obtained from Life Technologies.

DNA Preparation and Sequence Analysis

A cDNA clone from the murine choroid plexus library was sequenced to identify sequences of interest. The identified sequence was then used to clone and
30 sequence a second murine splice variant of the *don-1* gene. The identification and analysis is performed as follows.

First, 96-well plates were inoculated with individual choroid plexus library transformants in 1 ml
35 of LB-amp. These inoculations were based on the titers

- 63 -

of the cDNA transformants. The resulting cultures were grown for 15 to 16 hours at 37°C with aeration. Prior to DNA preparation, 100 ml of cell suspension was removed and added to 100 ml of 50% glycerol, mixed and stored at
5 -80°C (glycerol freeze plate). DNA was then prepared using the Wizard miniprep system (Promega; Madison, WI) employing modifications for a 96-well format.

The insert cDNAs of a number of clones were sequenced by standard, automated fluorescent
10 dideoxynucleotide sequencing using dye-primer chemistry (Applied Biosystems, Inc.; Foster City, CA) on Applied Biosystems 373 and 377 sequencers (Applied Biosystems). The primer used in this sequencing was proximal to the SRA promoter of the vector and therefore selective for
15 the 5' end of the clones, although other primers with this selectivity can also be used. The short cDNA sequences obtained in this manner were screened as follows.

First, each sequence was checked to determine if
20 it was a bacterial, ribosomal, or mitochondrial contaminant. Such sequences were excluded from the subsequent analysis. Second, sequence artifacts, such as vector and repetitive elements, were masked and/or removed from each sequence. Third, the remaining
25 sequences were searched against a copy of the GenBank nucleotide database using the BLASTN program (BLASTN 1.3MP: Altschul et al., *J. Mol. Bio.* 215:403, 1990). Fourth, the sequences were analyzed against a non-redundant protein database with the BLASTX program
30 (BLASTX 1.3MP: Altschul et al., *supra*). This protein database is a combination of the Swiss-Prot, PIR, and NCBI GenPept protein databases. The BLASTX program was run using the default BLOSUM-62 substitution matrix with the filter parameter: "xnu+seg". The score cutoff
35 utilized was 75.

- 64 -

Assembly of overlapping clones into contigs was done using the program Sequencher (Gene Codes Corp.; Ann Arbor, MI). The assembled contigs were analyzed using the programs in the GCG package (Genetic Computer Group, University Research Park, 575 Science Drive, Madison, WI 53711).

The above-described analysis resulted in the identification of a secreted, murine clone having an open reading frame of 139 amino acids. The protein encoded by this clone was named "murine Don-1." The amino-terminal portion of murine Don-1 has significant homology to the known heregulin gene. This portion is 41% identical to human heregulin based on a primary sequence alignment of the Ig and EGF domains of murine Don-1 with human heregulin.

This first splice variant of murine Don-1 was used as a probe to obtain an additional murine splice variant.

Splice variants of the human *don-1* gene were isolated in the same way from human fetal brain and fetal lung cDNA libraries (Clontech, Palo Alto, CA).

Example 2: Characterization of Don-1

The function of Don-1 polypeptide in a p185 assay and the expression pattern of Don-1 were examined as described below. Also described below is the expression of a recombinant form of soluble murine Don-1.

p185 Assay

MDA-MB453 cells (ATCC, Rockville, MD) were grown to 80% confluence in DMEM supplemented with 10% FCS in a humidified atmosphere of 5% CO₂ at 37°C. The cells were then replated in serum-free media for 24 hours before being exposed to NDF (100 ng/mL), EGF (100 ng/mL), or transfected 293Ebna-conditioned media (10%) for 15 minutes at 37°C. Cell lysates were prepared by

- 65 -

solubilizing cells in buffer (1% Triton X-100, 0.5% deoxycholate, 150 mM NaCl, 20 mM Tris pH 8.0, 1 mM EDTA, 30 mM $\text{Na}_4\text{P}_2\text{O}_7$, 50 mM NaF, 0.1 mM Na_3VO_4 , 10 $\mu\text{g/mL}$ aprotinin, and 1 mM PMSF), and 100 μg of protein was
5 separated on a 10% SDS PAGE gel. Following transfer to nitrocellulose, immunodetection of phosphorylated proteins was performed using the monoclonal antiphosphotyrosine antibody 4G10 (Upstate Biotechnology, NY) as described by the manufacturer and utilizing
10 Enhanced Chemiluminescence (ECL) (Amersham). NDF and EGF were purchased from R&D Systems (Minneapolis, MN).

Analysis of phosphorylated proteins by Western blotting revealed a robust induction of the 185 kDa protein in cells induced with NDF and in cells treated
15 with Don-1 EGF-transfected 293Ebna cells. The level of induction seen with Don-1 EGF was comparable to saturating amounts of NDF and represented an approximate ten-fold increase in phosphorylation over uninduced cells. No induction of phosphorylation was observed in
20 cells treated with EGF or the conditioned media of mock-transfected 293Ebna cells. This result demonstrates that Don-1 binds and activates a known member of the EGFR family, p185.

Analysis of Don-1 Expression

25 Northern Analysis

Northern analysis was used to examine Don-1 expression as follows. Mouse and human multiple tissue northern blots purchased from Clontech (Palo Alto, Ca) were hybridized, according to manufacturer's directions,
30 to a 1.4 kb Not/Sal fragment of murine Don-1 polypeptide SEQ ID NO:1, or to the 200 base-pair region encoding the EGF domain which extends from about amino acid location 104 to about amino acid location 140 of SEQ ID NO:1.

This Northern analysis revealed that Don-1 appears
35 to be highly expressed in the mouse brain, although

- 66 -

multiple transcripts were also observed in the spleen and lung. The message is also differentially expressed throughout embryogenesis, indicating a possible role in development. In all positive tissues, multiple
5 transcripts exist, the major sizes being about 4 kb and about 3 kb.

Human tissue Northern blots showed that human Don-1 is highly expressed in fetal brain and fetal lung tissues. In addition, two transcripts of about 4 kb and
10 3 kb were detected exclusively in the cerebellum of human adult tissue. No other normal adult human tissues appeared to express human Don-1. However, Don-1 transcripts were detected in a human colon adenocarcinoma cell line SW480 and in a human melanoma cell line G361.
15 In these tissues there were two major Don-1 transcripts of about 4.4 kb and about 3 kb each.

In Situ Analysis

In situ hybridizations were also used to examine Don-1 expression. Tissues for these hybridizations were
20 prepared as follows. Four to six week old C57BL/6 mice were cervically dislocated, and their brains were removed and frozen on dry ice. Ten μ m coronal frozen sections of brain were post-fixed with 4% formaldehyde in 1x phosphate buffered saline (PBS) (25°C) for 10 minutes,
25 rinsed two times in 1x PBS, rinsed once in 1 M triethanolamine-HCl (pH 8), and then incubated in 0.25% acetic anhydride/1 M triethanolamine-HCl for 10 minutes. Sections were then rinsed in 2x SSC. Tissue was dehydrated through a series of ethanol washes, 70%
30 ethanol for 1 minute, 80% for 1 minute, 95% for 2 minutes, and 100% ethanol for 1 minute. Sections were then incubated in 100% chloroform for 5 minutes and rinsed in 95% ethanol for 1 minute and 100% ethanol for 1 minute. Sections were air dried for 20 minutes.

- 67 -

Hybridizations were performed with ³⁵S-radiolabeled (5 x 10⁷ cpm/ml) cRNA probes encoding a 472 bp segment of the 5' end of the murine Don-1 gene (SEQ ID NO:1, nucleotides 68-540). Probes were incubated in the presence of 600 mM NaCl, 10 mM Tris, pH 7.5, 1 mM EDTA, 0.01% sheared herring sperm, 0.01% yeast tRNA, 0.05% total yeast sRNA Type X1, 1x Denhardt's solution, 50% formamide, 10% dextran sulfate, 100 mM DTT, 0.1% SDS, and 0.1% Na thiosulfate for 18 hours at 55°C.

After hybridization, slides were washed with 2x SSC. Sections were then incubated with 10 mM Tris-HCl (pH 7.6)/500 mM NaCl/1 mM EDTA (TNE) at 37°C for 10 minutes, incubated in 10 µg/ml RNase A in TNE at 37° for 30 minutes, and washed in TNE at 37°C for 30 minutes. Sections were then rinsed with 2x SSC at room temperature, then incubated with 2x SSC at 50°C for 1 hour, rinsed and incubated with 0.2x SSC at 55°C for 1 hour, and then incubated with 0.2x SSC at 60°C for 1 hour. Sections were then dehydrated through a series of ethanols, 50%, 70%, 80%, and 90% with 0.3 M NH₄OAc, and 100% ethanol. Sections were air dried and placed on Kodak Biomax MR scientific imaging film for 7 days at room temperature.

mRNA transcripts were localized to the cerebellum and Ammon's horn. Controls for the *in situ* hybridization experiments included the use of a sense probe which showed no signal above background levels and RNase treated tissue which showed a significantly reduced signal.

Expression Cloning

The EGF domain and flanking amino acids (amino acids 85-154 of SEQ ID NO:1) were amplified by PCR and then subcloned into a variety of commercially available bacterial expression vectors including pGEX (Pharmacia, Uppsala, Sweden), pMAL (NEB, Beverly, MA) and pTRX

- 68 -

(Invitrogen, San Diego, CA). Purification of recombinant material was performed as described by the manufacturer. This same domain was also subcloned into a mammalian expression vector, PN8E and then transfected into 293Ebna
5 cells as detailed by Gibco-BRL (Gaithersburg, MD). A leader sequence (MALPVTALLLPLALLLHAARP; SEQ ID NO:24) was fused to the N-terminal of the EGF domain by PCR and a Flag epitope tag was placed on the C-terminal, prior to subcloning into PN8E (Ho et al., *P.N.A.S. USA*, **90**:11267-
10 11271, 1993).

293Ebna cells at 80 percent confluence in 6-well dishes were transfected with 1.0 μ g DNA in 10 μ l lipofectamine (Gibco-BRL, Gaithersburg, MD) for 5 hours at 37°C in 5 percent CO₂ in an 800 μ l final volume.
15 Following incubation, DMEM and 10 percent Fetal Calf Serum were added, and the media was replaced 24 hours after the start of transfection. Culture supernatant was collected 48 hours later.

Preparation of Soluble Don-1

20 Soluble forms of recombinant murine or human Don-1, or domains thereof, can be produced in bacteria using the pGEX expression system as described above for the EGF domain of SEQ ID NO:1. The pGEX-Don-1 is purified on glutathione agarose and the Don-1 moiety released by
25 thrombin digestion. Following endotoxin removal on an Endotoxin BX column (Cape Cod Associates: Falmouth, MA) the Don-1 preparation is determined to contain low levels of endotoxin (<0.01 EU/ml) by the Limulus amebocyte lysate (LAL) assay (Cape Cod Associates).

30 Recombinant, soluble Don-1 is produced as follows. First, the murine Don-1 cDNA is amplified with a primer corresponding to a sequence at the 5' end of the sequence encoding, for example, the EGF domain (5' primer). The 5' primer, 5'-AAAAAAGAATTCCTCCATGTCAACAGCGTG-3' (SEQ ID
35 NO:25), has an EcoRI restriction enzyme cleavage site

- 69 -

followed by 18 nucleotides encoding the 5' flanking region of the EGF domain of murine Don-1. The 3' primer used was 5'-TCCTCTCTCGAGTCACTTAGGATCTGGCATGTA-3' (SEQ ID NO:26). This primer has complementary sequences encoding 5 amino acids 187 to 192 preceded by a termination codon and XhoI site.

These primer pairs were used for PCR amplification using the following conditions: 94°C for 30 seconds; 55°C for 30 seconds and 72°C for 90 seconds with 30 10 cycles. The resulting PCR product was cloned into the GST fusion protein vector pGEX (Pharmacia, Uppsala, Sweden). The fusion protein was produced in *E. coli* and purified according to the protocol supplied by the manufacturer. The Don-1 construct produced a protein of 15 approximately 7.0 kD after the cleavage of GST by thrombin.

Example 3: Mapping of the *don-1* Gene

These examples describe chromosome mapping of the mouse and human *don-1*.

20 Mouse Chromosome Mapping

The *don-1* gene was mapped to the proximal end of chromosome 18 in the mouse, utilizing a *Mus* 25 *spretus*/C57BL/6J backcross panel. Don-1 appears to be located close to *cdc25*, 17cM from the top of chromosome 18, between the markers D18Mit20 and D18Mit24.

PCR primers were used to amplify mouse genomic DNA using standard techniques. Primers were designed from noncoding sequences of murine *don-1* and were as follows:

Forward primer: 5'-AGAGGAAGGCCAAAGTAGTG-3' (SEQ 30 ID NO:33), and

Reverse primer: 5'-GTGGACCACAAGGTAAACAG-3' (SEQ ID NO:34).

Other potential primers include:

- 70 -

Forward primer: 5'-CACAGTCCACCCCTCAG-3' (SEQ ID NO:27), and

Reverse primer: 5'-GCTCTGGTAAGCAAACATGG-3' (SEQ ID NO:28).

5 Amplification conditions were 30 cycles at 95°C for 1 minute, 60°C for 1 minute, and 72°C for 45 seconds. Samples were run on nondenaturing 10% acrylamide SSCP gel at 20 W and 4°C for 2.5 hours.

Human Chromosome Mapping

10 Human *don-1* can be mapped to a particular chromosome by using a panel of radiation hybrids in a manner similar to that described for the mouse chromosome mapping.

The following primers are used to amplify human
15 genomic DNA from a panel of radiation hybrids (Genebridge 4, Research Genetics, Huntsville, AL):

Forward primer: 5'-TGTGAACTCCTCTGGCCTGT-3' (SEQ ID NO:29), and

Reverse primer: 5'-GAAGGGGCTGGGCATTTAAT-3' (SEQ
20 ID NO:30).

The amplification profile is as follows: 94°C for 30 seconds; 55°C for 30 seconds, and 72°C for 45 seconds with 30 cycles. Samples are resolved on 1% agarose TAE gel.

25 Deposit of Microorganisms

The following microorganisms were deposited with the American Type Culture Collection (ATCC), Rockville, Maryland, on July 3, 1996 and assigned the indicated accession number:

30 <u>Microorganism</u>	<u>ATCC Accession</u>
<u>No.</u>	
<u>E. coli</u> CpmDon-1a (membrane-bound murine Don-1)	98096
<u>E. coli</u> CpmDon-1b (membrane-bound human Don-1)	98097

- 71 -

E. coli CpmDon-2 (secreted murine Don-1)

98098

Deposit Statement

The subject cultures have been deposited under conditions that assure that access to the cultures will
5 be available during the pendency of the patent application to one determined by the Commissioner of Patents and Trademarks to be entitled thereto under 37 CFR 1.14 and 35 USC 122. The deposits are available as required by foreign patent laws in countries wherein
10 counterparts of the subject application, or its progeny, are filed. However, it should be understood that the availability of a deposit does not constitute a license to practice the subject invention in derogation of patent rights granted by governmental action.

15 Further, the subject culture deposits will be stored and made available to the public in accord with the provisions of the Budapest Treaty for the Deposit of Microorganisms, i.e., they will be stored with all the care necessary to keep them viable and uncontaminated for
20 a period of at least five years after the most recent request for the furnishing of a sample of the deposits, and in any case, for a period of at least 30 (thirty) years after the date of deposit or for the enforceable life of any patent which may issue disclosing the
25 cultures plus five years after the last request for a sample from the deposit. The depositor acknowledges the duty to replace the deposits should the depository be unable to furnish a sample when requested, due to the condition of the deposits. All restrictions on the
30 availability to the public of the subject culture deposits will be irrevocably removed upon the granting of a patent disclosing them.

- 72 -

Other Embodiments

The invention also features fragments, variants, analogs and derivatives of the Don-1 polypeptides described above that retain one or more of the biological
5 activities of Don-1 such as activation of receptor-type tyrosine kinases as described herein.

The invention includes naturally-occurring and non-naturally-occurring allelic variants. Compared to the most common naturally-occurring nucleotide sequence
10 encoding Don-1, the nucleic acid sequence encoding allelic variants may have a substitution, deletion, or addition of one or more nucleotides. The preferred allelic variants are functionally equivalent to naturally-occurring Don-1.

15 It is to be understood that while the invention has been described in conjunction with the detailed description thereof, that the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended
20 claims. Other aspects, advantages, and modifications are within the scope of the following claims.

-73-

SEQUENCE LISTING

(1) GENERAL INFORMATION

- (i) APPLICANT: Millennium Biotherapeutics, Inc.
- (ii) TITLE OF THE INVENTION: DON-1 GENE AND POLYPEPTIDES AND USES THEREFOR
- (iii) NUMBER OF SEQUENCES: 33
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Fish & Richardson, P.C.
 - (B) STREET: 225 Franklin Street
 - (C) CITY: Boston
 - (D) STATE: MA
 - (E) COUNTRY: US
 - (F) ZIP: 02110-2804
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Diskette
 - (B) COMPUTER: IBM Compatible
 - (C) OPERATING SYSTEM: Windows95
 - (D) SOFTWARE: FastSEQ for Windows Version 2.0
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER: US/PCT97/----
 - (B) FILING DATE: 18-AUG-1997
 - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: 08/752,307
 - (B) FILING DATE: 19-NOV-1996
 - (A) APPLICATION NUMBER: 08/699,591
 - (B) FILING DATE: 19-AUG-1996
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Meiklejohn, Ph.D., Anita L.
 - (B) REGISTRATION NUMBER: 35,283
 - (C) REFERENCE/DOCKET NUMBER: 09404/022WO1
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: 617-542-5070
 - (B) TELEFAX: 617-542-8906
 - (C) TELEX: 200154

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 2467 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: circular
- (ii) MOLECULE TYPE: cDNA
- (ix) FEATURE:
 - (A) NAME/KEY: Coding Sequence
 - (B) LOCATION: 79...1893
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

```

CCTAACGGCA AAAACATCAA GAAAGAGGTG GGCAAGATCC TGTGCACTGA CTGCGCCACC      60
CGGCCCAAGC TGAAGAAG  ATG AAG AGC CAG ACA GGA GAG GTG GGT GAG AAG      111
          Met Lys Ser Gln Thr Gly Glu Val Gly Glu Lys
              1              5              10

```

-74-

CAG TCG CTC AAG TGT GAG GCA GCG GCG GGA AAC CCC CAG CCC TCC TAT Gln Ser Leu Lys Cys Glu Ala Ala Ala Gly Asn Pro Gln Pro Ser Tyr 15 20 25	159
CGC TGG TTC AAG GAT GGC AAG GAA CTC AAC CGG AGT CGT GAT ATT CGC Arg Trp Phe Lys Asp Gly Lys Glu Leu Asn Arg Ser Arg Asp Ile Arg 30 35 40	207
ATC AAG TAT GGC AAT GTC AGA AAG AAC TCA CGG CTA CAG TTC AAC AAA Ile Lys Tyr Gly Asn Val Arg Lys Asn Ser Arg Leu Gln Phe Asn Lys 45 50 55	255
GTG AGG GTG GAG GAT GCC GGG GAG TAC GTC TGT GAG GCC GAG AAC ATC Val Arg Val Glu Asp Ala Gly Glu Tyr Val Cys Glu Ala Glu Asn Ile 60 65 70 75	303
CTT GGG AAG GAC ACC GTG AGG GGC CGA CTC CAT GTC AAC AGC GTG AGC Leu Gly Lys Asp Thr Val Arg Gly Arg Leu His Val Asn Ser Val Ser 80 85 90	351
ACC ACT CTG TCA TCC TGG TCG GGA CAT GCC CGG AAG TGC AAT GAG ACC Thr Thr Leu Ser Ser Trp Ser Gly His Ala Arg Lys Cys Asn Glu Thr 95 100 105	399
GCC AAG TCC TAC TGT GTG AAT GGA GGC GTG TGC TAC TAC ATC GAG GGC Ala Lys Ser Tyr Cys Val Asn Gly Gly Val Cys Tyr Tyr Ile Glu Gly 110 115 120	447
ATC AAC CAG CTC TCC TGC AAA TGT CCA AAC GGA TTC TTC GGA CAG AGA Ile Asn Gln Leu Ser Cys Lys Cys Pro Asn Gly Phe Phe Gly Gln Arg 125 130 135	495
TGT TTG GAG AAA CTG CCT TTG CGA TTG TAC ATG CCA GAT CCT AAG CAA Cys Leu Glu Lys Leu Pro Leu Arg Leu Tyr Met Pro Asp Pro Lys Gln 140 145 150 155	543
AAG GCT GAG GAG CTG TAC CAG AAG AGA GTG CTG ACA ATT ACT GGT ATC Lys Ala Glu Glu Leu Tyr Gln Lys Arg Val Leu Thr Ile Thr Gly Ile 160 165 170	591
TGT GTG GCC CTG CTG GTC GTG GGC ATC GTC TGT GTG GTC GCC TAC TGC Cys Val Ala Leu Leu Val Val Gly Ile Val Cys Val Val Ala Tyr Cys 175 180 185	639
AAG ACC AAA AAA CAG AGG AGG CAG ATG CAT CAT CAT CTC CGG CAG AAC Lys Thr Lys Lys Gln Arg Arg Gln Met His His His Leu Arg Gln Asn 190 195 200	687
ATG TGC CCA GCC CAC CAG AAC CGA AGC CTG GCC AAC GGG CCC AGC CAC Met Cys Pro Ala His Gln Asn Arg Ser Leu Ala Asn Gly Pro Ser His 205 210 215	735
CCT CGG CTG GAC CCT GAG GAG ATC CAG ATG GCA GAT TAC ATC TCC AAA Pro Arg Leu Asp Pro Glu Glu Ile Gln Met Ala Asp Tyr Ile Ser Lys 220 225 230 235	783
AAT GTG CCA GCT ACA GAC CAC GTG ATC CGG AGG GAA GCT GAG ACC ACG Asn Val Pro Ala Thr Asp His Val Ile Arg Arg Glu Ala Glu Thr Thr 240 245 250	831
TTC TCT GGG AGC CAC TCC TGT TCA CCT TCT CAC CAC TGC TCC ACA GCC Phe Ser Gly Ser His Ser Cys Ser Pro Ser His His Cys Ser Thr Ala 255 260 265	879
ACG CCC ACC TCC AGC CAC AGA CAT GAG AGC CAC ACG TGG AGC CTG GAA Thr Pro Thr Ser Ser His Arg His Glu Ser His Thr Trp Ser Leu Glu 270 275 280	927

-75-

CGT TCA GAG AGC CTG ACC TCG GAT TCC CAG TCA GGC ATC ATG CTA TCA Arg Ser Glu Ser Leu Thr Ser Asp Ser Gln Ser Gly Ile Met Leu Ser 285 290 295	975
TCA GTA GGC ACC AGC AAG TGC AAC AGC CCA GCA TGT GTG GAG GCA CGG Ser Val Gly Thr Ser Lys Cys Asn Ser Pro Ala Cys Val Glu Ala Arg 300 305 310 315	1023
GCG CGG AGG GCA GCA GCC TAC AGC CAG GAG GAG CGG CGC AGG GCT GCC Ala Arg Arg Ala Ala Ala Tyr Ser Gln Glu Glu Arg Arg Arg Ala Ala 320 325 330	1071
ATG CCA CCC TAC CAT GAC TCC ATA GAC TCG CTG CGT GAC TCT CCA CAC Met Pro Pro Tyr His Asp Ser Ile Asp Ser Leu Arg Asp Ser Pro His 335 340 345	1119
AGT GAA AGG TAC GTG TCA GCC TTG ACC ACG CCC GCT CGC CTC TCG CCC Ser Glu Arg Tyr Val Ser Ala Leu Thr Thr Pro Ala Arg Leu Ser Pro 350 355 360	1167
GTG GAC TTC CAC TAC TCG CTG GCC ACG CAG GTG CCG ACT TTC GAG ATC Val Asp Phe His Tyr Ser Leu Ala Thr Gln Val Pro Thr Phe Glu Ile 365 370 375	1215
ACG TCG CCC AAC TCT GAG CAT GCC GTG TCG CTG CCG CCC GCC GCG CCC Thr Ser Pro Asn Ser Glu His Ala Val Ser Leu Pro Pro Ala Ala Pro 380 385 390 395	1263
ATC AGC TAC CGC CTG GCG GAG CAG CAG CCG CTC CTG CGG CAT CCA GCG Ile Ser Tyr Arg Leu Ala Glu Gln Gln Pro Leu Leu Arg His Pro Ala 400 405 410	1311
CCG CCC GGC CCG GGG CCG GGG TCG GGG CCC GGA GCG GAC ATG CAG CGC Pro Pro Gly Pro Gly Pro Gly Ser Gly Pro Gly Ala Asp Met Gln Arg 415 420 425	1359
AGC TAC GAC AGC TAC TAC TAC CCT GCG GCG GGG CCC GGG CCG CGG CGC Ser Tyr Asp Ser Tyr Tyr Tyr Pro Ala Ala Gly Pro Gly Pro Arg Arg 430 435 440	1407
AGC GCC TGC GCG CTG GGA GGC AGC TTG GGC AGC CTG CCC GCC AGC CCC Ser Ala Cys Ala Leu Gly Gly Ser Leu Gly Ser Leu Pro Ala Ser Pro 445 450 455	1455
TTC CGC ATC CCG GAG GAC GAC GAG TAC GAG ACC ACG CAG GAG TGC GCG Phe Arg Ile Pro Glu Asp Asp Glu Tyr Glu Thr Thr Gln Glu Cys Ala 460 465 470 475	1503
CCC CCG CCG CCG CCG CGG CCG CGC ACG CGC GGC GCG TCC CGC AGG ACG Pro Pro Pro Pro Pro Arg Pro Arg Thr Arg Gly Ala Ser Arg Arg Thr 480 485 490	1551
TCG GCG GGG CCG CGG CGC TGG CGG CGC TCC CGG CTC AAC GGG TTG GCG Ser Ala Gly Pro Arg Arg Trp Arg Arg Ser Arg Leu Asn Gly Leu Ala 495 500 505	1599
GCG CAG CGC GCA CGC GCG GCG CGG GAC TCG CTG TCA TTG AGC AGC GGT Ala Gln Arg Ala Arg Ala Ala Arg Asp Ser Leu Ser Leu Ser Ser Gly 510 515 520	1647
TCG GGC TGC GGC TCG GCG TCG GCC TCG GAC GAC GAC GCG GAC GAC GCG Ser Gly Cys Gly Ser Ala Ser Ala Ser Asp Asp Ala Ala Asp Asp Ala 525 530 535	1695
GAC GGG GCG CTG GCG GCC GAG AGC ACG CCA TTC CTC GGC CTG CGA GCG Asp Gly Ala Leu Ala Ala Glu Ser Thr Pro Phe Leu Gly Leu Arg Ala 540 545 550 555	1743

-76-

GCG CAC GAC GCG TTG CGC TCG GAC TCG CCG CCG CTG TGC CCC GCG GCC 1791
 Ala His Asp Ala Leu Arg Ser Asp Ser Pro Pro Leu Cys Pro Ala Ala 570
 560 565

GAC AGC AGG ACT TAC TAC TCC CTG GAC AGC CAC AGC ACG CGC GCC AGC 1839
 Asp Ser Arg Thr Tyr Tyr Ser Leu Asp Ser His Ser Thr Arg Ala Ser 585
 575 580

AGC AGA CAC AGC CGG GGG CCG CCC ACG AGG GCC AAG CAG GAC TCG GGG 1887
 Ser Arg His Ser Arg Gly Pro Pro Thr Arg Ala Lys Gln Asp Ser Gly 600
 590 595

CCC CTC TAAGGCCCCC CGCCTCGCCC GCCCCACGTC TCCAAGGAGA GCGGAGACCA CC 1945
 Pro Leu 605

GACTGGAGAG GGAAAAGGAG CGAACAAAGA AATAAAAATA TTTTATTTT CTATAAAAGG 2005
 AAAAAAGTAT AACAAAATGT TTTATTTTCA TTTTAGCAAA AAAAATTGTC TTATAATACT 2065
 AGCTAACGGC AAAGACGTTT TTATAGGGAA ACTATTTATA TGTAACATCC TGATTTACAG 2125
 CTTCCGAAAA AAAAAAGAAA ACAACAAAAA AAAAAAATAA AAAAATCGA GGGGGGGCCC 2185
 GGTACCCAAT TCGCCCTATA GTGAGTCGTA TTACAATTCA CTGGCCGTCG TTTTACAACG 2245
 TCGTGACTGG GAAAACCTG GCGTTACCCA ACTTAATCGC CTTGCAGCAC ATCCCCCTT 2305
 CGCCAGCTGG CGTAATAGCG AAAAGGCCCG CACCGATCGC CCTTCCCAAC AGTTGCGCAG 2365
 CCTGAATGGC GAATGGCAAA TTGTAAGCGT TAATATTTTG TTAAATTC CTTAAATT 2425
 TTGTAAATC ACTCATTTT TAACCAATAG GCCGAAATCG GC 2467

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 605 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met Lys Ser Gln Thr Gly Glu Val Gly Glu Lys Gln Ser Leu Lys Cys
 1 5 10 15
 Glu Ala Ala Ala Gly Asn Pro Gln Pro Ser Tyr Arg Trp Phe Lys Asp
 20 25 30
 Gly Lys Glu Leu Asn Arg Ser Arg Asp Ile Arg Ile Lys Tyr Gly Asn
 35 40 45
 Val Arg Lys Asn Ser Arg Leu Gln Phe Asn Lys Val Arg Val Glu Asp
 50 55 60
 Ala Gly Glu Tyr Val Cys Glu Ala Glu Asn Ile Leu Gly Lys Asp Thr
 65 70 75 80
 Val Arg Gly Arg Leu His Val Asn Ser Val Ser Thr Thr Leu Ser Ser
 85 90 95
 Trp Ser Gly His Ala Arg Lys Cys Asn Glu Thr Ala Lys Ser Tyr Cys
 100 105 110
 Val Asn Gly Gly Val Cys Tyr Tyr Ile Glu Gly Ile Asn Gln Leu Ser
 115 120 125
 Cys Lys Cys Pro Asn Gly Phe Phe Gly Gln Arg Cys Leu Glu Lys Leu
 130 135 140
 Pro Leu Arg Leu Tyr Met Pro Asp Pro Lys Gln Lys Ala Glu Glu Leu
 145 150 155 160
 Tyr Gln Lys Arg Val Leu Thr Ile Thr Gly Ile Cys Val Ala Leu Leu
 165 170 175
 Val Val Gly Ile Val Cys Val Val Ala Tyr Cys Lys Thr Lys Lys Gln
 180 185 190
 Arg Arg Gln Met His His His Leu Arg Gln Asn Met Cys Pro Ala His
 195 200 205
 Gln Asn Arg Ser Leu Ala Asn Gly Pro Ser His Pro Arg Leu Asp Pro
 210 215 220
 Glu Glu Ile Gln Met Ala Asp Tyr Ile Ser Lys Asn Val Pro Ala Thr
 225 230 235 240

-77-

```

Asp His Val Ile Arg Arg Glu Ala Glu Thr Thr Phe Ser Gly Ser His
      245      250      255
Ser Cys Ser Pro Ser His His Cys Ser Thr Ala Thr Pro Thr Ser Ser
      260      265      270
His Arg His Glu Ser His Thr Trp Ser Leu Glu Arg Ser Glu Ser Leu
      275      280      285
Thr Ser Asp Ser Gln Ser Gly Ile Met Leu Ser Ser Val Gly Thr Ser
      290      295      300
Lys Cys Asn Ser Pro Ala Cys Val Glu Ala Arg Ala Arg Arg Ala Ala
      305      310      315      320
Ala Tyr Ser Gln Glu Glu Arg Arg Arg Ala Ala Met Pro Pro Tyr His
      325      330      335
Asp Ser Ile Asp Ser Leu Arg Asp Ser Pro His Ser Glu Arg Tyr Val
      340      345      350
Ser Ala Leu Thr Thr Pro Ala Arg Leu Ser Pro Val Asp Phe His Tyr
      355      360      365
Ser Leu Ala Thr Gln Val Pro Thr Phe Glu Ile Thr Ser Pro Asn Ser
      370      375      380
Glu His Ala Val Ser Leu Pro Pro Ala Ala Pro Ile Ser Tyr Arg Leu
      385      390      395      400
Ala Glu Gln Gln Pro Leu Leu Arg His Pro Ala Pro Pro Gly Pro Gly
      405      410      415
Pro Gly Ser Gly Pro Gly Ala Asp Met Gln Arg Ser Tyr Asp Ser Tyr
      420      425      430
Tyr Tyr Pro Ala Ala Gly Pro Gly Pro Arg Arg Ser Ala Cys Ala Leu
      435      440      445
Gly Gly Ser Leu Gly Ser Leu Pro Ala Ser Pro Phe Arg Ile Pro Glu
      450      455      460
Asp Asp Glu Tyr Glu Thr Thr Gln Glu Cys Ala Pro Pro Pro Pro Pro
      465      470      475      480
Arg Pro Arg Thr Arg Gly Ala Ser Arg Arg Thr Ser Ala Gly Pro Arg
      485      490      495
Arg Trp Arg Arg Ser Arg Leu Asn Gly Leu Ala Ala Gln Arg Ala Arg
      500      505      510
Ala Ala Arg Asp Ser Leu Ser Leu Ser Ser Gly Ser Gly Cys Gly Ser
      515      520      525
Ala Ser Ala Ser Asp Asp Asp Ala Asp Asp Ala Asp Gly Ala Leu Ala
      530      535      540
Ala Glu Ser Thr Pro Phe Leu Gly Leu Arg Ala Ala His Asp Ala Leu
      545      550      555      560
Arg Ser Asp Ser Pro Pro Leu Cys Pro Ala Ala Asp Ser Arg Thr Tyr
      565      570      575
Tyr Ser Leu Asp Ser His Ser Thr Arg Ala Ser Ser Arg His Ser Arg
      580      585      590
Gly Pro Pro Thr Arg Ala Lys Gln Asp Ser Gly Pro Leu
      595      600      605

```

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1607 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: Coding Sequence
- (B) LOCATION: 79...621

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

```

CCTAACGGCA AAAACATCAA GAAAGAGGTG GGCAAGATCC TGTGCACTGA CTGCGCCACC      60
CGGCCCCAAGC TGAAGAAG  ATG AAG AGC CAG ACA GGA GAG GTG GGT GAG AAG      111
      Met Lys Ser Gln Thr Gly Glu Val Gly Glu Lys
      1              5              10

```

-78-

CAG TCG CTC AAG TGT GAG GCA GCG GCG GGA AAC CCC CAG CCC TCC TAT	159
Gln Ser Leu Lys Cys Glu Ala Ala Ala Gly Asn Pro Gln Pro Ser Tyr	
15 20 25	
CGC TGG TTC AAG GAT GGC AAG GAA CTC AAC CGG AGT CGT GAT ATT CGC	207
Arg Trp Phe Lys Asp Gly Lys Glu Leu Asn Arg Ser Arg Asp Ile Arg	
30 35 40	
ATC AAG TAT GGC AAT GTC AGA AAG AAC TCA CGG CTA CAG TTC AAC AAA	255
Ile Lys Tyr Gly Asn Val Arg Lys Asn Ser Arg Leu Gln Phe Asn Lys	
45 50 55	
GTG AGG GTG GAG GAT GCC GGG GAG TAC GTC TGT GAG GCC GAG AAC ATC	303
Val Arg Val Glu Asp Ala Gly Glu Tyr Val Cys Glu Ala Glu Asn Ile	
60 65 70 75	
CTT GGG AAG GAC ACC GTG AGG GGC CGA CTC CAT GTC AAC AGC GTG AGC	351
Leu Gly Lys Asp Thr Val Arg Gly Arg Leu His Val Asn Ser Val Ser	
80 85 90	
ACC ACT CTG TCA TCC TGG TCG GGA CAT GCC CGG AAG TGC AAT GAG ACC	399
Thr Thr Leu Ser Ser Trp Ser Gly His Ala Arg Lys Cys Asn Glu Thr	
95 100 105	
GCC AAG TCC TAC TGT GTG AAT GGA GGC GTG TGC TAC TAC ATC GAG GGC	447
Ala Lys Ser Tyr Cys Val Asn Gly Gly Val Cys Tyr Tyr Ile Glu Gly	
110 115 120	
ATC AAC CAG CTC TCC TGC AAA TGT CCA AAC GGA TTC TTC GGA CAG AGA	495
Ile Asn Gln Leu Ser Cys Lys Cys Pro Asn Gly Phe Phe Gly Gln Arg	
125 130 135	
TGT TTG GAG AAA CTG CCT TTG CGA TTG TAC ATG CCA GAT CCT AAG CAA	543
Cys Leu Glu Lys Leu Pro Leu Arg Leu Tyr Met Pro Asp Pro Lys Gln	
140 145 150 155	
AGT GTC CTG TGG GAT ACA CCG GGG ACA GGT GTC AGC AGT TCG CAA TGG	591
Ser Val Leu Trp Asp Thr Pro Gly Thr Gly Val Ser Ser Ser Gln Trp	
160 165 170	
TCA ACT TCT CCA AGC ACC TTG GAT TTG AAT TGAAGGAGGC TGAGGAGCTG TAC	644
Ser Thr Ser Pro Ser Thr Leu Asp Leu Asn	
175 180	
CAGAAGAGAG TGCTGACAA TACTGGTATC TGTGTGGCCC TGCTGGTTCGT GGGCATCGTC	704
TGTGTGGTCG CCTACTGCAA GACCAAAAAA CAGAGGAGGC AGATGCATCA TCATCTCCGG	764
CAGAACATGT GCCCAGCCCA CCAGAACCGA AGCCTGGCCA ACGGGCCAG CCACCCTCGG	824
CTGGACCCCTG AGGAGATCCA GATGGCAGAT TACATCTCCA AAAATGTGCC AGCTACAGAC	884
CACGTGATCC GGAGGGAAGC TGAGACCACG TTCTCTGGGA GCCACTCCTG TTCACCTTCT	944
CACCACTGCT CCACAGCCAC GCCCACCTCC AGCCACAGAC ATGAGAGCCA CACGTGGAGC	1004
CTGGAACGTT CAGAGAGCCT GACCTCGGAT TCCCAGTCAG GCATCATGCT ATCATCAGTA	1064
GGCACCAGCA AGTGCAACAG CCCAGCATGT GTGGAGGCAC GGGCGCGGAG GGCAGCAGCC	1124
TACAGCCAGG AGGAGCGGCG CAGGGCTGCC ATGCCACCCT ACCATGACTC CATAGACTCG	1184
CTGCGTGA CTCCACACAG TGAAAGGTAC GTGTCAGCCT TGACCAGGCC CGCTCGCCTC	1244
TOGCCCCGTGG ACTTCCACTA CTCGCTGGCC ACGCAGGTGC CGACTTTCGA GATCAGTCG	1304
CCCAACTCTG CGCATGCCGT GTCGCTGCCG CCCGCCGCGC CCATCAGCTA CCGCCTGGCG	1364
GAGCAGCAGC CGCTCCTGCG GCATCCAGCG CCGCCCGGCC CGGGGCCGGG GTCGGGGCCC	1424
GGAGCGGACA TGCAGCGCAG CTACGACAGC TACTACTACC CTGCGGCGGG GCCCGGGCCG	1484
CGGCGCAGCG CCTGCGCGCT GGGAGGCAGC TTGGGCAGCC TGCCCGCCAG CCCCTTCCGC	1544
ATCCCGGAGG ACGACGAGTA CGAGACCACG CAGGAGTGCG CGCCCCCGCC GCCCGCGCGG	1604
CCG	1607

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 181 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

-79-

(ii) MOLECULE TYPE: protein

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

```

Met Lys Ser Gln Thr Gly Glu Val Gly Glu Lys Gln Ser Leu Lys Cys
 1      5      10
Glu Ala Ala Ala Gly Asn Pro Gln Pro Ser Tyr Arg Trp Phe Lys Asp
 20      25      30
Gly Lys Glu Leu Asn Arg Ser Arg Asp Ile Arg Ile Lys Tyr Gly Asn
 35      40      45
Val Arg Lys Asn Ser Arg Leu Gln Phe Asn Lys Val Arg Val Glu Asp
 50      55      60
Ala Gly Glu Tyr Val Cys Glu Ala Glu Asn Ile Leu Gly Lys Asp Thr
 65      70      75      80
Val Arg Gly Arg Leu His Val Asn Ser Val Ser Thr Thr Leu Ser Ser
 85      90      95
Trp Ser Gly His Ala Arg Lys Cys Asn Glu Thr Ala Lys Ser Tyr Cys
100      105      110
Val Asn Gly Gly Val Cys Tyr Tyr Ile Glu Gly Ile Asn Gln Leu Ser
115      120      125
Cys Lys Cys Pro Asn Gly Phe Phe Gly Gln Arg Cys Leu Glu Lys Leu
130      135      140
Pro Leu Arg Leu Tyr Met Pro Asp Pro Lys Gln Ser Val Leu Trp Asp
145      150      155      160
Thr Pro Gly Thr Gly Val Ser Ser Ser Gln Trp Ser Thr Ser Pro Ser
165      170      175
Thr Leu Asp Leu Asn
180

```

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1884 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: Coding Sequence
- (B) LOCATION: 664...1883

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

```

CAGCTACAGC GACAGCAGCA GCAGCAGCAG CGAGAGGAGC AGCAGCAGCA GCAGCAGCAG      60
CAGCGAGAGC GGCAGCAGCA GCAGGAGCAG CAGCAACAAC AGCAGCATCT CTCGTCCCGC      120
TGCGCCCCCA GAGCCGCGGC CGCAGCAACA GCCGAGCCCC CGCAGCCCCG CAGCCCGGAG      180
AGCCGCCGCC CGTTCGCGAG CCGCAGCCGC CGGCGGCATG AGGCGCGACC CGGCCCCCGG      240
CTTCTCCATG CTGCTCTTCG GTGTGTGCGT CGCCTGCTAC TCGCCCAGCC TCAAGTCAGT      300
GCAGGACCAG GCGTACAAGG CACCCGTGGT GGTGGAGGGC AAGGTACAGG GGCTGGTCCC      360
AGCCGGCGGC TCCAGCTCCA ACAGCACCCG AGAGCCGCCG GCCTCGGGTC GGGTGGCGTT      420
GGTAAAGGTG CTGGACAAGT GGCCGCTCCG GAGCGGGGGG CTGCAGCGCG AGCAGGTGAT      480
CAGCGTGGGC TCCTGTGTGC CGCTCGAAAG GAACCAGCGC TACATCTTTT TCCTGGAGCC      540
CACGGAACAG CCCTTAGTCT TTAAGACGGC CTTTGCCCCC CTGATACCAA CGGCAAAAAT      600
CTCAAGAAAG AGGTGGGCAA GATCCTGTGC ACTGGCTGCG CCACCCGGCC CAAGTTGAAG      660

AAG ATG AAG AGC CAG ACG GGA CAG GTG GGT GAG AAG CAA TCG CTG AAG      708
Met Lys Ser Gln Thr Gly Gln Val Gly Glu Lys Gln Ser Leu Lys
 1      5      10

TGT GAG GCA GCA GCC GGT AAT CCC CAG CCT TCC TAC CGT TGG TTC AAG      756
Cys Glu Ala Ala Gly Asn Pro Gln Pro Ser Tyr Arg Trp Phe Lys
20      25      30

```

-80-

GAT GGC AAG GAG CTC AAC CGC AGC CGA GAC ATT CGC ATC AAA TAT GGC Asp Gly Lys Glu Leu Asn Arg Ser Arg Asp Ile Arg Ile Lys Tyr Gly 35 40 45	804
AAC GGC AGA AAG AAC TCA CGA CTA CAG TTC AAC AAG GTG AAG GTG GAG Asn Gly Arg Lys Asn Ser Arg Leu Gln Phe Asn Lys Val Lys Val Glu 50 55 60	852
GAC GCT GGG GAG TAT GTC TGC GAG GCC GAG AAC ATC CTG GGG AAG GAC Asp Ala Gly Glu Tyr Val Cys Glu Ala Glu Asn Ile Leu Gly Lys Asp 65 70 75	900
ACC GTC CGG GGC CGG CTT TAC GTC AAC AGC GTG AGC ACC ACC CTG TCA Thr Val Arg Gly Arg Leu Tyr Val Asn Ser Val Ser Thr Thr Leu Ser 80 85 90 95	948
TCC TGG TCG GGG CAC GCC CGG AAG TGC AAC GAG ACA GCC AAG TCC TAT Ser Trp Ser Gly His Ala Arg Lys Cys Asn Glu Thr Ala Lys Ser Tyr 100 105 110	996
TGC GTC AAT GGA GGC GTC TGC TAC TAC ATC GAG GGC ATC AAC CAG CTC Cys Val Asn Gly Gly Val Cys Tyr Tyr Ile Glu Gly Ile Asn Gln Leu 115 120 125	1044
TCC TGC AAA TGT CCA AAT GGA TTC TTC GGA CAG AGA TGT TTG GAG AAA Ser Cys Lys Cys Pro Asn Gly Phe Phe Gly Gln Arg Cys Leu Glu Lys 130 135 140	1092
CTG CCT TTG CGA TTG TAC ATG CCA GAT CCT AAG CAA AAG CAC CTT GGA Leu Pro Leu Arg Leu Tyr Met Pro Asp Pro Lys Gln Lys His Leu Gly 145 150 155	1140
TTT GAA TTA AAG GAA GCC GAG GAG CTG TAC CAG AAG AGG GTC CTG ACC Phe Glu Leu Lys Glu Ala Glu Glu Leu Tyr Gln Lys Arg Val Leu Thr 160 165 170 175	1188
ATC ACG GGC ATC TGC GTG GCT CTG CTG GTC GTG GGC ATC GTC TGT GTG Ile Thr Gly Ile Cys Val Ala Leu Leu Val Val Gly Ile Val Cys Val 180 185 190	1236
GTG GCC TAC TGC AAG ACC AAA AAA CAG CGG AAG CAG ATG CAC AAC CAC Val Ala Tyr Cys Lys Thr Lys Lys Gln Arg Lys Gln Met His Asn His 195 200 205	1284
CTC CGG CAG AAC ATG TGC CCG GCC CAT CAG AAC CGG AGC TTG GCC AAT Leu Arg Gln Asn Met Cys Pro Ala His Gln Asn Arg Ser Leu Ala Asn 210 215 220	1332
GGG CCC AGC CAC CCC CGG CTG GAC CCA GAG GAG ATC CAG ATG GCA GAT Gly Pro Ser His Pro Arg Leu Asp Pro Glu Glu Ile Gln Met Ala Asp 225 230 235	1380
TAT ATT TCC AAG AAC GTG CCA GCC ACA GAC CAT GTC ATC AGG AGA GAA Tyr Ile Ser Lys Asn Val Pro Ala Thr Asp His Val Ile Arg Arg Glu 240 245 250 255	1428
ACT GAG ACC ACC TTC TCT GGG AGC CAC TCC TGT TCT CCT TCT CAC CAC Thr Glu Thr Thr Phe Ser Gly Ser His Ser Cys Ser Pro Ser His His 260 265 270	1476
TGC TCC ACA GCC ACA CCC ACC TCC AGC CAC AGA CAC GAG AGC CAC ACG Cys Ser Thr Ala Thr Pro Thr Ser Ser His Arg His Glu Ser His Thr 275 280 285	1524
TGG AGC CTG GAA CGT TCT GAG AGC CTG ACT TCT GAC TCC CAG TCG GGG Trp Ser Leu Glu Arg Ser Glu Ser Leu Thr Ser Asp Ser Gln Ser Gly 290 295 300	1572

-81-

ATC ATG CTA TCA TCA GTG GGT ACC AGC AAA TGC AAC AGC CCA GCA TGT	1620
Ile Met Leu Ser Ser Val Gly Thr Ser Lys Cys Asn Ser Pro Ala Cys	
305 310 315	
GTG GAG GCC CGG GCA AGG CGG GCA GCA GCC TAC AAC CTG GAG GAG CGG	1668
Val Glu Ala Arg Ala Arg Arg Ala Ala Ala Tyr Asn Leu Glu Glu Arg	
320 325 330 335	
CGC AGG GCC ACC GCG CCA CCC TAT CAC GAT TCC GTG GAC TCC CTT CGC	1716
Arg Arg Ala Thr Ala Pro Pro Tyr His Asp Ser Val Asp Ser Leu Arg	
340 345 350	
GAC TCC CCA CAC AGC GAG AGG TAC GTG TCG GCC CTG ACC ACG CCC GCG	1764
Asp Ser Pro His Ser Glu Arg Tyr Val Ser Ala Leu Thr Thr Pro Ala	
355 360 365	
CGC CTC TCG CCC GTG GAC TTC CAC TAC TCG CTG GCC ACG CAG GTG CCA	1812
Arg Leu Ser Pro Val Asp Phe His Tyr Ser Leu Ala Thr Gln Val Pro	
370 375 380	
ACT TTC GAG ATC ACG TCC CCC AAC TCG GCG CAC GCC GTG TCG CTG CCG	1860
Thr Phe Glu Ile Thr Ser Pro Asn Ser Ala His Ala Val Ser Leu Pro	
385 390 395	
CCG GCG GCG CCC ATC AGT TAC CGC	1884
Pro Ala Ala Pro Ile Ser Tyr Arg	
400 405	

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 407 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Met	Lys	Ser	Gln	Thr	Gly	Gln	Val	Gly	Glu	Lys	Gln	Ser	Leu	Lys	Cys
1				5					10					15	
Glu	Ala	Ala	Ala	Gly	Asn	Pro	Gln	Pro	Ser	Tyr	Arg	Trp	Phe	Lys	Asp
			20					25						30	
Gly	Lys	Glu	Leu	Asn	Arg	Ser	Arg	Asp	Ile	Arg	Ile	Lys	Tyr	Gly	Asn
		35					40					45			
Gly	Arg	Lys	Asn	Ser	Arg	Leu	Gln	Phe	Asn	Lys	Val	Lys	Val	Glu	Asp
	50					55					60				
Ala	Gly	Glu	Tyr	Val	Cys	Glu	Ala	Glu	Asn	Ile	Leu	Gly	Lys	Asp	Thr
	65				70					75				80	
Val	Arg	Gly	Arg	Leu	Tyr	Val	Asn	Ser	Val	Ser	Thr	Thr	Leu	Ser	Ser
			85						90					95	
Trp	Ser	Gly	His	Ala	Arg	Lys	Cys	Asn	Glu	Thr	Ala	Lys	Ser	Tyr	Cys
			100					105					110		
Val	Asn	Gly	Gly	Val	Cys	Tyr	Tyr	Ile	Glu	Gly	Ile	Asn	Gln	Leu	Ser
	115						120					125			
Cys	Lys	Cys	Pro	Asn	Gly	Phe	Phe	Gly	Gln	Arg	Cys	Leu	Glu	Lys	Leu
	130					135					140				
Pro	Leu	Arg	Leu	Tyr	Met	Pro	Asp	Pro	Lys	Gln	Lys	His	Leu	Gly	Phe
	145				150				155					160	
Glu	Leu	Lys	Glu	Ala	Glu	Glu	Leu	Tyr	Gln	Lys	Arg	Val	Leu	Thr	Ile
			165						170					175	
Thr	Gly	Ile	Cys	Val	Ala	Leu	Leu	Val	Gly	Ile	Val	Cys	Val	Val	
		180						185				190			
Ala	Tyr	Cys	Lys	Thr	Lys	Lys	Gln	Arg	Lys	Gln	Met	His	Asn	His	Leu
	195						200					205			

-82-

```

Arg Gln Asn Met Cys Pro Ala His Gln Asn Arg Ser Leu Ala Asn Gly
210      215      220
Pro Ser His Pro Arg Leu Asp Pro Glu Glu Ile Gln Met Ala Asp Tyr
225      230      235      240
Ile Ser Lys Asn Val Pro Ala Thr Asp His Val Ile Arg Arg Glu Thr
      245      250      255
Glu Thr Thr Phe Ser Gly Ser His Ser Cys Ser Pro Ser His His Cys
      260      265      270
Ser Thr Ala Thr Pro Thr Ser Ser His Arg His Glu Ser His Thr Trp
      275      280      285
Ser Leu Glu Arg Ser Glu Ser Leu Thr Ser Asp Ser Gln Ser Gly Ile
      290      295      300
Met Leu Ser Ser Val Gly Thr Ser Lys Cys Asn Ser Pro Ala Cys Val
      305      310      315      320
Glu Ala Arg Ala Arg Arg Ala Ala Ala Tyr Asn Leu Glu Glu Arg Arg
      325      330      335
Arg Ala Thr Ala Pro Pro Tyr His Asp Ser Val Asp Ser Leu Arg Asp
      340      345      350
Ser Pro His Ser Glu Arg Tyr Val Ser Ala Leu Thr Thr Pro Ala Arg
      355      360      365
Leu Ser Pro Val Asp Phe His Tyr Ser Leu Ala Thr Gln Val Pro Thr
      370      375      380
Phe Glu Ile Thr Ser Pro Asn Ser Ala His Ala Val Ser Leu Pro Pro
      385      390      395      400
Ala Ala Pro Ile Ser Tyr Arg
      405

```

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1476 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: Coding Sequence
- (B) LOCATION: 69...1475

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

```

CGGGCGGCGG GGGCGCAGCG CGGCAGCGGA GAGCTGAGGC CGTCCCACCG CCTGGGACCC      60
CGTGCAGA ATG TCG GAG TCC AGG AGG AGG GGC CGC GGC CGC GGC AAG AAG      110
Met Ser Glu Ser Arg Arg Arg Gly Arg Gly Arg Gly Lys Lys
      1      5      10
CAC CCA GAG GGG AGG AAG CGG GAG AGG GAG CCC GAT CCC GGG GAG AAA      158
His Pro Glu Gly Arg Lys Arg Glu Arg Glu Pro Asp Pro Gly Glu Lys
      15      20      25      30
GCC ACC CGG CCC AAG TTG AAG AAG ATG AAG AGC CAG ACG GGA CAG GTG      206
Ala Thr Arg Pro Lys Leu Lys Lys Met Lys Ser Gln Thr Gly Gln Val
      35      40      45
GGT GAG AAG CAA TCG CTG AAG TGT GAG GCA GCA GCC GGT AAT CCC CAG      254
Gly Glu Lys Gln Ser Leu Lys Cys Glu Ala Ala Ala Gly Asn Pro Gln
      50      55      60
CCT TCC TAC CGT TGG TTC AAG GAT GGC AAG GAG CTC AAC CGC AGC CGA      302
Pro Ser Tyr Arg Trp Phe Lys Asp Gly Lys Glu Leu Asn Arg Ser Arg
      65      70      75
GAC ATT CGC ATC AAA TAT GGC AAC GGC AGA AAG AAC TCA CGA CTA CAG      350
Asp Ile Arg Ile Lys Tyr Glu Asn Gly Arg Lys Asn Ser Arg Leu Gln
      80      85      90

```

-83-

TTC	AAC	AAG	GTG	AAG	GTG	GAG	GAC	GCT	GGG	GAG	TAT	GTC	TGC	GAG	GCC	398
Phe	Asn	Lys	Val	Lys	Val	Glu	Asp	Ala	Gly	Glu	Tyr	Val	Cys	Glu	Ala	
95					100					105					110	
GAG	AAC	ATC	CTG	GGG	AAG	GAC	ACC	GTC	CGG	GGC	CGG	CTT	TAC	GTC	AAC	446
Glu	Asn	Ile	Leu	Gly	Lys	Asp	Thr	Val	Arg	Gly	Arg	Leu	Tyr	Val	Asn	
			115						120					125		
AGC	GTG	AGC	ACC	ACC	CTG	TCA	TCC	TGG	TCG	GGG	CAC	GCC	CGG	AAG	TGC	494
Ser	Val	Ser	Thr	Thr	Leu	Ser	Ser	Trp	Ser	Gly	His	Ala	Arg	Lys	Cys	
			130					135					140			
AAC	GAG	ACA	GCC	AAG	TCC	TAT	TGC	GTC	AAT	GGA	GGC	GTC	TGC	TAC	TAC	542
Asn	Glu	Thr	Ala	Lys	Ser	Tyr	Cys	Val	Asn	Gly	Gly	Val	Cys	Tyr	Tyr	
		145					150					155				
ATC	GAG	GGC	ATC	AAC	CAG	CTC	TCC	TGC	AAA	TGT	CCA	AAT	GGA	TTC	TTC	590
Ile	Glu	Gly	Ile	Asn	Gln	Leu	Ser	Cys	Lys	Cys	Pro	Asn	Gly	Phe	Phe	
	160				165						170					
GGA	CAG	AGA	TGT	TTG	GAG	AAA	CTG	CCT	TTG	CGA	TTG	TAC	ATG	CCA	GAT	638
Gly	Gln	Arg	Cys	Leu	Glu	Lys	Leu	Pro	Leu	Arg	Leu	Tyr	Met	Pro	Asp	
175				180					185						190	
CCT	AAG	CAA	AAA	GCC	GAG	GAG	CTG	TAC	CAG	AAG	AGG	GTC	CTG	ACC	ATC	686
Pro	Lys	Gln	Lys	Ala	Glu	Glu	Leu	Tyr	Gln	Lys	Arg	Val	Leu	Thr	Ile	
			195						200					205		
ACG	GGC	ATC	TGC	GTG	GCT	CTG	CTG	GTC	GTG	GGC	ATC	GTC	TGT	GTG	GTG	734
Thr	Gly	Ile	Cys	Val	Ala	Leu	Leu	Val	Val	Gly	Ile	Val	Cys	Val	Val	
			210					215					220			
GCC	TAC	TGC	AAG	ACC	AAA	AAA	CAG	CGG	AAG	CAG	ATG	CAC	AAC	CAC	CTC	782
Ala	Tyr	Cys	Lys	Thr	Lys	Lys	Gln	Arg	Lys	Gln	Met	His	Asn	His	Leu	
		225					230				235					
CGG	CAG	AAC	ATG	TGC	CCG	GCC	CAT	CAG	AAC	CGG	AGC	TTG	GCC	AAT	GGG	830
Arg	Gln	Asn	Met	Cys	Pro	Ala	His	Gln	Asn	Arg	Ser	Leu	Ala	Asn	Gly	
		240				245					250					
CCC	AGC	CAC	CCC	CGG	CTG	GAC	CCA	GAG	GAG	ATC	CAG	ATG	GCA	GAT	TAT	878
Pro	Ser	His	Pro	Arg	Leu	Asp	Pro	Glu	Glu	Ile	Gln	Met	Ala	Asp	Tyr	
					260					265					270	
ATT	TCC	AAG	AAC	GTG	CCA	GCC	ACA	GAC	CAT	GTC	ATC	AGG	AGA	GAA	ACT	926
Ile	Ser	Lys	Asn	Val	Pro	Ala	Thr	Asp	His	Val	Ile	Arg	Arg	Glu	Thr	
				275					280					285		
GAG	ACC	ACC	TTC	TCT	GGG	AGC	CAC	TCC	TGT	TCT	CCT	TCT	CAC	CAC	TGC	974
Glu	Thr	Thr	Phe	Ser	Gly	Ser	His	Ser	Cys	Ser	Pro	Ser	His	His	Cys	
			290					295					300			
TCC	ACA	GCC	ACA	CCC	ACC	TCC	AGC	CAC	AGA	CAC	GAG	AGC	CAC	ACG	TGG	1022
Ser	Thr	Ala	Thr	Pro	Thr	Ser	Ser	His	Arg	His	Glu	Ser	His	Thr	Trp	
		305					310					315				
AGC	CTG	GAA	CGT	TCT	GAG	AGC	CTG	ACT	TCT	GAC	TCC	CAG	TCG	GGG	ATC	1070
Ser	Leu	Glu	Arg	Ser	Glu	Ser	Leu	Thr	Ser	Asp	Ser	Gln	Ser	Gly	Ile	
		320				325					330					
ATG	CTA	TCA	TCA	GTG	GGT	ACC	AGC	AAA	TGC	AAC	AGC	CCA	GCA	TGT	GTG	1118
Met	Leu	Ser	Ser	Val	Gly	Thr	Ser	Lys	Cys	Asn	Ser	Pro	Ala	Cys	Val	
		335			340					345					350	
GAG	GCC	CGG	GCA	AGG	CGG	GCA	GCA	GCC	TAC	AAC	CTG	GAG	GAG	CGG	CGC	1166
Glu	Ala	Arg	Ala	Arg	Arg	Ala	Ala	Ala	Tyr	Asn	Leu	Glu	Glu	Arg	Arg	
				355					360					365		

-84-

AGG GCC ACC GCG CCA CCC TAT CAC GAT TCC GTG GAC TCC CTT CGC GAC	1214
Arg Ala Thr Ala Pro Pro Tyr His Asp Ser Val Asp Ser Leu Arg Asp	
370 375 380	
TCC CCA CAC AGC GAG AGG TAC GTG TCG GCC CTG ACC ACG CCC GCG CGC	1262
Ser Pro His Ser Glu Arg Tyr Val Ser Ala Leu Thr Thr Pro Ala Arg	
385 390 395	
CTC TCG CCC GTG GAC TTC CAC TAC TCG CTG GCC ACG CAG GTG CCA ACT	1310
Leu Ser Pro Val Asp Phe His Tyr Ser Leu Ala Thr Gln Val Pro Thr	
400 405 410	
TTC GAG ATC ACG TCC CCC AAC TCG GCG CAC GCC GTG TCG CTG CCG CCG	1358
Phe Glu Ile Thr Ser Pro Asn Ser Ala His Ala Val Ser Leu Pro Pro	
415 420 425 430	
GCG GCG CCC ATC AGT TAC CGC CTG GCC GAG CAG CAG CCG TTA CTG CGG	1406
Ala Ala Pro Ile Ser Tyr Arg Leu Ala Glu Gln Gln Pro Leu Leu Arg	
435 440 445	
CAC CCG GCG CCC CCC GGC CCG GGA CCC GGA CCC GGG CCC GGG CCC GGG	1454
His Pro Ala Pro Pro Gly Pro Gly Pro Gly Pro Gly Pro Gly Pro Gly	
450 455 460	
CCC GGC GCA GAC ACC GGA ATT C	1476
Pro Gly Ala Asp Thr Gly Ile	
465	

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 469 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Met	Ser	Glu	Ser	Arg	Arg	Arg	Gly	Arg	Gly	Arg	Gly	Lys	Lys	His	Pro
1				5				10						15	
Glu	Gly	Arg	Lys	Arg	Glu	Arg	Glu	Pro	Asp	Pro	Gly	Glu	Lys	Ala	Thr
			20					25					30		
Arg	Pro	Lys	Leu	Lys	Lys	Met	Lys	Ser	Gln	Thr	Gly	Gln	Val	Gly	Glu
			35				40					45			
Lys	Gln	Ser	Leu	Lys	Cys	Glu	Ala	Ala	Ala	Gly	Asn	Pro	Gln	Pro	Ser
			50			55					60				
Tyr	Arg	Trp	Phe	Lys	Asp	Gly	Lys	Glu	Leu	Asn	Arg	Ser	Arg	Asp	Ile
				70						75				80	
Arg	Ile	Lys	Tyr	Gly	Asn	Gly	Arg	Lys	Asn	Ser	Arg	Leu	Gln	Phe	Asn
			85						90					95	
Lys	Val	Lys	Val	Glu	Asp	Ala	Gly	Glu	Tyr	Val	Cys	Glu	Ala	Glu	Asn
			100					105					110		
Ile	Leu	Gly	Lys	Asp	Thr	Val	Arg	Gly	Arg	Leu	Tyr	Val	Asn	Ser	Val
			115					120					125		
Ser	Thr	Thr	Leu	Ser	Ser	Trp	Ser	Gly	His	Ala	Arg	Lys	Cys	Asn	Glu
			130			135					140				
Thr	Ala	Lys	Ser	Tyr	Cys	Val	Asn	Gly	Gly	Val	Cys	Tyr	Tyr	Ile	Glu
				150						155				160	
Gly	Ile	Asn	Gln	Leu	Ser	Cys	Lys	Cys	Pro	Asn	Gly	Phe	Phe	Gly	Gln
			165						170					175	
Arg	Cys	Leu	Glu	Lys	Leu	Pro	Leu	Arg	Leu	Tyr	Met	Pro	Asp	Pro	Lys
			180					185					190		
Gln	Lys	Ala	Glu	Glu	Leu	Tyr	Gln	Lys	Arg	Val	Leu	Thr	Ile	Thr	Gly
			195				200						205		

-85-

```

Ile Cys Val Ala Leu Leu Val Val Gly Ile Val Cys Val Val Ala Tyr
 210          215          220
Cys Lys Thr Lys Lys Gln Arg Lys Gln Met His Asn His Leu Arg Gln
 225          230          235          240
Asn Met Cys Pro Ala His Gln Asn Arg Ser Leu Ala Asn Gly Pro Ser
          245          250          255
His Pro Arg Leu Asp Pro Glu Glu Ile Gln Met Ala Asp Tyr Ile Ser
          260          265          270
Lys Asn Val Pro Ala Thr Asp His Val Ile Arg Arg Glu Thr Glu Thr
          275          280          285
Thr Phe Ser Gly Ser His Ser Cys Ser Pro Ser His His Cys Ser Thr
          290          295          300
Ala Thr Pro Thr Ser Ser His Arg His Glu Ser His Thr Trp Ser Leu
 305          310          315          320
Glu Arg Ser Glu Ser Leu Thr Ser Asp Ser Gln Ser Gly Ile Met Leu
          325          330          335
Ser Ser Val Gly Thr Ser Lys Cys Asn Ser Pro Ala Cys Val Glu Ala
          340          345          350
Arg Ala Arg Arg Ala Ala Ala Tyr Asn Leu Glu Glu Arg Arg Ala
          355          360          365
Thr Ala Pro Pro Tyr His Asp Ser Val Asp Ser Leu Arg Asp Ser Pro
          370          375          380
His Ser Glu Arg Tyr Val Ser Ala Leu Thr Thr Pro Ala Arg Leu Ser
 385          390          395          400
Pro Val Asp Phe His Tyr Ser Leu Ala Thr Gln Val Pro Thr Phe Glu
          405          410          415
Ile Thr Ser Pro Asn Ser Ala His Ala Val Ser Leu Pro Pro Ala Ala
          420          425          430
Pro Ile Ser Tyr Arg Leu Ala Glu Gln Gln Pro Leu Leu Arg His Pro
          435          440          445
Ala Pro Pro Gly Pro Gly Pro Gly Pro Gly Pro Gly Pro Gly
          450          455          460
Ala Asp Thr Gly Ile
 465

```

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 422 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

```

Met Ser Glu Arg Lys Glu Gly Arg Gly Lys Gly Lys Gly Lys Lys Lys
  1          5          10          15
Asp Arg Gly Ser Arg Gly Lys Pro Gly Pro Ala Glu Gly Asp Pro Ser
          20          25          30
Pro Ala Leu Pro Pro Arg Leu Lys Glu Met Lys Ser Gln Glu Ser Ala
          35          40          45
Ala Gly Ser Lys Leu Val Leu Arg Cys Glu Thr Ser Ser Glu Tyr Ser
          50          55          60
Ser Leu Arg Phe Lys Trp Phe Lys Asn Gly Asn Glu Leu Asn Arg Lys
          65          70          75          80
Asn Lys Pro Glu Asn Ile Lys Ile Gln Lys Lys Pro Gly Lys Ser Glu
          85          90          95
Leu Arg Ile Asn Lys Ala Ser Leu Ala Asp Ser Gly Glu Tyr Met Cys
          100          105          110
Lys Val Ile Ser Lys Leu Gly Asn Asp Ser Ala Ser Ala Asn Ile Thr
          115          120          125
Ile Val Glu Ser Asn Glu Phe Ile Thr Gly Met Pro Ala Ser Thr Glu
          130          135          140
Thr Ala Tyr Val Ser Ser Glu Ser Pro Ile Arg Ile Ser Val Ser Thr
          145          150          155          160
Glu Gly Ala Asn Thr Ser Ser Ser Thr Ser Thr Ser Thr Thr Gly Thr
          165          170          175

```

-86-

```

Ser His Leu Ile Lys Cys Ala Glu Lys Glu Lys Thr Phe Cys Val Asn
      180      185      190
Gly Gly Glu Cys Phe Thr Val Lys Asp Leu Ser Asn Pro Ser Arg Tyr
      195      200      205
Leu Cys Lys Cys Gln Pro Gly Phe Thr Gly Ala Arg Cys Thr Glu Asn
      210      215      220
Val Pro Met Lys Val Gln Thr Gln Glu Lys Ala Glu Glu Leu Tyr Gln
      225      230      235      240
Lys Arg Val Leu Thr Ile Thr Gly Ile Cys Ile Ala Leu Leu Val Val
      245      250      255
Gly Ile Met Cys Val Val Ala Tyr Cys Lys Thr Lys Lys Gln Arg Gln
      260      265      270
Lys Leu His Asp Arg Leu Arg Gln Ser Leu Arg Ser Glu Arg Ser Asn
      275      280      285
Leu Val Asn Ile Ala Asn Gly Pro His His Pro Asn Pro Pro Pro Glu
      290      295      300
Asn Val Gln Leu Val Asn Gln Tyr Val Ser Lys Asn Val Ile Ser Ser
      305      310      315      320
Glu His Ile Val Glu Arg Glu Val Glu Thr Ser Phe Ser Thr Ser His
      325      330      335
Tyr Thr Ser Thr Ala His His Ser Thr Thr Val Thr Gln Thr Pro Ser
      340      345      350
His Ser Trp Ser Asn Gly His Thr Glu Ser Val Ile Ser Glu Ser Asn
      355      360      365
Ser Val Ile Met Met Ser Ser Val Glu Asn Ser Arg His Ser Ser Pro
      370      375      380
Ala Gly Gly Pro Arg Gly Arg Leu His Gly Leu Gly Gly Pro Arg Asp
      385      390      395      400
Asn Ser Phe Leu Arg His Ala Arg Glu Thr Pro Asp Ser Tyr Arg Asp
      405      410      415
Ser Pro His Ser Glu Arg
      420

```

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 645 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

```

Met Ser Glu Arg Lys Glu Gly Arg Gly Lys Gly Lys Gly Lys Lys Lys
  1      5      10      15
Glu Arg Gly Ser Gly Lys Lys Pro Glu Ser Ala Ala Gly Ser Gln Ser
  20      25      30
Pro Ala Leu Pro Pro Arg Leu Lys Glu Met Lys Ser Gln Glu Ser Ala
  35      40      45
Ala Gly Ser Lys Leu Val Leu Arg Cys Glu Thr Ser Ser Glu Tyr Ser
  50      55      60
Ser Leu Arg Phe Lys Trp Phe Lys Asn Gly Asn Glu Leu Asn Arg Lys
  65      70      75      80
Asn Lys Pro Gln Asn Ile Lys Ile Gln Lys Lys Pro Gly Lys Ser Glu
  85      90      95
Leu Arg Ile Asn Lys Ala Ser Leu Ala Asp Ser Gly Glu Tyr Met Cys
  100      105      110
Lys Val Ile Ser Lys Leu Gly Asn Asp Ser Ala Ser Ala Asn Ile Thr
  115      120      125
Ile Val Glu Ser Asn Glu Ile Ile Thr Gly Met Pro Ala Ser Thr Glu
  130      135      140
Gly Ala Tyr Val Ser Ser Glu Ser Pro Ile Arg Ile Ser Val Ser Thr
  145      150      155      160
Glu Gly Ala Asn Thr Ser Ser Ser Thr Ser Thr Ser Thr Thr Gly Thr
  165      170      175
Ser His Leu Val Lys Cys Ala Glu Lys Glu Lys Thr Phe Cys Val Asn
  180      185      190

```

-87-

Gly	Gly	Glu	Cys	Phe	Met	Val	Lys	Asp	Leu	Ser	Asn	Pro	Ser	Arg	Tyr
		195					200					205			
Leu	Cys	Lys	Cys	Pro	Asn	Glu	Phe	Thr	Gly	Asp	Arg	Cys	Gln	Asn	Tyr
		210				215					220				
Val	Met	Ala	Ser	Phe	Tyr	Lys	His	Leu	Gly	Ile	Glu	Phe	Met	Glu	Ala
225					230					235					240
Glu	Glu	Leu	Tyr	Gln	Lys	Arg	Val	Leu	Thr	Ile	Thr	Gly	Ile	Cys	Ile
				245						250				255	
Ala	Leu	Leu	Val	Val	Gly	Ile	Met	Cys	Val	Val	Ala	Tyr	Cys	Lys	Thr
			260					265					270		
Lys	Lys	Gln	Arg	Lys	Lys	Leu	His	Asp	Arg	Leu	Arg	Gln	Ser	Leu	Arg
		275					280					285			
Ser	Glu	Arg	Asn	Asn	Met	Met	Asn	Ile	Ala	Asn	Gly	Pro	His	His	Pro
	290					295					300				
Asn	Pro	Pro	Pro	Glu	Asn	Val	Gln	Leu	Val	Asn	Gln	Tyr	Val	Ser	Lys
305					310					315					320
Asn	Val	Ile	Ser	Ser	Glu	His	Ile	Val	Glu	Arg	Glu	Ala	Glu	Thr	Ser
			325						330					335	
Phe	Ser	Thr	Ser	His	Tyr	Thr	Ser	Thr	Ala	His	His	Ser	Thr	Thr	Val
			340					345					350		
Thr	Gln	Thr	Pro	Ser	His	Ser	Trp	Ser	Asn	Gly	His	Thr	Glu	Ser	Ile
		355					360					365			
Leu	Ser	Glu	Ser	His	Ser	Val	Ile	Val	Met	Ser	Ser	Val	Glu	Asn	Ser
	370					375					380				
Arg	His	Ser	Ser	Pro	Thr	Gly	Gly	Pro	Arg	Gly	Arg	Leu	Asn	Gly	Thr
385					390					395					400
Gly	Gly	Pro	Arg	Glu	Cys	Asn	Ser	Phe	Leu	Arg	His	Ala	Arg	Glu	Thr
				405					410					415	
Pro	Asp	Ser	Tyr	Arg	Asp	Ser	Pro	His	Ser	Glu	Arg	Tyr	Val	Ser	Ala
			420					425					430		
Met	Thr	Thr	Pro	Ala	Arg	Met	Ser	Pro	Val	Asp	Phe	His	Thr	Pro	Ser
		435					440					445			
Ser	Pro	Lys	Ser	Pro	Pro	Ser	Glu	Met	Ser	Pro	Pro	Val	Ser	Ser	Met
	450					455				460					
Thr	Val	Ser	Met	Pro	Ser	Met	Ala	Val	Ser	Pro	Phe	Met	Glu	Glu	Glu
465					470					475					480
Arg	Pro	Leu	Leu	Leu	Val	Thr	Pro	Pro	Arg	Leu	Arg	Glu	Lys	Lys	Phe
				485					490					495	
Asp	His	His	Pro	Gln	Gln	Phe	Ser	Ser	Phe	His	His	Asn	Pro	Ala	His
			500					505				510			
Asp	Ser	Asn	Ser	Leu	Pro	Ala	Ser	Pro	Leu	Arg	Ile	Val	Glu	Asp	Glu
		515					520					525			
Glu	Tyr	Glu	Thr	Thr	Gln	Glu	Tyr	Glu	Pro	Ala	Gln	Glu	Pro	Val	Lys
	530					535					540				
Lys	Leu	Ala	Asn	Ser	Arg	Arg	Ala	Lys	Arg	Thr	Lys	Pro	Asn	Gly	His
545					550					555					560
Ile	Ala	Asn	Arg	Leu	Glu	Val	Asp	Ser	Asn	Thr	Ser	Ser	Gln	Ser	Ser
			565						570					575	
Asn	Ser	Glu	Ser	Glu	Thr	Glu	Asp	Glu	Arg	Val	Gly	Glu	Asp	Thr	Pro
		580						585				590			
Phe	Leu	Gly	Ile	Gln	Asn	Pro	Leu	Ala	Ala	Ser	Leu	Glu	Ala	Thr	Pro
	595					600						605			
Ala	Phe	Arg	Leu	Ala	Asp	Ser	Arg	Thr	Asn	Pro	Ala	Gly	Arg	Phe	Ser
	610					615					620				
Thr	Gln	Glu	Glu	Ile	Gln	Ala	Arg	Leu	Ser	Ser	Val	Ile	Ala	Asn	Gln
625					630					635					640
Asp	Pro	Ile	Ala	Val											
				645											

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 47 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

-88-

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

Gly	His	Ala	Arg	Lys	Cys	Asn	Glu	Thr	Ala	Lys	Ser	Tyr	Cys	Val	Asn
1				5					10					15	
Gly	Gly	Val	Cys	Tyr	Tyr	Ile	Glu	Gly	Ile	Asn	Gln	Leu	Ser	Cys	Lys
			20					25					30		
Cys	Pro	Asn	Gly	Phe	Phe	Gly	Gln	Arg	Cys	Leu	Glu	Lys	Leu	Pro	
		35				40						45			

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 50 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

Ser	His	Leu	Val	Lys	Cys	Ala	Glu	Lys	Glu	Lys	Thr	Phe	Cys	Val	Asn
1				5					10					15	
Gly	Gly	Glu	Cys	Phe	Met	Val	Lys	Asp	Leu	Ser	Asn	Pro	Ser	Arg	Tyr
			20					25					30		
Leu	Cys	Lys	Cys	Gln	Pro	Gly	Phe	Thr	Gly	Ala	Arg	Cys	Thr	Glu	Asn
		35				40						45			
Val	Pro														
	50														

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 50 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

Ser	His	Leu	Ile	Lys	Cys	Ala	Glu	Lys	Glu	Lys	Thr	Phe	Cys	Val	Asn
1				5					10					15	
Gly	Gly	Glu	Cys	Phe	Thr	Val	Lys	Asp	Leu	Ser	Asn	Pro	Ser	Arg	Tyr
			20					25					30		
Leu	Cys	Lys	Cys	Gln	Pro	Gly	Phe	Thr	Gly	Ala	Arg	Cys	Thr	Glu	Asn
		35				40						45			
Val	Pro														
	50														

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 50 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

Ser	His	Leu	Val	Lys	Cys	Ala	Glu	Lys	Glu	Lys	Thr	Phe	Cys	Val	Asn
1				5					10					15	
Gly	Gly	Glu	Cys	Phe	Met	Val	Lys	Asp	Leu	Ser	Asn	Pro	Ser	Arg	Tyr
			20					25					30		
Leu	Cys	Lys	Cys	Pro	Asn	Glu	Phe	Thr	Gly	Asp	Arg	Cys	Gln	Asn	Tyr
		35				40						45			

-89-

Val Met
50

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 50 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

```

Ser His Leu Thr Lys Cys Asp Ile Lys Gln Lys Ala Phe Cys Val Asn
 1             5             10             15
Gly Gly Glu Cys Tyr Met Val Lys Asp Leu Pro Asn Pro Pro Arg Tyr
          20             25             30
Leu Cys Arg Cys Pro Asn Glu Phe Thr Gly Asp Arg Cys Gln Asn Tyr
          35             40             45
Val Met
 50

```

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 46 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

```

Gly Lys Arg Asp Pro Cys Leu Arg Lys Tyr Lys Asp Phe Cys Ile His
 1             5             10             15
Gly Glu Cys Lys Tyr Val Lys Glu Leu Arg Ala Pro Ser Cys Ile Cys
          20             25             30
His Pro Gly Tyr His Gly Glu Arg Cys His Gly Leu Ser Leu
          35             40             45

```

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 47 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

```

Asn Ser Asp Ser Glu Cys Pro Leu Ser His Asp Gly Tyr Cys Leu His
 1             5             10             15
Asp Gly Val Cys Met Tyr Ile Glu Ala Leu Asp Lys Tyr Ala Cys Asn
          20             25             30
Cys Val Val Gly Tyr Ile Gly Glu Arg Cys Gln Tyr Arg Asp Leu
          35             40             45

```

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 46 amino acids

-90-

(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

```

Lys Lys Lys Asn Pro Cys Asn Ala Glu Phe Gln Asn Phe Cys Ile His
 1      5      10      15
Gly Glu Cys Lys Tyr Ile Glu His Leu Glu Ala Val Thr Cys Lys Cys
      20      25      30
Gln Gln Glu Tyr Phe Gly Glu Arg Cys Gly Glu Lys Ser Met
      35      40      45

```

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 46 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

```

Ser His Phe Asn Asp Cys Pro Asp Ser His Thr Gln Phe Cys Phe His
 1      5      10      15
Gly Thr Cys Arg Phe Leu Val Gln Glu Asp Lys Pro Ala Cys Val Cys
      20      25      30
His Ser Gly Tyr Val Gly Ala Arg Cys Glu His Ala Asp Leu
      35      40      45

```

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

```

Val Leu Thr Ile Thr Gly Ile Cys Val Ala Leu Leu Val Val Gly Ile
 1      5      10      15
Val Cys Val Val Ala Tyr Cys
      20

```

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

(A) NAME/KEY: Coding Sequence
(B) LOCATION: 9...9
(D) OTHER INFORMATION: where Xaa at position 9 is
Isoleucine or Valine

(A) NAME/KEY: Other
(B) LOCATION: 17...17
(D) OTHER INFORMATION: where Xaa at position 17 is
Methionine or Valine

-91-

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

Val Leu Thr Ile Thr Gly Ile Cys Xaa Ala Leu Leu Val Val Gly Ile
1 5 10 15
Xaa Cys Val Val Ala Tyr Cys
20

(2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

GACTTGGCTC TCTCG

15

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

GGACTCCGAC ATTCT

15

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro
20

(2) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 29 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

AAAAAGAATT CCTCCATGTC AACAGCGTG

29

(2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 33 base pairs
- (B) TYPE: nucleic acid

-92-

- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

TCCTCTCTCG AGTCACTTAG GATCTGGCAT GTA

33

(2) INFORMATION FOR SEQ ID NO:27:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 17 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

CACAGTCCAC CCCTCAG

17

(2) INFORMATION FOR SEQ ID NO:28:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

GCTCTGGTAA GCAAACATGG

20

(2) INFORMATION FOR SEQ ID NO:29:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

TGTGAAGTCC TCTGGCCTGT

20

(2) INFORMATION FOR SEQ ID NO:30:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

GAAGGGGCTG GGCATTTAAT

20

(2) INFORMATION FOR SEQ ID NO:31:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2268 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

-93-

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: Coding Sequence

(B) LOCATION: 69...2009

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

```

CGGGCGGCGG GGGCGCAGCG CGGCAGCGGA GAGCTGAGGC CGTCCACCG CCTGGGACCC      60
CGTGCAGA ATG TCG GAG TCC AAG AGG AGG GGC CGC GGC CGC GGC AAG AAG      110
Met Ser Glu Ser Lys Arg Arg Gly Arg Gly Arg Gly Lys Lys
  1          5          10
CAC CCA GAG GGG AGG AAG CGG GAG AGG GAG CCC GAT CCC GGG GAG AAA      158
His Pro Glu Gly Arg Lys Arg Glu Arg Glu Pro Asp Pro Gly Glu Lys
 15          20          25          30
GCC ACC CGG CCC AAG TTG AAG AAG ATG AAG AGC CAG ACG GGA CAG GTG      206
Ala Thr Arg Pro Lys Leu Lys Lys Met Lys Ser Gln Thr Gly Gln Val
          35          40          45
GGT GAG AAG CAA TCG CTG AAG TGT GAG GCA GCA GCC GGT AAT CCC CAG      254
Gly Glu Lys Gln Ser Leu Lys Cys Glu Ala Ala Ala Gly Asn Pro Gln
          50          55          60
CCT TCC TAC CGT TGG TTC AAG GAT GGC AAG GAG CTC AAC CGC AGC CGA      302
Pro Ser Tyr Arg Trp Phe Lys Asp Gly Lys Glu Leu Asn Arg Ser Arg
          65          70          75
GAC ATT CGC ATC AAA TAT GGC AAC GGC AGA AAG AAC TCA CGA CTA CAG      350
Asp Ile Arg Ile Lys Tyr Gly Asn Gly Arg Lys Asn Ser Arg Leu Gln
          80          85          90
TTC AAC AAG GTG AAG GTG GAG GAC GCT GGG GAG TAT GTC TGC GAG GCC      398
Phe Asn Lys Val Lys Val Glu Asp Ala Gly Glu Tyr Val Cys Glu Ala
          95          100          105          110
GAG AAC ATC CTG GGG AAG GAC ACC GTC CGG GGC CGG CTT TAC GTC AAC      446
Glu Asn Ile Leu Gly Lys Asp Thr Val Arg Gly Arg Leu Tyr Val Asn
          115          120          125
AGC GTG AGC ACC ACC CTG TCA TCC TGG TCG GGG CAC GCC CGG AAG TGC      494
Ser Val Ser Thr Thr Leu Ser Ser Trp Ser Gly His Ala Arg Lys Cys
          130          135          140
AAC GAG ACA GCC AAG TCC TAT TGC GTC AAT GGA GGC GTC TGC TAC TAC      542
Asn Glu Thr Ala Lys Ser Tyr Cys Val Asn Gly Gly Val Cys Tyr Tyr
          145          150          155
ATC GAG GGC ATC AAC CAG CTC TCC TGC AAA TGT CCA AAT GGA TTC TTC      590
Ile Glu Gly Ile Asn Gln Leu Ser Cys Lys Cys Pro Asn Gly Phe Phe
          160          165          170
GGA CAG AGA TGT TTG GAG AAA CTG CCT TTG CGA TTG TAC ATG CCA GAT      638
Gly Gln Arg Cys Leu Glu Lys Leu Pro Leu Arg Leu Tyr Met Pro Asp
          175          180          185          190
CCT AAG CAA AAA GCC GAG GAG CTG TAC CAG AAG AGG GTC CTG ACC ATC      686
Pro Lys Gln Lys Ala Glu Glu Leu Tyr Gln Lys Arg Val Leu Thr Ile
          195          200          205
ACG GGC ATC TGC GTG GCT CTG CTG GTC GTG GGC ATC GTC TGT GTG GTG      734
Thr Gly Ile Cys Val Ala Leu Leu Val Val Gly Ile Val Cys Val Val
          210          215          220
GCC TAC TGC AAG ACC AAA AAA CAG CGG AAG CAG ATG CAC AAC CAC CTC      782
Ala Tyr Cys Lys Thr Lys Lys Gln Arg Lys Gln Met His Asn His Leu
          225          230          235

```

-94-

CGG Arg	CAG Gln	AAC Asn	ATG Met	TGC Cys	CCG Pro	GCC Ala	CAT His	CAG Gln	AAC Asn	CGG Arg	AGC Ser	TTG Leu	GCC Ala	AAT Asn	GGG Gly	830
240						245					250					
CCC Pro	AGC Ser	CAC His	CCC Pro	CGG Arg	CTG Leu	GAC Asp	CCA Pro	GAG Glu	GAG Glu	ATG Met	CAG Gln	ATG Met	GCA Ala	GAT Asp	TAT Tyr	878
255					260					265					270	
ATT Ile	TCC Ser	AAG Lys	AAC Asn	GTG Val	CCA Pro	GCC Ala	ACA Thr	GAC Asp	CAT His	GTC Val	ATC Ile	AGG Arg	AGA Arg	GAA Glu	ACT Thr	926
				275					280					285		
GAG Glu	ACC Thr	ACC Thr	TTC Phe	TCT Ser	GGG Gly	AGC Ser	CAC His	TCC Ser	TGT Cys	TCT Ser	CCT Pro	TCT Ser	CAC His	CAC His	TGC Cys	974
			290					295					300			
TCC Ser	ACA Thr	GCC Ala	ACA Thr	CCC Pro	ACC Thr	TCC Ser	AGC Thr	CAC His	AGA Arg	CAC His	GAG Glu	AGC Ser	CAC His	ACG Thr	TGG Trp	1022
		305					310					315				
AGC Ser	CTG Leu	GAA Glu	CGT Arg	TCT Ser	GAG Glu	AGC Ser	CTG Leu	ACT Thr	TCT Ser	GAC Asp	TCC Ser	CAG Gln	TCG Ser	GGG Gly	ATC Ile	1070
	320					325					330					
ATG Met	CTA Leu	TCA Ser	TCA Ser	GTG Val	GGT Gly	ACC Thr	AGC Ser	AAA Lys	TGC Cys	AAC Asn	AGC Ser	CCA Pro	GCA Ala	TGT Cys	GTG Val	1118
335					340					345					350	
GAG Glu	GCC Ala	CGG Arg	GCA Ala	AGG Arg	CGG Arg	GCA Ala	GCA Ala	GCC Ala	TAC Tyr	AAC Asn	CTG Leu	GAG Glu	GAG Glu	CGG Arg	CGC Arg	1166
				355					360					365		
AGG Arg	GCC Ala	ACC Thr	GCG Ala	CCA Pro	CCC Pro	TAT Tyr	CAC His	GAT Asp	TCC Ser	GTG Val	GAC Asp	TCC Ser	CTT Leu	CGC Arg	GAC Asp	1214
			370					375					380			
TCC Ser	CCA Pro	CAC His	AGC Ser	GAG Glu	AGG Arg	TAC Tyr	GTG Val	TCG Ser	GCC Ala	CTG Leu	ACC Thr	ACG Thr	CCC Pro	GCG Ala	CGC Arg	1262
		385					390					395				
CTC Leu	TCG Ser	CCC Pro	GTG Val	GAC Asp	TTC Phe	CAC His	TAC Tyr	TCG Ser	CTG Leu	GCC Ala	ACG Thr	CAG Gln	GTG Val	CCA Pro	ACT Thr	1310
	400					405					410					
TTC Phe	GAG Glu	ATC Ile	ACG Thr	TCC Ser	CCC Pro	AAC Asn	TCG Ser	GCG Ala	CAC His	GCC Ala	GTG Val	TCG Ser	CTG Leu	CCG Pro	CCG Pro	1358
415					420					425					430	
GCG Ala	GCG Ala	CCC Pro	ATC Ile	AGT Ser	TAC Tyr	CGC Arg	CTG Leu	GCC Ala	GAG Glu	CAG Gln	CAG Gln	CCG Pro	TTA Leu	CTG Leu	CGG Arg	1406
				435					440					445		
CAC His	CCG Pro	GCG Ala	CCC Pro	CCC Pro	GGC Gly	CCG Pro	GGA Gly	CCC Pro	GGA Gly	CCC Pro	GGG Gly	CCC Pro	GGG Gly	CCC Pro	GGG Gly	1454
			450					455					460			
CCC Pro	GGC Gly	GCA Ala	GAC Asp	ATG Met	CAG Gln	CGC Arg	AGC Ser	TAT Tyr	GAC Asp	AGC Ser	TAC Tyr	TAT Tyr	TAC Tyr	CCC Pro	GCG Ala	1502
		465					470					475				
GCG Ala	GGG Gly	CCC Pro	GGA Gly	CCG Pro	CGG Arg	CGC Arg	GGG Gly	ACC Thr	TGC Cys	GCG Ala	CTC Leu	GGC Gly	GGC Gly	AGC Ser	CTG Leu	1550
	480					485					490					
GGC Gly	AGC Ser	CTG Leu	CCT Pro	GCC Ala	AGC Ser	CCC Pro	TTC Phe	CGC Arg	ATC Ile	CCC Pro	GAG Glu	GAC Asp	GAC Asp	GAG Glu	TAC Tyr	1598
495					500					505					510	

-95-

GAG ACC ACG CAG GAG TGC GCG CCC CCG CCG CCG CCG CCG CCG CCG CCG	1646
Glu Thr Thr Gln Glu Cys Ala Pro Pro Pro Pro Pro Pro Pro Pro Pro Pro	
515 520 525	
CGC GGT GCG TCC CGC AGG ACG TCG GCG GGG CCC CCG CGC TGG CGC CGC	1694
Arg Gly Ala Ser Arg Arg Thr Ser Ala Gly Pro Arg Arg Trp Arg Arg	
530 535 540	
TCG CGC CTC AAC GGG CTG GCG GCG CAG CGC GCA CCG GCG GCG AGG GAC	1742
Ser Arg Leu Asn Gly Leu Ala Ala Gln Arg Ala Arg Ala Ala Arg Asp	
545 550 555	
TCG CTG TCG CTG AGC AGC GGC TCG GGC GGC GGC TCA GCC TCG GCG TCG	1790
Ser Leu Ser Leu Ser Ser Gly Ser Gly Gly Gly Ser Ala Ser Ala Ser	
560 565 570	
GAC GAC GAC GCG GAC GAC GCG GAC GGG GCG CTG GCG GCC GAG AGC ACA	1838
Asp Asp Asp Ala Asp Asp Ala Asp Gly Ala Leu Ala Ala Glu Ser Thr	
575 580 585 590	
CCT TTC CTG GGC CTG CGT GGG GCG CAC GAC GCG CTG CGC TCG GAC TCG	1886
Pro Phe Leu Gly Leu Arg Gly Ala His Asp Ala Leu Arg Ser Asp Ser	
595 600 605	
CCG CCA CTG TGC CCG GCG GCC GAC AGC AGG ACT TAC TAC TCA CTG GAC	1934
Pro Pro Leu Cys Pro Ala Ala Asp Ser Arg Thr Tyr Tyr Ser Leu Asp	
610 615 620	
AGC CAC AGC ACG CGG GCC AGC AGC AGA CAC AGC CGC GGG CCG CCC CCG	1982
Ser His Ser Thr Arg Ala Ser Ser Arg His Ser Arg Gly Pro Pro Pro	
625 630 635	
CGG GCC AAG CAG GAC TCG GCG CCA CTC TAGGGCCCCG CCGCGCGCCC CTCCGCC	2036
Arg Ala Lys Gln Asp Ser Ala Pro Leu	
640 645	
CCGCCCCGCC CACTATCTTT AAGGAGACCA GAGACCGCCT ACTGGAGAGA AAGGAGGAAA	2096
AAAGAAATAA AAATATTTTT ATTTCTATA AAAGGAAAAA AGTATAACAA AATGTTTTAT	2156
TTTCATTTTA GCAAAAATTG TCTTATAATA CTAGCTAACG GCAAAGGCGT TTTTATAGGG	2216
AAACTATTTA TATGTAACAT CCTGATTAC AGCTTCGGAA AAAAAAAGA AA	2268

(2) INFORMATION FOR SEQ ID NO:32:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 647 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

Met Ser Glu Ser Lys Arg Arg Gly Arg Gly Arg Gly Lys Lys His Pro	
1 5 10 15	
Glu Gly Arg Lys Arg Glu Arg Glu Pro Asp Pro Gly Glu Lys Ala Thr	
20 25 30	
Arg Pro Lys Leu Lys Lys Met Lys Ser Gln Thr Gly Gln Val Gly Glu	
35 40 45	
Lys Gln Ser Leu Lys Cys Glu Ala Ala Ala Gly Asn Pro Gln Pro Ser	
50 55 60	
Tyr Arg Trp Phe Lys Asp Gly Lys Glu Leu Asn Arg Ser Arg Asp Ile	
65 70 75 80	
Arg Ile Lys Tyr Gly Asn Gly Arg Lys Asn Ser Arg Leu Gln Phe Asn	
85 90 95	
Lys Val Lys Val Glu Asp Ala Gly Glu Tyr Val Cys Glu Ala Glu Asn	
100 105 110	

-96-

Ile Leu Gly Lys Asp Thr Val Arg Gly Arg Leu Tyr Val Asn Ser Val
 115 120 125
 Ser Thr Thr Leu Ser Ser Trp Ser Gly His Ala Arg Lys Cys Asn Glu
 130 135 140
 Thr Ala Lys Ser Tyr Cys Val Asn Gly Gly Val Cys Tyr Tyr Ile Glu
 145 150 155 160
 Gly Ile Asn Gln Leu Ser Cys Lys Cys Pro Asn Gly Phe Phe Gly Gln
 165 170 175
 Arg Cys Leu Glu Lys Leu Pro Leu Arg Leu Tyr Met Pro Asp Pro Lys
 180 185 190
 Gln Lys Ala Glu Glu Leu Tyr Gln Lys Arg Val Leu Thr Ile Thr Gly
 195 200 205
 Ile Cys Val Ala Leu Leu Val Val Gly Ile Val Cys Val Val Ala Tyr
 210 215 220
 Cys Lys Thr Lys Lys Gln Arg Lys Gln Met His Asn His Leu Arg Gln
 225 230 235 240
 Asn Met Cys Pro Ala His Gln Asn Arg Ser Leu Ala Asn Gly Pro Ser
 245 250 255
 His Pro Arg Leu Asp Pro Glu Glu Met Gln Met Ala Asp Tyr Ile Ser
 260 265 270
 Lys Asn Val Pro Ala Thr Asp His Val Ile Arg Arg Glu Thr Glu Thr
 275 280 285
 Thr Phe Ser Gly Ser His Ser Cys Ser Pro Ser His His Cys Ser Thr
 290 295 300
 Ala Thr Pro Thr Ser Thr His Arg His Glu Ser His Thr Trp Ser Leu
 305 310 315 320
 Glu Arg Ser Glu Ser Leu Thr Ser Asp Ser Gln Ser Gly Ile Met Leu
 325 330 335
 Ser Ser Val Gly Thr Ser Lys Cys Asn Ser Pro Ala Cys Val Glu Ala
 340 345 350
 Arg Ala Arg Arg Ala Ala Ala Tyr Asn Leu Glu Glu Arg Arg Arg Ala
 355 360 365
 Thr Ala Pro Pro Tyr His Asp Ser Val Asp Ser Leu Arg Asp Ser Pro
 370 375 380
 His Ser Glu Arg Tyr Val Ser Ala Leu Thr Thr Pro Ala Arg Leu Ser
 385 390 395 400
 Pro Val Asp Phe His Tyr Ser Leu Ala Thr Gln Val Pro Thr Phe Glu
 405 410 415
 Ile Thr Ser Pro Asn Ser Ala His Ala Val Ser Leu Pro Pro Ala Ala
 420 425 430
 Pro Ile Ser Tyr Arg Leu Ala Glu Gln Gln Pro Leu Leu Arg His Pro
 435 440 445
 Ala Pro Pro Gly Pro Gly Pro Gly Pro Gly Pro Gly Pro Gly Pro Gly
 450 455 460
 Ala Asp Met Gln Arg Ser Tyr Asp Ser Tyr Tyr Tyr Pro Ala Ala Gly
 465 470 475 480
 Pro Gly Pro Arg Arg Gly Thr Cys Ala Leu Gly Gly Ser Leu Gly Ser
 485 490 495
 Leu Pro Ala Ser Pro Phe Arg Ile Pro Glu Asp Asp Glu Tyr Glu Thr
 500 505 510
 Thr Gln Glu Cys Ala Pro Pro Pro Pro Pro Arg Pro Arg Ala Arg Gly
 515 520 525
 Ala Ser Arg Arg Thr Ser Ala Gly Pro Arg Arg Trp Arg Arg Ser Arg
 530 535 540
 Leu Asn Gly Leu Ala Ala Gln Arg Ala Arg Ala Arg Asp Ser Leu
 545 550 555 560
 Ser Leu Ser Ser Gly Ser Gly Gly Gly Ser Ala Ser Ala Ser Asp Asp
 565 570 575
 Asp Ala Asp Asp Ala Asp Gly Ala Leu Ala Ala Glu Ser Thr Pro Phe
 580 585 590
 Leu Gly Leu Arg Gly Ala His Asp Ala Leu Arg Ser Asp Ser Pro Pro
 595 600 605
 Leu Cys Pro Ala Ala Asp Ser Arg Thr Tyr Tyr Ser Leu Asp Ser His
 610 615 620
 Ser Thr Arg Ala Ser Ser Arg His Ser Arg Gly Pro Pro Pro Arg Ala
 625 630 635 640
 Lys Gln Asp Ser Ala Pro Leu
 645

-97-

(2) INFORMATION FOR SEQ ID NO:33:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 139 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

Arg	Ile	Lys	Tyr	Gly	Asn	Gly	Arg	Lys	Asn	Ser	Arg	Leu	Gln	Phe	Asn	1	5	10	15
Lys	Val	Arg	Val	Glu	Asp	Ala	Gly	Glu	Tyr	Val	Cys	Glu	Ala	Glu	Asn	20	25	30	
Ile	Leu	Gly	Lys	Asp	Thr	Val	Arg	Gly	Arg	Leu	His	Val	Asn	Ser	Val	35	40	45	
Ser	Thr	Thr	Leu	Ser	Ser	Trp	Ser	Gly	His	Ala	Arg	Lys	Cys	Asn	Glu	50	55	60	
Thr	Ala	Lys	Ser	Tyr	Cys	Val	Asn	Gly	Gly	Val	Cys	Tyr	Tyr	Ile	Glu	65	70	75	80
Gly	Ile	Asn	Gln	Leu	Ser	Cys	Lys	Cys	Pro	Asn	Gly	Phe	Phe	Gly	Gln	85	90	95	
Arg	Cys	Leu	Glu	Lys	Leu	Pro	Leu	Arg	Leu	Tyr	Met	Pro	Asp	Pro	Lys	100	105	110	
Gln	Ser	Val	Leu	Trp	Asp	Thr	Pro	Gly	Thr	Gly	Val	Ser	Ser	Ser	Gln	115	120	125	
Trp	Ser	Thr	Ser	Pro	Ser	Thr	Leu	Asp	Leu	Asn						130	135		

- 98 -

What is claimed is:

1. An isolated nucleic acid encoding a Don-1 polypeptide.
2. An isolated nucleic acid of claim 1, wherein
5 the nucleic acid encodes an amino acid sequence of SEQ ID NO:2, 4, 6, 8, or 32.
3. A nucleic acid of claim 1, wherein said nucleic acid encodes a soluble Don-1 polypeptide.
4. A nucleic acid of claim 1, wherein said
10 nucleic acid comprises the nucleotide sequence of SEQ ID NO:1, 3, 5, 7, or 31.
5. A nucleic acid of claim 1, wherein said nucleic acid encodes the epidermal growth factor (EGF) domain of Don-1 having SEQ ID NO:11.
- 15 6. A nucleic acid of claim 1, wherein said nucleic acid encodes the extracellular domain of Don-1.
7. A nucleic acid encoding a hybrid polypeptide, said hybrid polypeptide comprising a first portion and a second portion, said first portion comprising a Don-1
20 polypeptide and said second portion comprising an immunoglobulin constant (Fc) region.
8. A nucleic acid of claim 7, wherein the first portion comprises the epidermal growth factor (EGF) domain of Don-1.
- 25 9. A nucleic acid of claim 1 encoding the amino acid sequence of the Ig domain of Don-1.

- 99 -

10. A nucleic acid of claim 1 encoding the amino acid sequence of the transmembrane (TM) domain of Don-1.

11. An isolated nucleic acid of claim 1 comprising the nucleotide sequence of the *don-1* gene
5 contained in A.T.C.C. deposit 98096, 98097, or 98098.

12. An isolated nucleic acid of claim 1 that hybridizes to the nucleotide sequence of SEQ ID NO:1, 3, 5, 7, or 31 or its complement.

13. An isolated nucleic acid of claim 12, wherein
10 the nucleic acid encodes a polypeptide that activates receptor-type tyrosine kinases that have a molecular weight of about 185 kDa.

14. An isolated nucleic acid of claim 1 that hybridizes to the nucleotide sequence of the *don-1* gene
15 contained in A.T.C.C. deposit 98096, 98097, or 98098.

15. An isolated nucleic acid of claim 14, wherein the nucleic acid encodes a polypeptide that activates receptor-type tyrosine kinases that have a molecular weight of about 185 kDa.

20 16. An isolated nucleic acid of claim 1 that hybridizes to the nucleotide sequence of the transmembrane (TM) domain of the *don-1* gene, wherein the isolated nucleic acid encodes a polypeptide that activates receptor-type tyrosine kinases that have a
25 molecular weight of about 185 kDa.

17. An isolated nucleic acid of claim 1 that hybridizes to the nucleotide sequence of the epidermal growth factor (EGF) domain of the *don-1* gene, wherein the

- 100 -

isolated nucleic acid encodes a polypeptide that activates receptor-type tyrosine kinases that have a molecular weight of about 185 kDa.

18. A host cell comprising the nucleic acid of
5 claim 1.

19. A nucleic acid vector comprising the nucleic acid of claim 1.

20. A nucleic acid vector of claim 19, wherein the vector is an expression vector.

10 21. A substantially pure Don-1 polypeptide.

22. A substantially pure polypeptide of claim 21, wherein said polypeptide is soluble.

23. A polypeptide of claim 21, wherein said polypeptide comprises the epidermal growth factor (EGF)
15 domain of Don-1.

24. A polypeptide of claim 21, wherein said polypeptide comprises the extracellular domain of Don-1.

25. A polypeptide of claim 21, wherein said polypeptide comprises the amino acid sequence of SEQ ID
20 NO:2, 4, 6, 8, or 32.

26. A polypeptide of claim 21, wherein said polypeptide is encoded by the nucleic acid sequence of SEQ ID NO:1, 3, 5, 7, or 31.

- 101 -

27. A polypeptide of claim 21, wherein said polypeptide is encoded by the *don-1* gene contained in A.T.C.C. deposit 98096, 98097, or 98098.

28. A substantially pure polypeptide of claim 21,
5 wherein the polypeptide is at least 80% identical to the amino acid sequence of the epidermal growth factor (EGF) domain of Don-1.

29. The polypeptide of claim 28, wherein the EGF domain has the sequence of SEQ ID NO:11.

10 30. A substantially pure polypeptide of claim 1, wherein the polypeptide is at least 80% identical to the amino acid sequence of the Ig domain of Don-1.

31. The polypeptide of claim 30, wherein the Ig domain extends from about amino acid 16 to about amino
15 acid 70 in SEQ ID NO:2, 4, or 6, or from about amino acid 54 to about amino acid 108 in SEQ ID NOS:8 and 32.

32. A substantially pure polypeptide of claim 1,
wherein the polypeptide is at least 90% identical to the amino acid sequence of the transmembrane (TM) domain of
20 Don-1.

33. The polypeptide of claim 32, wherein the TM domain has the sequence of SEQ ID NO:20.

34. A substantially pure polypeptide comprising a first portion and a second portion, said first portion
25 comprising a Don-1 polypeptide and said second portion comprising an immunoglobulin constant (Fc) region or a detectable marker.

- 102 -

35. An antibody that specifically binds to a Don-1 polypeptide.

36. A pharmaceutical composition comprising a polypeptide of claim 21.

5 37. A method for detecting Don-1 in a sample, the method comprising:
 obtaining a biological sample;
 contacting the sample with an anti-Don-1 antibody of claim 35 under conditions that allow the formation of
10 Don-1-antibody complexes; and
 detecting the complexes, if any, as an indication of the presence of Don-1 in the biological sample.

 38. A method for stimulating proliferation of a cell, the method comprising administering to the cell an
15 amount of a Don-1 polypeptide effective to stimulate proliferation of the cell.

 39. A method for decreasing proliferation of a cell, the method comprising administering to the cell an amount of a Don-1 polypeptide inhibitor effective to
20 decrease proliferation of the cell.

 40. A method of claim 39, wherein said inhibitor is an antibody that selectively binds to Don-1.

 41. A method of obtaining a splice variant cDNA of the *don-1* gene, the method comprising
25 obtaining a labeled probe comprising an isolated nucleic acid that encodes all or a portion of the epidermal growth factor (EGF) domain of Don-1;
 screening a nucleic acid fragment library with the labeled probe under conditions that allow hybridization

- 103 -

of the probe to nucleic acid fragments in the library to form nucleic acid duplexes;

isolating labeled duplexes, if any; and

preparing a full-length cDNA from the fragments in
5 any labeled duplex to obtain a splice variant cDNA of the *don-1* gene.

42. A method of claim 41, wherein the EGF domain has the amino acid sequence of SEQ ID NO:11.

43. A method of obtaining a gene related to the
10 *don-1* gene, the method comprising

obtaining a labeled probe comprising an isolated nucleic acid that encodes all or a portion of the transmembrane (TM) domain of Don-1;

screening a nucleic acid fragment library with the
15 labeled probe under conditions that allow hybridization of the probe to nucleic acid fragments in the library to form nucleic acid duplexes;

isolating labeled duplexes, if any; and

preparing a full-length gene sequence from the
20 nucleic acid fragments in any labeled duplex to obtain a gene related to the *don-1* gene.

44. A method of claim 43, wherein the TM domain has the amino acid sequence of SEQ ID NO:20.

CCTAACGGCAAAAACATCAAGAAAGAGGTGGGCAAGATCCTGTGCACTGACTGGCG																				56
M K S Q T G E V G E K Q S L																				14
CACCCGCGCCCAAGCTGAAGAAG	ATG	AAG	AGC	CAG	ACA	GGA	GAG	GTC	GCT	GAG	AAG	CAG	TGC	CTC	120					
K C E A A A G N P Q P S Y R W F K D G K	134																			
AAG	TGT	GAG	GCA	GCG	GCG	GGA	AAC	CCC	CAG	CCC	TCC	TAT	CGC	TGG	TTC	AAG	GAT	GCC	AAG	180
E L N R S R D I R I K Y G N V R K N S R	54																			
GAA	CTC	AAC	CGG	ACT	CCT	GAT	ATT	CGC	ATC	AAG	TAT	GCC	AAT	GTC	AGA	AAG	AAC	TCA	CGG	240
L Q F N K V R V E D A G E Y V C E A E N	74																			
CTA	CAG	TTC	AAC	AAA	GTG	AGG	GTG	GAG	GAT	CCC	GGG	GAG	TAC	GTC	TGT	GAG	GCC	GAG	AAC	100
I L G K D T V R G R L H V N S V S T T L	94																			
ATC	CTT	GGG	AAG	GAC	ACC	GTG	AGG	GGC	CGA	CTC	CAT	GTC	AAC	AGC	GTG	AGC	ACC	ACT	CTG	160
S S W S G H A R K C N E T A K S Y C V N	114																			
TCA	TCC	TGG	TGG	GGA	CAT	GCC	CGG	AAG	TCC	AAT	CAG	ACC	GGC	AAG	TCC	TAC	TGT	GTG	AAT	420
G G V C Y Y I E G I N Q L S C K C P N G	134																			
GGA	GGC	GTG	TGC	TAC	TAC	ATC	GAG	GGC	ATC	AAC	CAG	CTC	TCC	TGC	AAA	TGT	CGA	AAC	GGA	480
F F G Q R C L E K L P L R L Y M P D P K	154																			
TTC	TTC	GGA	CAG	AGA	TGT	TTC	GAG	AAA	CTG	CCT	TTC	CGA	TTC	TAC	ATC	CCA	GAT	CCT	AAG	540
Q K A E E L Y Q K R V L T I T G I C V A	174																			
CAA	AAG	GCT	GAG	GAG	CTG	TAC	CAG	AAG	AGA	GTG	CTG	ACA	ATT	ACT	GCT	ATC	TGT	GTG	GCC	600
L L V V G I V C V V A Y C K T X X Q R R	194																			
CTG	CTG	GTG	GTG	GCC	ATC	GTG	TGT	GTG	GTG	GCC	TAC	TGC	AAG	ACC	AAA	AAA	CAG	ACC	AGG	660
Q H E H H L R Q N M C P A H Q N R S L A	214																			
CAG	ATC	CAT	CAT	CAT	CTC	CGG	CAG	AAC	ATG	TGC	CCA	GCC	CAC	CAG	AAC	CGA	AGC	GTG	GCC	720
N G P S H P R L D P E E I Q M A D Y I S	234																			
AAC	GGG	CCC	AGC	CAC	CCT	CGG	CTG	GAC	CCT	GAG	GAG	ATC	CAG	ATG	GCA	GAT	TAC	ATC	TCC	780
K N V P A T D H V I R R E A E T T F S G	254																			
AAA	AAT	GTG	CCA	GCT	ACA	GAC	CAC	GTG	ATC	CGG	AGG	GAA	GCT	GAG	ACC	ACC	TTC	TCT	GGG	840
S H S C S P S H H C S T A T P T S S H R	274																			
AGC	CAC	TCC	TCT	TCA	CCT	TCT	CAC	CAC	TGC	TCC	ACA	GCC	ACG	CCC	ACC	TCC	AGC	CAC	AGA	900
H E S H T W S L E R S E S L T S D S Q S	294																			
CAT	GAG	AGC	CAC	ACC	TGG	AGC	CTG	GAA	CCT	TCA	GAG	AGC	CTG	ACC	TCC	GAT	TCC	CAG	TCA	960
G I M L S S V G T S K C N S P A C V E A	314																			
GCC	ATC	ATC	CTA	TCA	TCA	GTA	GGC	ACC	AGC	AAC	TGC	AAC	AGC	CCA	GCA	TGT	GTG	GAG	GCA	1020
R A R R A A A Y S Q E E R R R A A M P P	334																			
CGG	GCC	CGG	AGC	GCA	GCA	GCC	TAC	AGC	CAG	GAG	GAG	CGG	CTC	AGC	GCT	GCC	ATG	CCA	CCC	1080
Y H D S I D S L R D S P H S E R Y V S A	354																			
TAC	CAT	GAC	TCC	ATA	GAC	TCC	CTG	CCT	GAC	TCT	CCA	CAC	AGT	GAA	AGG	TAC	CTG	TCA	GCC	1140

CCCCCCCCCCCCCCCCCCCCCACTCTCTTCAACGAGAGCGGAGACCAACCGACTGGAGAGCGGAAAGGAGCGCAACAAGCA
AATAAAAAATATTTTATATTTCTATAAAAGGAAAAAAGTATAACAAAAATGTTTTATTTTCATTTTAGCAAAAAAATGTT
CTTATAATACTAGCTAACCGGCAAGACACTTTTTATAGGGAAACTATTTATATGTAACATCTCTGATTTACAGCTTCGGAA
AAAAAAAAAGAACAAACAAAAAATAAAAAAAAAAAAAAACTCGAGGGGGGGGGGGGGTACCCAAATTCGGCTTATAGTGAGTC
GTATTACAAATTCACCTGGCGCTCTTTTACAAAGCTGCTGACTCGGAAACCTTGGCGTTACCCAACTTAATCGCGCTTCCA
GCACATCGCGCTTTTCGGCAGCTGGCGTAAATAGCGAAAAAGCGGGGGGACCGGATCGCGCTTTCCCAACAGTTGCGCAGCGCTGA
ATCGCGAATCGCAATTTGTAAGCGTTAATATTTTGTTAAAAATCGCGTTAAAATTTGTTAAATCACTCAATTTTAAAC
CAATAGCGCGAAATCGGC (587 12 100:1)

Fig. 2

CCTAACGGCAAAAACATCAAGAAAGAGGTGGGCAAGATCCTGTGCACTGACTGGCC	56
M K S Q T G E V G E K Q S L	14
CACCCGCCCCAAGCTGAAGAAG ATG AAG AGC CAG ACA GGA GAG GTG GGT GAG AAG CAG TCG CTC	120
K C E A A A G N P Q P S Y R W F K D G K	34
AAG TGT GAG GCA GCG GCG GGA AAC CCC CAG CCC TCC TAT CGC TGG TTC AAG GAT GGC AAG	180
E L N R S R D I R I K Y G N V R K H S R	54
GAA CTC AAC CGG AGT CGT GAT ATT CGC ATC AAG TAT GGC AAT GTC AGA AAG AAC TCA CGC	240
L Q F N K V R V E D A G E Y V C E A E N	74
CTA CAG TTC AAC AAA GTG AGG GTG GAG GAT GGC GGG GAG TAC GTC TGT GAG GCC GAG AAC	300
I L G K D T V R G R L H V N S V S T T L	94
ATC CTT GGG AAG GAC ACC GTG AGG GGC CGA CTC CAT GTC AAC AGC GTG AGC ACC ACT CTC	360
S S W S G H A R K C N E T A K S Y C V N	114
TCA TCC TGG TCG GGA CAT GCC CGG AAG TCC AAT GAG ACC GCC AAG TCC TAC TGT GTG AAT	420
G G V C Y Y I E G I N Q L S C K C P N G	134
GGA GGC GTG TCC TAC TAC ATC GAG GGC ATC AAC CAG CTC TCC TCC AAA TGT CCA AAC GGA	480
F F G Q R C L E K L P L R L Y M P D P K	154
TTC TTC GGA CAG AGA TGT TTG GAG AAA CTG CTT TTG CGA TTG TAC ATG CCA GAT CTT AAG	540
Q S V L W D T P G G T G V S S S Q W S T S	174
CAA ACT GTC CTC TGG GAT ACA CCG GGG ACA GGT GTC AGC AGT TCG CAA TGG TCA ACT TCT	600
P S T L D L N * (SER 15 NO:14)	181
CCA AGC ACC TTG CAT TTG AAT TGA	624
AGCAGGCTGAGGAGCTGTACCAGAAGAGAGTCTGTGACAATTACTGGTATCTCTGTGGCCCTGCTGGTCTGTGGGCATCTT	
CTGTCTGGTCTGGCTACTGTCAAGACCAAAAAACAGAGGAGGGCAGATGCAATCATATCTCTGGCAGAACATGTGCCCAAGCC	
CACCAAGAACCGAAGCTTGGCCAAAGGGCCCAAGCCACCCCTGGCTGGACCCCTGAGGAGATCCAGATGGCAGATTACATCT	
CCAAAAATGTGCCAGCTACAGACCCAGCTCATCTGGGAGGGGAAGCTGAGACCCACCTTCTCTGGGAGCCACTCTCTGTTCAAC	
TTCTCAACCACTGCTTCACAGCCCAAGCCCACTTCCAGCCACAGACATGAGAGCCACAGCTGGAGCCCTGGAACTTTCAGAG	
AGCTTGACCTCGGATTCCTCAGTCAAGGCATCATCTATCATCACTAGCCACCCAGCCAGTGGCAACAGCCCAAGCATGTGTTC	
AGGCACGGGGCGGAGGGCAGCCAGCTTACAGCCAGGAGGAGCGGGCCAGGGCTGCCATGCCACCCCTACCAATGACTCCAT	
AGACTTCTGCTGCTCACTTCTCCACACAGTGAAGGTACGTGTCAAGCTTGACCACGGCCCGCTGCTCTCTGGCCGCTGGAC	
TTCCACTACTCTGCTGGCCACCCAGGTGCTGACTTTTCAGATCAAGTGGCCCAACTCTTGGCAATGCCGTCTCGGTGCTGGC	
CCCCCGCCCACTAGCTACCCGCTTGGCCAGCCAGCCAGCCGCTCTCTGGCCATCCAGCCCTGCCCCCGGGCCGGG	
GTGGGGCCCGGAGCGGACATGCAGCCAGCTACCCAGCTACTACTACCTTGGGGCGGGGGCCCGGGCGGGCGGAGC	
GCCTGCCCCCTGGGAGCCAGCTTGGGAGCCCTGCCCGCCAGCCCTTCCGCAATCCCGAGGACGACGAGTACGAGACCA	
CCAGGAGTGGGGCCCTGGCCCGCCCGCCCGCCCG	(SER 15 NO:15)

Fig. 3

CAGCTACAGCGGAGCAGGCAGCCAGCACGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG	60
CAGCGGAGAGCGGCCAGCAGCAGCAGGAGCAGCAGCAACAACAGCAGCATCTCTGTTCCTCCC	120
TCCCCCCCCCCAGAGCCCCCCCCCCCCAGCAAACAGCEGAGCEGCGAGCCCCGAGCEGCGAG	180
AGCCCCCGCCCCCTTCCGAGCCCGAGCCCCCGGGCGCATGAGGGCGGACC CGCCCCCGG	240
CTTCTCCATGTCTGCTCTTTCCGTGTGTCCGTCCGCTGCTACTGCCCCAGCCCTCAAGTGAGT	300
G CAGGACCAGGCGGTACAAGGCACCCG TGGTGGTGGAGGGCAAGGTACAGGGGCTGGTCCC	360
AGCCGGCGGCTCCA GCTCCA ACAGCA CCGGAGAGCCGCGCCCTCGGGTCGGGTGGCGGT	420
GGTA AAGGTGCTGGACA AGTGGCCGCTCCGGAGCGGGGGGCTGCAGCCGAGCAGGTGAT	480
CAGCGTGGGCTCCTGTGTGCCGCTCGAAAGGA ACCAGCGCTACATCTTTTTCTCTGGAGCC	540
CACGGAACAGCCCTTAGTCTTTAAGACGGCCTTTGCCCGCCCTGATACCAACGGCAAAAAT	600
CTCAAGA AAAGAGGTGGGCAAGATCCTGTGCA CTGACTCGCCACCCGGCCCCAAGTTGAAG	660
M K S Q T G O V G E R Q S L K C E A A AAGATGAAGAGCCAGACGGGACAGGTGGGTGAGAAGCAATCGCTGAAGTGTGAGGCAGCA	720
A G N P Q P S Y R W F K D G K E L N R S GCCGGTAATCCCCAGCCTTCTACCGCTTGGTTC AAGGATGGCAAGGAGCTCAACEG CAGC	780
R D I R I K Y G N G R K N S R L Q P N K CGAGACATTCC CATCA ATATGGCAACGGCAGAA GA ACTCAGGACTACAGTTC AACAG	840
V K V E D A G E Y V C E A E N I L G K D GTGAAGGTGGAGGACGCTGGGGAGTATGTCTGCGAGGGCCGAGA ACATCCTGGGGAAGGAC	900
T V B G R L Y V N S V S T T L S S W S G ACCGTCCGGGCGCGGCTTTACGTC AACAGCGTGAGCACCACCGCTGTCATCCTGGTGGGG	960
H A R K K C N E T A K S Y C V N G G V C Y CAGCCCCGGAAGTCAACGAGACAGCCAAGTCTT ATTGCGTCAATGGAGGGCTCTGCTAC	1020
Y I E G I N Q L S C K C P N G F F G Q R TACATCGAGGGCATCAAC CAGCTCTCTCTGCAAAATGTCCAATGGATTCTTCGGACAGAGA ¹²⁴	1080
C L E K L P L R L Y M P D P K Q K H L G TGTTTGGAGAACTGCCCTTTCGGA TTGTACATGCCAGATCCTTAAGCAAAAGCACCTTGG	1140
F E L K E A E E L Y Q K R V L T I T G I TTTGAATTAAGGAAGCCGAGGAGCTGTACCAGAAGAGG GTCTGTACCATCAGGGGCATC	1200
C V A L L V V G I V C V V A Y C K T K K TGCGTGGCTCTGCTGGTCTGTTGGGCATCGTCTGTGTGGTGG CCTACTGCAAGACCAAAAA	1260
Q R K Q M H N H L R Q N M C P A H Q N R CAGCGGAAGCAGATGCACAACCACTTCGGGCAGAACATGTGCCCGGCGCCATCAGAACCGG	1320
S L A N G P S H P R L D P E E I Q M A D AGCTTGCGCAATGGGCGCCAGCCACCTCCCGGCTGGACCCAGAGGAGATCCAGATGCCAGAT	1380

FIGURE 3 (continued)

Y I S K N V P A T D H V I R R E T E T T 1440
TATATTTCCAAGAACGTGCCAGCCACAGACCATGTTCATCAGGAGAGAAACTGAGACCACC
F S G S H S C S P S H H C S T A T P T S 1500
TTCTCTGGGAGCCCACTCCTGTTCTCCTTCTCACCAGTGTCTCCACAGCCACACCCACCTCC
S H R H E S H T W S L E R S E S L T S D 1560
AGCCACAGACACGAGAGCCACACGTTGGAGCCTGGAACTTCTGAGAGCCTGACTTCTGAC
S Q S G I M L S S V G T S K C N S P A C 1620
TCCCAGTCGGGGATCATGCTATCATCAGTGGGTACCAGCAAATGCCAACAGCCCAGCATGT
V E A R A R R A A A Y N L E E R R R A T 1680
GTGGAGCCCCGGGCAAGCCGGCCAGCAGCCTACAACCTGGAGGAGCGGGCCAGGGCCACC
A P P Y H D S V D S L R D S P H S E R Y 1740
GCGCCACCTATCAGGATTCCGTGGACTCCCTTCGGGACTCCCCACACAGCGAGAGGTAC
V S A L T T P A R L S P V D F H Y S L A 1800
GTGTGGGCGCTGACCACGCCCCCGCGCTCTCGGCGCGTGGACTTCCACTACTCGCTGGCC
T Q V P T F E I T S P N S A K A V S L P 1860
ACGCAGGTGCCAACTTTCGAGATCACGTCCCCCAACTCGGGCCACGCCCTGTCCCTGCCCG
P A A P I S Y R (SER 1A NO:6)
CCGGCGGCGCCCATCAGTTACCGC 1884 (SER 1A NO:5)

Fig. 4

CGGGCGGGGGGGGGCGCAGCGCGGCAGCGGAGAGCTGAGGCCGTCCACCGCCTGGGACCC 60

M S E S R R R G R G R G K K H P E
CGTGCAAAATGTCGGAGTCCAGGAGGAGGGGCGCGCGCGCGCAAGAAAGCACCAGAGG 120

G R K R E R E P D P G E K A T R P K L K
GGAGGAAGCGGGAGAGGGAGCCCCGATCCCGGGGAGAAAGCCACCGCGCCCAAGTTGAAGA 180

K M K S Q T G Q V G E K Q S L K C E A A
AGATGAAGAGCCAGACGGGACAGGTGGGTGAGAAGCAATCGCTGAAGTGTGAGGCAGCAG 240

A G N P Q P S Y R W F K D G K E L N R S
CCGGTAATCCCCAGCCTTCTACCGTTGGTTCAAGGATGGCAAGGAGCTCAACCGCAGCC 300

R D I R I K Y G N G R K N S R L Q P N K
GAGACATTCCCATCAAATATGGCAACGGCAGAAAGAACTCAGGACTACAGTTCAACAAGC 360

V K V E D A G E Y V C E A E N I L G K D
TGAAGGTGGAGGACGCTGGGGAGTATGTTCTGCGAGGCCGAGAACAATCTGGGGAGGACA 420

T V R G R L Y V N S V S T T L S S W S G
CCGTCCGGGGCGGGCTTTACGTCAACAGCGTGAGCACCCCTGTCTATCTGCTGGGGGC 480

H A R K C N E T A K S Y C V N G G V C Y
ACGCCCCGAAGTGCAACGAGACAGCCAAAGTCTTATGGCGTCAATGGAGGCGTCTGCTACT 540

Y I E G I N Q L S C K C P N G F P G Q R
ACATCGAGGGCATCAACAGCTCTCTGCAAAATGTCAAATGGATTCTTCGGACAGAGAT 600

C L E K L P L R L Y M P D P K Q K A E E
GTTTGGAGAAACTGCCCTTTGCGATTGTACATGCCAGATCCTAAGCAAAAAGCCGAGGAGC 660

L Y Q K R V L T I T G I C V A L L V V G
TGTACCAGAAGAGGGTCTCTGACCATCACGGGCATCTGCGTGGCTCTGCTGGTCTGTTGGCA 720

I V C V V A Y C K T K K Q R K Q M H N H
TCGTCTGTGTGGTGGCTACTGCAAGACCAAAAACAGCGGAAGCAGATGCACAACCACC 780

L R Q N M C P A H Q N R S L A N G P S H
TCCGGCAGAACATGTGCCCCGGCCATCAGAACCGGAGCTTGGCCAAATGGGGCCAGCCACC 840

P R L D P E E I O M A D Y I S K N V P A
CCCCGCTGGACCCAGAGGAGATCCAGATGGCAGATTATATTTCAAGAACGTGCCAGCCA 900

T D H V I R R E T E T T F S G S H S C S
CAGACCATGTCAATCAGGAGAGAACTGAGACCACCTTCTCTGGGAGCCACTCTGTTTCTC 960

P S H H C S T A T P T S S H R H E S H T
CTTCTCAACCACTGCTCCACAGCCACACCCACCTCCAGCCACAGACACGAGAGCCACAGT 1020

W S L E R S E S L T S D S Q S G I M L S
GGAGCCTGGAAAGTTCTGAGAGCCTGACTTCTGACTCCCAAGTCGGGGATCATGCTATCAT 1080

S V G T S K C N S P A C V E A R A R R A
CAGTGGGTACCAGCAAAATGCAACAGCCAGCATGTGTGGAGGCCCGGGCAAGCGGGCAG 1140

FIGURE 4 (continued)

A A Y N L E E R R R A T A P P Y H D S V
CAGCCTACAACCTGGAGGAGCGGGCGAGGGCCACCGCGCCACCCCTATCAGGATTCGGTGG 1200

D S L R D S P H S E R Y V S A L T T P A
ACTCCCTTGGGGACTCCCCACACAGCGAGAGGTACGTGTGGCCCTGACCAGCGCCCGGC 1260

R L S P V D F H Y S L A T Q V P T F E I
GCTCTCGCCCGTGGACTTCCACTACTCGCTGGCCACGCAGGTGCCAACTTTCGAGATCA 1320

T S P N S A H A V S L P P A A P I S Y R
CGTCCCCCAACTCGGGCGCAGCCCGTGTCTGCTGCGCGCGCGCGCGCCCATCAGTTACCGCC 1380

L A E Q Q P L L R H P A P P G P G P G P
TGGCCGAGCAGCAGCCGTTACTGCGGCACCCGGCGCCCCCGGGCCCGGGACCCCGACCCG 1440

G P G P G P G A D T G I
GGCCCCGGCCCCGGCCCCGGCGCAGACACCGGAATTC 1476

(~~SEQ~~ ID NO: 8)
(~~SEQ~~ ID NO: 7)

```

      1                                     50
(Seq ID NO: 9) nd# M SERKEGRGK GKGGKQDRGS RGRPGPAEGD P SPALPPRLK EMKSEQESAAG
(Seq ID NO: 10) hrg-b M SERKEGRGK GKGGKQDRGS GKGPESAAGS Q SPALPPRLK EMKSEQESAAG
      Seq ID NO: 8 MSESRRRGR. GRGKXHPGR KREREPDP.. GEXATRPRLK KMKSQTGQVG
      Seq ID NO: 6 ..... M K S Q T G Q V G
      Seq ID NO: 2 ..... M K S Q T G V G
      Seq ID NO: 4 .....

      51                                     100
      nd# SKLVLRCTTS SEYSSLRPKW FNGMELNRK NKPENIXIQK KPGKSELRLN
      hrg-b SKLVLRCTTS SEYSSLRPKW FNGMELNRK NKPQNIKIQK KPGKSELRLN
      EKQSLKCEAA AGNPQPSYRW FKDGKELNR. SRDIRIKYGN GRKNSRLQFN
      EKQSLKCEAA AGNPQPSYRW FKDGKELNR. SRDIRIKYGN GRKNSRLQFN
      EKQSLKCEAA AGNPQPSYRW FKDGKELNR. SRDIRIKYGN VRKNSRLQFN
      ..... RIKYGN GRKNSRLQFN

      101                                     150
      nd# KASLADSGEY MCKVTSKLGK DSASANTIV ESNEFITGMP ASTETAYVSS
      hrg-b KASLADSGEY MCKVTSKLGK DSASANTIV ESNEIITGMP ASTEGAYVSS
      KVKVEDAGEY VCEAENILGK DTVRGRLYV. ....
      KVKVEDAGEY VCEAENILGK DTVRGRLYV. ....
      KVRVEDAGEY VCEAENILGK DTVRGRLYV. ....
      KVRVEDAGEY VCEAENILGK DTVRGRLYV. ....

      151                                     200
      nd# ESPIRISVST EGANTSSSTS TSTTGTSKLI KCAEKERTYC VNGGCVTYIE
      hrg-b ESPIRISVST EGANTSSSTS TSTTGTSKLV KCAEKERTYC VNGGCVTYIE
      ..... NSVST ..... TLSSWS ..... GHAR KCMETAKSYC VNGGCVTYIE
      ..... NSVST ..... TLSSWS ..... GHAR KCMETAKSYC VNGGCVTYIE
      ..... NSVST ..... TLSSWS ..... GHAR KCMETAKSYC VNGGCVTYIE
      ..... NSVST ..... TLSSWS ..... GHAR KCMETAKSYC VNGGCVTYIE

      201                                     250
      nd# DLSNPSRYLC KCQPGFTGAR CTENV..... PMKVQ.... TOEXAEELY
      hrg-b DLSNPSRYLC KCPNFTGDR CQNYVMASFY KHLGIE.... FMEAEELY
      GINQLS...C KCPNGFFGQR CLEKLPLRLY MPDPKQK... AEELY
      GINQLS...C KCPNGFFGQR CLEKLPLRLY MPDPKQK... AEELY
      GINQLS...C KCPNGFFGQR CLEKLPLRLY MPDPKQK... AEELY
      GINQLS...C KCPNGFFGQR CLEKLPLRLY MPDPKQSVL. ....

      251                                     300
      nd# QKRLTITGI CIALLVGIV CVVAYCKTKK QRQKLHDLRL QSLRSERSNL
      hrg-b QKRLTITGI CIALLVGIV CVVAYCKTKK QRQKLHDLRL QSLRSERNNM
      QKRLTITGI CIALLVGIV CVVAYCKTKK QRQKMHHLR QNMCPAHQN.
      QKRLTITGI CIALLVGIV CVVAYCKTKK QRQKMHHLR QNMCPAHQN.
      QKRLTITGI CIALLVGIV CVVAYCKTKK QRQKMHHLR QNMCPAHQN.
      ..WDPGTGV SSSQWSTSPS TLGLN*.....

```

Seq ID NO: 20

Fig. 5

9/13

FIGURE 5 (continued)

```

301                                     350
ndf VNIANGPHHP NPPPENVLQV NQYVSKNVIS SEHIVEREVE TSFSTSHYTS
hrg-b VNIANGPHHP NPPPENVLQV NQYVSKNVIS SEHIVEREAE TSFSTSHYTS
SEQ ID NO: 5 RSLANGPSHP RLDPEEIQM. ADYTISKNVPA TDHVIRRETE TTFSGSHSCS
SEQ ID NO: 6 RSLANGPSHP RLDPEEIQM. ADYTISKNVPA TDHVIRRETE TTFSGSHSCS
SEQ ID NO: 2 RSLANGPSHP RLDPEEIQM. ADYTISKNVPA TDHVIRREAE TTFSGSHSCS
.....

351                                     400
ndf TANKSTTVTQ TP.....SHS WSNHGTESVI SESNSVIDMS SVENSRHSS?
hrg-b TANKSTTVTQ TP.....SHS WSNHGTESIL SESHSVTVMs SVENSRHSS?
PSKHCSTATP TSSHRHESHT WSLERSES LT SDSQSGIMLS SVGTSKCNsP
PSKHCSTATP TSSHRHESHT WSLERSES LT SDSQSGIMLS SVGTSKCNsP
PSKHCSTATP TSSHRHESHT WSLERSES LT SDSQSGIMLS SVGTSKCNsP
.....

401                                     450
ndf A..GGPRGRL HGLOGPRD.N SFLRHARETP DSYRDSPHSE R*.....
hrg-b T..GGPRGRL NGTGGPRECN SFLRHARETP DSYRDSPHSE RYVSAMITPA
ACVEARARRA AAYNLEERRR ATAPPYHDSV DSLRDSPHSE RYVSALITPA
ACVEARARRA AAYNLEERRR ATAPPYHDSV DSLRDSPHSE RYVSALITPA
ACVEARARRA AAYSQEERRR AAMPYHDSI DSLRDSPHSE RYVSALITPA
.....

451                                     500
ndf .....
hrg-b RLSFVDFHYS SSPKSPPSEM SPPVSSMTVS MPMAVSPFH EERPLLVT
RLSFVDFHYS LATQVPTFEI TSPNSAHAVS LPPAAPISYR LAEQQPLLKH
RLSFVDFHYS LATQVPTFEI TSPNSAHAVS LPPAAPISYR .....
RLSFVDFHYS LATQVPTFEI TSPNSAHAVS LPPAAPISYR LAEQQPLLKH
.....

501                                     550
ndf .....
hrg-b PFRLEKQFD MHPQQFSSTH HNPARDNSIL PASPLRVED EETETQEYE
PAPPGPGPGP GPGPGPGADT GI.....
PAPPGPGPGS GPGADMORSY DSYTTPAAGP GPRRSACALC GSLGSLPASP
.....

551                                     600
ndf .....
hrg-b PAQETVTKLA NSRRAKRTKP NGHIANRLEV DSNTSSQSSN SESETERERV
.....
FRIPEDDEYE TTOECAPPPP PRPRTRGASR RTSAGPRRWR RSLNGLAAQ
.....

```

FIGURE 5 (CONTINUED)

	601		650
ndf			
hrg-b	GEDTPFLGIG	NPLAASLEAT	PAFRLADSRT NPAGRFSTOE EIQARLSSVT
SEQ ID NO: 8			
SEQ ID NO: 6			
SEQ ID NO: 2	RARAARDSL	LSSGSGCCSA	SASDDADDA DGALAAESTP FLGLRAAHDA
SEQ ID NO: 4			
	651		696
ndf			
hrg-b	ANQOPIAV*		
			
			
	LRSDSPPLCP	AASRTYYSL	DSKSTRASSR HSRGPPTRAK QDSGFL
			

11/13

		Ser
don-1	GHARKNETAKSYVNGGVVYIEGINQLS...KCPNGFFGQRLEXLP	11
hrg-a	SHLVKQAEKERTFVNGGECFMVKDLSNPSRYLCKCPGFTGARCTENVP	12
ndf	SHLIKQAEKERTFVNGGECFTVKDLSNPSRYLCKCPGFTGARCTENVP	13
hrg-b	SHLVKQAEKERTFVNGGECFMVKDLSNPSRYLCKCPNEFTGDRCONYVM	14
aria	SHLTKQDIKQKAFVNGGECFMVKDLPNPPRYLCKCPNEFTGDRCONYVM	15
human hb-egf	GKRDHQLRKYKDFCIH.GECKYVKELRAPSL...CICHPGYHGERCHGLSL	16
human egf	NSDSECPLSHDGYCLHDGVCMYTEALDKYA...CNCVVGYYIGERCQYRDL	17
amphiregulin	KGNPNQNAEFQNFQIH.GECKYIERLEAVT...CKCQDEYFGERCGEKSM	18
TGF-a	SHFNTCPDSHTQFQFH.GICRFLVQEDKPA...CVCCHSGYVGARCEADL	19

Fig. 6

CCCCCCCCCCCCGCGAGCGCGCGCAGCGGAGAGCTGAGGCCCTCCACCGCCTGGGACCCCGTGCAGA																		M	S	2
																		ATG	TGG	74
E	S	R	R	R	G	R	G	R	G	K	K	H	P	E	G	R	K	R	E	22
GAG	TCC	AGG	AGG	AGG	GGC	CGC	GGC	CGC	GGC	AAG	AAG	CAC	CCA	GAG	GGG	AGG	AAG	CGG	GAG	134
R	E	P	D	P	G	E	K	A	T	R	P	K	L	K	K	M	K	S	Q	42
AGG	GAG	CCC	GAT	CCC	GGG	GAG	AAA	GCC	ACC	CGG	CCC	AAG	TTG	AAG	AAG	ATG	AAG	AGC	CAG	194
T	G	Q	V	G	E	K	Q	S	L	K	C	E	A	A	A	G	N	P	Q	62
ACG	GGA	CAG	GTG	GGT	GAG	AAG	CAA	TCG	CTG	AAG	TGT	GAG	GCA	GCA	GCC	GGT	AAT	CCC	CAG	255
P	S	Y	R	W	F	K	D	G	K	E	L	N	R	S	R	D	I	R	I	82
CCT	TCC	TAC	CGT	TGG	TTC	AAG	GAT	GGC	AAG	GAG	CTC	AAC	CGC	AGC	CGA	GAC	ATT	CGC	ATC	314
K	Y	G	N	G	R	K	N	S	R	L	Q	F	N	K	V	K	V	E	D	102
AAA	TAT	GGC	AAC	GGC	AGA	AAG	AAC	TCA	CGA	CTA	CAG	TTC	AAC	AAG	GTG	AAG	GTG	GAG	GAC	174
A	G	E	Y	V	C	E	A	E	N	I	L	G	K	D	T	V	R	G	R	122
GCT	GGG	GAG	TAT	GTC	TGC	GAG	GCC	GAG	AAC	ATC	CTG	GGG	AAG	GAC	ACC	GTC	CGG	GGC	CGG	434
L	Y	V	N	S	V	S	T	T	L	S	S	W	S	G	H	A	R	K	C	142
CTT	TAC	GTC	AAC	AGC	GTG	AGC	ACC	ACC	CTG	TCA	TCC	TGG	TGG	GGG	CAC	GCC	CGG	AAG	TGC	494
N	E	T	A	K	S	Y	C	V	N	G	G	V	C	Y	Y	I	E	G	I	162
AAC	GAG	ACA	GCC	AAG	TCC	TAT	TGC	GTC	AAT	OGA	GCC	GTC	TGC	TAC	TAC	ATC	GAG	GGC	ATC	554
N	Q	L	S	C	K	C	P	N	G	F	F	G	Q	R	C	L	E	K	L	182
AAC	CAG	CTC	TCC	TGC	AAA	TGT	CCA	AAT	GGA	TTC	TTC	GGA	CAG	AGA	TGT	TTG	GAG	AAA	CTG	614
P	L	R	L	Y	M	P	D	P	K	Q	K	A	E	E	L	Y	Q	K	R	202
CCT	TTG	CGA	TTG	TAC	ATG	CCA	GAT	CCT	AAG	CAA	AAA	GCC	GAG	GAG	CTG	TAC	CAG	AAG	AGG	674
V	L	T	I	T	G	I	C	V	A	L	L	V	V	G	I	V	C	V	V	222
GTC	CTG	ACC	ATC	ACG	GGC	ATC	TGC	GTG	GCT	CTG	CTG	GTC	GTC	GGC	ATC	GTC	TGT	GTG	GTG	734
A	Y	C	K	T	K	K	Q	R	K	Q	M	H	N	H	L	R	Q	N	M	242
GCC	TAC	TGC	AAG	ACC	AAA	AAA	CAG	CGG	AAG	CAG	ATG	CAC	AAC	CAC	CTC	CGG	CAG	AAC	ATG	794
C	P	A	H	Q	N	R	S	L	A	N	G	P	S	H	P	R	L	D	P	262
TGC	CCG	GCC	CAT	CAG	AAC	CGG	AGC	TTG	GCC	AAT	GGG	CCC	AGC	CAC	CCC	CGG	CTG	GAC	CCA	854
E	E	I	Q	M	A	D	Y	I	S	K	N	V	P	A	T	D	H	V	I	282
GAG	GAG	ATC	CAG	ATG	GCA	GAT	TAT	ATT	TCC	AAG	AAC	GTG	CCA	GCC	ACA	GAC	CAT	GTC	ATC	914
R	R	E	T	E	T	T	F	S	G	S	H	S	C	S	P	S	H	H	C	302
AGG	AGA	GAA	ACT	GAG	ACC	ACC	TTC	TCT	GGG	AGC	CAC	TCC	TGT	TCT	CCT	TCT	CAC	CAC	TGC	974
S	T	A	T	P	T	S	S	H	R	H	E	S	H	T	W	S	L	E	R	322
TCC	ACA	GCC	ACA	CCC	ACC	TCC	AGC	CAC	AGA	CAC	GAG	AGC	CAC	ACG	TGG	AOC	CTG	GAA	CGT	1034
S	E	S	L	T	S	D	S	Q	S	G	I	M	L	S	S	V	G	T	S	342
TCT	GAG	AGC	CTG	ACT	TCT	GAC	TCC	CAG	TCG	GGG	ATC	ATG	CTA	TCA	TCA	GTG	GGT	ACC	AGC	1094
K	C	N	S	P	A	C	V	E	A	R	A	R	R	A	A	A	Y	N	L	362
AAA	TGC	AAC	AGC	CCA	GCA	TGT	GTG	GAG	GCC	CGG	GCA	AGG	CGG	GCA	GCA	GCC	TAC	AAC	CTG	1154
E	E	R	R	R	A	T	A	P	P	Y	H	D	S	V	D	S	L	R	D	382
GAG	GAG	CGG	CGC	AGG	GCC	ACC	GGG	CCA	CCC	TAT	CAC	GAT	TCC	GTG	GAC	TCC	CTT	CGC	GAC	1214
S	P	H	S	E	R	Y	V	S	A	L	T	T	P	A	R	L	S	P	V	402

Fig. 7 (continued)

TCC CCA CAC AGC GAG AGG TAC GTG TCG GCC CTG ACC ACG CCC GCG CGC CTC TCG CCC GTG	1274
D F H Y S L A T Q V P T F E I T S P N S	422
GAC TTC CAC TAC TCG CTG GCC ACG CAG GTG CCA ACT TTC GAG ATC ACG TCC CCC AAC TCG	1334
A H A V S L P P A A P I S Y R L A E Q Q	442
GCG CAC GCC GTG TCG CTG CCG CCG GCG GCG CCC ATC AGT TAC CCG CTG GCC GAG CAG CAG	1394
P L L R H P A P P G P G P G P G P G P G	462
CCG TTA CTG CCG CAC CCG GCG CCC CCC CCG GGA CCC GGA CCC GCG CCC GCG CCC GCG	1454
P G A D M Q R S Y T S Y Y Y P A A G P G	482
CCC GGC GCA GAC ATG CAG CCG AGC TAT CTC AGC TAC TAT TAC CCC GCG GCG GCG CCC GGA	1514
P R R G T C A L G G S L G S L P A S P F	502
CCG CCG CCG GCG ACC TCG GCG CTC GCG GCG AGC CTG GCG AGC CTG CCT GCC AGC CCC TTC	1574
R I P E D D E Y E T T Q E C A P P P P P	522
CCG ATC CCC GAG GAC GAC GAG TAC GAG ACC ACG CAG GAG TGC GCG CCC CCG CCG CCG CCG	1634
R P R A R G A S R R T S A G P R R W R R	542
CCG CCG CCG GCG CCG GGT GCG TCC CCG AGG ACG TCG GCG GCG CCC CCG CCG TCG CCG CCG	1694
S R L N G L A A Q R A R A A R D S L S L	562
TCG CCG CTC AAC GGG CTG GCG GCG CAG CCG GCA CCG GCG GCG AGG GAC TCG CTG TCG CTG	1754
S S G S G G G S A S A S D D D A D D A D	582
AGC AGC GGC TCG GGC GGC GGC TCA GCC TCG GCG TCG GAC GAC GAC GCG GAC GAC GCG GAC	1814
G A L A A E S T P F L G L R G A H D A L	602
GGG GCG CTG GCG GCC GAG AGC ACA CCT TTC CTG GCG CTG CGT GCG GCG CAC GAC GCG CTG	1874
R S D S P P L C P A A D S R T Y Y S L D	622
CCG TCG GAC TCG CCG CCA CTG TCG CCG GCG GCC GAC AGC AGG ACT TAC TAC TCA CTG GAC	1934
S H S T R A S S R H S R G P P P R A K Q	642
AGC CAC AGC ACG CCG GCC AGC AGC AGA CAC AGC CCG GCG CCG CCC CCG CCG GCC AAG CAG	1994
D S A P L . (SEQ ID NO: 32)	648
GAC TCG GCG CCA CTC TAG	2012
GGCCCCGGCCGGCCCCCTCCCCCCCCCCCCCACTATCTTTAAGGAGACCAGAGACCGCCTACTGGAGAGAAAGGA	2091
GGAAAAAGAAATAAAAAATATTTTATTTTCTATAAAAGGAAAAAGTATAACAAAATGTTTTATTTTCATTTTAGCAA	2170
AAATTGCTTTATAATACTAGCTAACGGCAAAGCGTTTTTATAGGGAACTATTTTATATGTAACTCCTGATTTACAGC	2249
TTCCGAAAAAAAAGAAA (SEQ ID NO: 31)	2268

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/14585

A. CLASSIFICATION OF SUBJECT MATTER IPC(6) :Please See Extra Sheet. US CL :Please See Extra Sheet. According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 435/6, 252.3, 320.1, 325; 436/94, 501; 514/2; 530/324, 350, 387.1; 536/23.5, 24.31; 935/1, 9, 11, 76, 77, 78 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Nierman et al., eds., ATCC/NIH Repository Catalogue of Human and Mouse DNA Probes and Libraries, 1994, pages 1-70; see pages 1-58.	1-20
X	WO 94/08007 A1 (PRESIDENT AND FELLOWS OF HARVARD COLLEGE) 14 April 1994 (14.04.94), see entire document.	1-3, 5-10, 14-20
X	Stratagene Cloning Systems catalogue, 1994, pages 304-305.	12
A	HARDIE et al., The Protein Kinase FactsBook," 1995, pages 165-167.	1-44
☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "B" earlier document published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "Z" document member of the same patent family	
Date of the actual completion of the international search 20 SEPTEMBER 1997		Date of mailing of the international search report 23 DEC 1997
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer BRADLEY L. SISSON Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/14585

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	CULOUSCOU et al., "HER4 Receptor Activation and Phosphorylation of the She Proteins by Recombinant Hergultin-Fe Fusion Proteins," The Journal of Biological Chemistry. 26 May 1995, Vol. 270, No. 21 pages 12857-12863; see the entire document.	1-44
A	WEN et al., "Neu. Differentiation Factor: A Transmembrane Glycoprotein Containing an EGF Domain and an Immunoglobulin Homology Unit," Cell. Vol. 69, 01 May 1992, pages 559-572.	1-44
A	TZAHAR et al., "ErbB-3 and ErbB-4 Function as the Respective Low and High Affinity Receptors of All Neu Differentiation Factor/Heregulin Isoforms," The Journal of Biological Chemistry. 07 October 1994, Vol. 269, Number 40, pages 25226-25233.	1-44
A	SLAMON et al., "Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neu Oncogene," Science. 09 January 1987, volume 235, pages 177-182.	1-44

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/14585

A. CLASSIFICATION OF SUBJECT MATTER:

IPC (6):

C07H 21/04; C07K 1/00, 16/00; A61K 38/00; G01N 33/00, 33/566; A01N 37/18

A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

435/320.1, 325; 436/94, 501; 514/2; 530/324, 350, 387.1; 536/23.5